Apheresis Market - Global Forecast to 2025

APHERESIS MARKET - GLOBAL FORECAST TO 2025
MarketsandMarkets™ is the world's largest revenue impact company, serving over 7500 customers. 80% of
the top 2000 companies globally rely on us for identifying the new high growth and niche revenue
opportunities.
In the face of constant technology innovation and market disruption, we help organizations plan and
operationalize their future revenue mix decisions by identifying over 30,000 high growth opportunities
ranging from $1B to $500B across 90+ industry trends and markets. Organizations choose
MarketsandMarkets™ to stay ahead of the curve and accelerate their revenue decisions and
implementations by 6 – 12 months, giving them a unique, first-mover advantage.
Our revenue impact methodology provides quantified and actionable insights on converged, granular, and
connected market eco-systems that result from disruptive technologies and high-growth markets. We provide
an extended lens on not only what will impact our client’s revenue but also what will impact their clients’
revenues, continually uncovering latent opportunities.
We work across all major B2B industries with C-level executives in functions such as Strategy, Marketing,
Sales, R&D, Product, and M&A. MarketsandMarkets™ brings exclusive high-growth markets intelligence
generated by over 850 SMEs and analysts along with its proprietary Revenue Impact platform
(Knowledge Store).
Copyright © 2020 MarketsandMarkets™

All Rights Reserved. This document contains highly confidential information and is the sole property of
MarketsandMarkets™. No part of it shall be circulated, copied, quoted, or otherwise reproduced without the
prior written approval of MarketsandMarkets™
2
JANUARY 2020 © MarketsandMarkets™
TABLE OF CONTENTS
1 INTRODUCTION ........................................................................................................ 24
1.1 OBJECTIVES OF THE STUDY ...........................................................................................................24
1.2 MARKET DEFINITION AND SCOPE ..................................................................................................24
1.2.1 MARKETS COVERED ....................................................................................................... 25
1.2.2 YEARS CONSIDERED FOR THE STUDY .............................................................................. 26
1.3 CURRENCY ...................................................................................................................................26
1.4 LIMITATIONS ................................................................................................................................26
1.5 STAKEHOLDERS ...........................................................................................................................27
2 RESEARCH METHODOLOGY ...................................................................................... 28

2.1 RESEARCH APPROACH .................................................................................................................28
2.1.1 SECONDARY RESEARCH ................................................................................................. 28
2.1.1.1 Key data from secondary sources ....................................................................... 29
2.1.2 PRIMARY RESEARCH ...................................................................................................... 30
2.1.2.1 Key data from primary sources ........................................................................... 30
2.1.2.2 Breakdown of primaries ..................................................................................... 31
2.2 MARKET SIZE ESTIMATION ............................................................................................................31
2.3 DATA TRIANGULATION APPROACH ................................................................................................34
2.4 MARKET SHARE ESTIMATION ........................................................................................................35
2.4.1 ASSUMPTIONS FOR THE STUDY ...................................................................................... 35
3 EXECUTIVE SUMMARY .............................................................................................. 36
4 PREMIUM INSIGHTS ................................................................................................ 43

4.1 APHERESIS MARKET OVERVIEW ....................................................................................................43
4.2 EUROPE: APHERESIS MARKET, BY APPLICATION ...........................................................................44
4.3 GEOGRAPHIC SNAPSHOT OF THE APHERESIS MARKET (2018).......................................................45
4.4 GEOGRAPHIC MIX: APHERESIS MARKET, 2019–2025 (USD MILLION) ...........................................46
4.5 APHERESIS MARKET: DEVELOPING VS. DEVELOPED MARKETS,
2019 VS. 2025 (USD MILLION) .....................................................................................................46
5 MARKET OVERVIEW.................................................................................................. 47
5.1 INTRODUCTION ............................................................................................................................47
5.2 MARKET DYNAMICS: IMPACT ANALYSIS ........................................................................................47
5.2.1 DRIVERS ........................................................................................................................ 48
5.2.1.1 Rising prevalence of chronic diseases and growing number
of trauma and injury cases ................................................................................. 48
5.2.1.2 Increasing demand for source plasma from biopharmaceutical
companies ........................................................................................................ 49
3
5.2.1.3 Rising demand for blood components and growing concerns

regarding blood safety ....................................................................................... 49
5.2.1.4 Increase in the number of complex surgical procedures ...................................... 50
5.2.1.5 Favorable reimbursement for apheresis procedures............................................ 51
5.2.2 RESTRAINTS................................................................................................................... 51
5.2.2.1 High cost of apheresis devices & therapeutic apheresis procedures
and installation of apheresis devices through rental model ................................. 51
5.2.2.2 Fewer blood donations using apheresis due to lack of awareness........................ 52
5.2.2.3 Stringent donor recruitment criteria ................................................................... 53
5.2.3 OPPORTUNITIES ............................................................................................................. 53
5.2.3.1 Apheresis for leukemia and pediatric patients .................................................... 53
5.2.3.2 Emerging economies with increasing investments from
government bodies and leading players ............................................................. 54
5.2.4 CHALLENGES ................................................................................................................. 54
5.2.4.1 Recruitment of voluntary non-remunerated donors ............................................. 54
5.2.4.2 Safety of blood transfusion in developing countries ............................................ 55
6 INDUSTRY INSIGHTS ................................................................................................ 56

6.1 INDUSTRY TRENDS .......................................................................................................................56
6.1.1 NEW INDICATIONS FOR PLASMA PRODUCTS ................................................................... 56
6.1.2 INCREASING NUMBER OF COLLABORATIONS, AGREEMENTS,
AND PARTNERSHIPS ...................................................................................................... 57
6.2 PORTER’S FIVE FORCE ANALYSIS ..................................................................................................58
6.2.1 THREAT FROM NEW ENTRANTS ....................................................................................... 58
6.2.2 THREAT FROM SUBSTITUTES .......................................................................................... 59
6.2.3 BARGAINING POWER OF SUPPLIERS .............................................................................. 59
6.2.4 BARGAINING POWER OF BUYERS ................................................................................... 59
6.2.5 INTENSITY OF COMPETITIVE RIVALRY .............................................................................. 60
6.3 REGULATORY ANALYSIS ................................................................................................................60
6.3.1 NORTH AMERICA ............................................................................................................ 60
6.3.1.1 US .................................................................................................................... 60
6.3.1.2 Canada ............................................................................................................. 61
6.3.2 EUROPE ......................................................................................................................... 61
6.3.3 ASIA PACIFIC ................................................................................................................. 61
6.3.3.1 Japan ................................................................................................................ 61
6.3.3.2 China ................................................................................................................ 62
6.3.3.3 India ................................................................................................................. 63
7 APHERESIS MARKET, BY PRODUCT .......................................................................... 64

7.1 INTRODUCTION ............................................................................................................................65
7.2 APHERESIS DISPOSABLES ...........................................................................................................66
7.2.1 RECURRENT USE OF APHERESIS DISPOSABLES TO DRIVE
GROWTH IN THIS MARKET SEGMENT............................................................................... 66
7.3 APHERESIS DEVICES ....................................................................................................................67
4
7.3.1 CENTRIFUGAL APHERESIS DEVICES ................................................................................ 68

7.3.1.1 Increasing installation of centrifugal apheresis devices in hospitals
for therapeutic apheresis drives market growth .................................................. 68
7.3.2 MEMBRANE SEPARATORS.............................................................................................. 70
7.3.2.1 Difficulties in separating huge volumes of plasma from milliliters of
whole blood—a key factor limiting the adoption of these devices ......................... 70
8 APHERESIS MARKET, BY PROCEDURE ...................................................................... 73

8.1 INTRODUCTION ............................................................................................................................74
8.2 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS) ................................................................75
8.2.1 INCREASING NUMBER OF BLOOD COMPONENT DONATIONS
USING APHERESIS DEVICES TO SUPPORT MARKET GROWTH ........................................... 75
8.3 THERAPEUTIC APHERESIS ............................................................................................................76
8.3.1 THERAPEUTIC APHERESIS DISPOSABLES ....................................................................... 78
8.3.1.1 Neurological disorders....................................................................................... 80
8.3.1.1.1 Neurological disorders hold a major share in the
therapeutic apheresis disposables market ........................................... 80
8.3.1.2 Blood disorders ................................................................................................. 82
8.3.1.2.1 Increasing prevalence and incidence of hematologic and
genetic disorders will boost the demand for therapeutic
apheresis disposables......................................................................... 82
8.3.1.3 Renal disorders ................................................................................................. 83
8.3.1.3.1 Therapeutic plasma exchange is regarded as one of the
most useful treatment options for several renal disorders ..................... 83
8.3.1.4 Autoimmune disorders ...................................................................................... 84
8.3.1.4.1 With the introduction of novel and effective biologic agents
for the treatment of various autoimmune disorders,
therapeutic apheresis is indicated only in severe cases ........................ 84
8.3.1.5 Metabolic disorders .......................................................................................... 85
8.3.1.5.1 Increasing adoption of plasmapheresis for the treatment of
diabetes and other metabolic disorders drives the growth of
this segment ....................................................................................... 85
8.3.1.6 Cardiovascular disorders ................................................................................... 87
8.3.1.6.1 Low-density lipoprotein (LDL) apheresis is mainly used in
the treatment of cardiovascular disorders ............................................ 87
8.3.1.7 Other disorders ................................................................................................. 88
8.3.2 THERAPEUTIC APHERESIS DEVICES ................................................................................ 89
8.3.2.1 Centrifugation-based devices are one of the most commonly
adopted therapeutic apheresis devices .............................................................. 89
9 APHERESIS MARKET, BY TECHNOLOGY ..................................................................... 92

9.1 INTRODUCTION ............................................................................................................................93
9.2 CENTRIFUGATION .........................................................................................................................94
9.2.1 CONTINUOUS FLOW CENTRIFUGATION ............................................................................ 96
9.2.1.1 Continuous flow is preferred in both blood collection and therapeutic
apheresis procedures ........................................................................................ 96
5
9.2.2 INTERMITTENT FLOW CENTRIFUGATION........................................................................... 97

9.2.2.1 The need for a single venipuncture site is a major factor driving the
demand for intermittent flow centrifugation........................................................ 97
9.3 MEMBRANE SEPARATION .............................................................................................................98
9.3.1 HIGHER EFFICACY OF THIS TECHNOLOGY ACCOUNTS FOR ITS HIGH USAGE
IN DEVELOPED WESTERN EUROPEAN COUNTRIES AND JAPAN......................................... 98
10 APHERESIS MARKET, BY APPLICATION ................................................................... 101

10.1 INTRODUCTION ......................................................................................................................... 102
10.2 PLASMAPHERESIS .................................................................................................................... 102
10.2.1 PLASMAPHERESIS IS THE LARGEST APPLICATION SEGMENT
IN THE APHERESIS MARKET ..........................................................................................102
10.3 PLATELETPHERESIS ................................................................................................................... 105
10.3.1 INCREASING DEMAND FOR PLATELETS IN TRANSFUSIONS TO
DRIVE MARKET GROWTH ..............................................................................................105
10.4 ERYTHROCYTAPHERESIS............................................................................................................ 107
10.4.1 INCREASING DEMAND FOR RED BLOOD CELLS FOR TRANSFUSION IN
SURGICAL PROCEDURES TO DRIVE MARKET GROWTH...................................................107
10.5 LEUKAPHERESIS ....................................................................................................................... 108
10.5.1 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE
THE LEUKAPHERESIS MARKET ......................................................................................108
10.6 PHOTOPHERESIS ....................................................................................................................... 109
10.6.1 PHOTOPHERESIS IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING
THE FORECAST PERIOD ................................................................................................109
10.7 OTHER APPLICATIONS ............................................................................................................... 111
11 APHERESIS MARKET, BY END USER........................................................................ 112

11.1 INTRODUCTION ......................................................................................................................... 113
11.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS ............................................ 114
11.2.1 BLOOD COLLECTION CENTERS AND BLOOD COMPONENT PROVIDERS
HOLD A MAJOR SHARE OF THE APHERESIS MARKET ......................................................114
11.3 HOSPITALS AND TRANSFUSION CENTERS .................................................................................. 115
11.3.1 HOSPITALS AND TRANSFUSION CENTERS SEGMENT IS EXPECTED TO
GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD ......................................115
11.4 OTHER END USERS .................................................................................................................... 116
12 APHERESIS MARKET, BY REGION ........................................................................... 118

12.1 INTRODUCTION ......................................................................................................................... 119
12.2 NORTH AMERICA ....................................................................................................................... 120
12.2.1 US ...............................................................................................................................125
12.2.1.1 The US dominates the North American apheresis market ..................................125
12.2.2 CANADA.......................................................................................................................129
12.2.2.1 The demand for plasma protein products in Canada is on the rise,
which is a key factor driving market growth .......................................................129
12.3 EUROPE .................................................................................................................................... 133
6
12.3.1 GERMANY ....................................................................................................................139

12.3.1.1 Germany is the fastest-growing market for apheresis in Europe .........................139
12.3.2 FRANCE .......................................................................................................................143
12.3.2.1 Increasing need for blood components to drive the market for
apheresis in France .........................................................................................143
12.3.3 ITALY............................................................................................................................147
12.3.3.1 Therapeutic plasma exchange and LDL apheresis are widely adopted
therapeutic apheresis procedures, thereby driving market growth
in Italy .............................................................................................................147
12.3.4 UK ...............................................................................................................................150
12.3.4.1 Increasing demand for source plasma to cater to the growing
consumption of plasma-derived products (IVIG) driving apheresis
market growth in the UK...................................................................................150
12.3.5 SPAIN ..........................................................................................................................154
12.3.5.1 Growing demand for blood components and plasma-derived
products for the treatment of chronic diseases in the elderly is
a key factor driving market growth in Spain.......................................................154
12.3.6 REST OF EUROPE .........................................................................................................158
12.4 ASIA PACIFIC............................................................................................................................. 162
12.4.1 CHINA ..........................................................................................................................166
12.4.1.1 China accounts for the largest share of the APAC apheresis market ...................166
12.4.2 JAPAN ..........................................................................................................................170
12.4.2.1 Increasing demand for technologically advanced products drives
the market growth in Japan ..............................................................................170
12.4.3 INDIA ...........................................................................................................................173
12.4.3.1 In India, the increasing demand for blood components and growing
applications of plasma derivatives are major factors driving the
growth of the apheresis market ........................................................................173
12.4.4 REST OF ASIA PACIFIC ..................................................................................................177
12.5 LATIN AMERICA ......................................................................................................................... 181
12.5.1 BRAZIL .........................................................................................................................184
12.5.1.1 Brazil offers lucrative growth opportunities in the apheresis market
due to an increasing number of blood and plasma donations ............................184
12.5.2 MEXICO .......................................................................................................................188
12.5.2.1 Rapidly growing geriatric population is a key factor driving market
growth in Mexico .............................................................................................188
12.5.3 REST OF LATIN AMERICA ..............................................................................................191
12.6 MIDDLE EAST & AFRICA ............................................................................................................. 194
13 COMPETITIVE LANDSCAPE ..................................................................................... 199

13.1 OVERVIEW ................................................................................................................................. 199
13.2 MARKET SHARE ANALYSIS ......................................................................................................... 200
13.2.1 GLOBAL APHERESIS MARKET SHARE ANALYSIS ............................................................200
13.2.2 GLOBAL CENTRIFUGATION MARKET SHARE ANALYSIS ...................................................201
13.2.3 GLOBAL MEMBRANE SEPARATION MARKET SHARE ANALYSIS ......................................202
7
13.3 COMPETITIVE LEADERSHIP MAPPING ........................................................................................ 202

13.3.1 VISIONARY LEADERS ....................................................................................................203
13.3.2 INNOVATORS ...............................................................................................................203
13.3.3 DYNAMIC DIFFERENTIATORS ........................................................................................203
13.3.4 EMERGING COMPANIES ...............................................................................................203
13.4 COMPETITIVE SITUATION AND TRENDS....................................................................................... 204
13.4.1 PRODUCT LAUNCHES & APPROVALS ............................................................................204
13.4.2 EXPANSIONS ...............................................................................................................205
13.4.3 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS ...............................................206
13.4.4 ACQUISITIONS .............................................................................................................207
14 COMPANY PROFILES .............................................................................................. 208

14.1 TERUMO BCT, INC. .................................................................................................................... 208
14.1.1 BUSINESS OVERVIEW...................................................................................................208
14.1.2 PRODUCTS OFFERED ...................................................................................................209
14.1.3 RECENT DEVELOPMENTS..............................................................................................209
14.1.4 STRATEGIC OVERVIEW ..................................................................................................210
14.1.5 COMPETITIVE ANALYSIS ...............................................................................................210
14.2 FRESENIUS SE & CO. KGAA ....................................................................................................... 211
14.3 HAEMONETICS CORPORATION ................................................................................................... 215
14.4 BAXTER INTERNATIONAL INC...................................................................................................... 218
14.5 ASAHI KASEI MEDICAL CO. LTD. (A SUBSIDIARY OF ASAHI KASEI CORPORATION) ....................... 221
8
14.6 B. BRAUN MELSUNGEN AG ........................................................................................................ 224

14.6.4 MNM VIEW ...................................................................................................................225
14.7 CERUS CORPORATION ............................................................................................................... 226
14.7.4 MNM VIEW ...................................................................................................................228
14.8 KANEKA CORPORATION ............................................................................................................. 229
14.9 KAWASUMI LABORATORIES, INC. .............................................................................................. 231
14.10 NIKKISO CO., LTD. ..................................................................................................................... 233
14.11 MACOPHARMA SA ..................................................................................................................... 235
14.12 MILTENYI BIOTEC ....................................................................................................................... 236
14.13 OTSUKA HOLDINGS CO., LTD. .................................................................................................... 238
14.14 MEDICA SPA ............................................................................................................................. 239
14.15 MALLINCKRODT PLC.................................................................................................................. 240
14.16 MEDICAP CLINIC GMBH ............................................................................................................ 242
14.17 LMB TECHNOLOGIE GMBH......................................................................................................... 243
9
14.18 BIOELETTRONICA SRL ................................................................................................................ 244

14.19 INFOMED .................................................................................................................................. 245
14.20 CYTOSORBENTS CORPORATION ................................................................................................. 246
14.21 TORAY MEDICAL CO., LTD. ......................................................................................................... 249
15 APPENDIX .............................................................................................................. 250

15.1 INSIGHTS FROM INDUSTRY EXPERTS ......................................................................................... 250
15.2 DISCUSSION GUIDE .................................................................................................................. 251
15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL ...................................... 256
15.4 AVAILABLE CUSTOMIZATIONS .................................................................................................... 258
15.5 RELATED REPORTS .................................................................................................................... 258
15.6 AUTHOR DETAILS ....................................................................................................................... 259
10
LIST OF TABLES
TABLE 1 REQUIRED UNITS OF BLOOD AND BLOOD COMPONENTS, BY TYPE OF SURGERY 50

TABLE 2 US: PAYMENT RATES FOR APHERESIS PROCEDURES, 2016–2018 51
TABLE 3 ESTIMATED BLOOD DONATIONS BY WHO REGION, 2013 52
TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS 53
TABLE 5 APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 65
TABLE 6 APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 66
TABLE 7 APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 67
TABLE 8 APHERESIS DEVICES MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 68
TABLE 9 LIST OF CENTRIFUGAL APHERESIS DEVICES AVAILABLE IN THE MARKET 69
TABLE 10 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY,
2017–2025 (USD MILLION) 70
TABLE 11 LIST OF MEMBRANE SEPARATORS AVAILABLE IN THE MARKET 71
TABLE 12 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 72
TABLE 13 APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 74
TABLE 14 APHERESIS DEVICES USED FOR AUTOMATED BLOOD COLLECTION PROCEDURES 75
TABLE 15 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS) MARKET,
BY COUNTRY, 2017–2025 (USD MILLION) 76
TABLE 16 THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 77
TABLE 17 THERAPEUTIC APHERESIS MARKET BY COUNTRY, 2017–2025 (USD MILLION) 78
TABLE 18 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 79
TABLE 19 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY,
2017–2025 (USD MILLION) 80
TABLE 20 NEUROLOGICAL DISORDERS TREATED USING THERAPEUTIC APHERESIS 81
TABLE 21 NEUROLOGICAL DISORDERS: ESTIMATED DALYS, BY REGION, 2015 VS. 2030 81
TABLE 22 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR NEUROLOGICAL
DISORDERS, BY COUNTRY, 2017–2025 (USD MILLION) 82
TABLE 23 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR BLOOD DISORDERS,
TABLE 24 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR RENAL DISORDERS,
TABLE 25 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR AUTOIMMUNE
TABLE 26 METABOLIC DISORDERS: ESTIMATED DALYS BY REGION,
2015 VS. 2030 (THOUSANDS) 86
TABLE 27 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR METABOLIC DISORDERS,
TABLE 28 CARDIOVASCULAR DISORDERS: ESTIMATED DALYS BY REGION,
2015 VS. 2030 (THOUSANDS) 87
TABLE 29 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR CARDIOVASCULAR
TABLE 30 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR OTHER DISORDERS,
TABLE 31 KEY PRODUCTS AVAILABLE IN THE MARKET FOR THERAPEUTIC APHERESIS 90
11
TABLE 32 THERAPEUTIC APHERESIS DEVICES MARKET, BY COUNTRY,

2017–2025 (USD MILLION) 91
TABLE 33 CENTRIFUGATION VS. MEMBRANE SEPARATION 93
TABLE 34 APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 94
TABLE 35 CONTINUOUS FLOW CENTRIFUGATION VS. INTERMITTENT FLOW CENTRIFUGATION 94
TABLE 36 CENTRIFUGATION MARKET: KEY PLAYERS AND PRODUCTS 95
TABLE 37 CENTRIFUGATION MARKET, BY TYPE, 2017–2025 (USD MILLION) 95
TABLE 38 CENTRIFUGATION MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 96
TABLE 39 CONTINUOUS FLOW CENTRIFUGATION MARKET, BY COUNTRY,
2017–2025 (USD MILLION) 97
TABLE 40 INTERMITTENT FLOW CENTRIFUGATION MARKET, BY COUNTRY,
2017–2025 (USD MILLION) 98
TABLE 41 SIZE OF BLOOD COMPONENTS 99
TABLE 42 MEMBRANE SEPARATION MARKET: KEY PLAYERS AND PRODUCTS 99
TABLE 43 MEMBRANE SEPARATION MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 100
TABLE 44 APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 102
TABLE 45 TOTAL SOURCE PLASMA COLLECTION IN THE US & EUROPE,
2007–2017 (MILLION LITERS) 103
TABLE 46 KEY PRODUCTS AVAILABLE FOR PLASMAPHERESIS AND THERAPEUTIC
PLASMA EXCHANGE 104
TABLE 47 APHERESIS MARKET FOR PLASMAPHERESIS, BY COUNTRY,
2017–2025 (USD MILLION) 105
TABLE 48 KEY PRODUCTS AVAILABLE FOR PLATELETPHERESIS 106
TABLE 49 APHERESIS MARKET FOR PLATELETPHERESIS, BY COUNTRY,
2017–2025 (USD MILLION) 106
TABLE 50 KEY PRODUCTS AVAILABLE FOR ERYTHROCYTAPHERESIS 107
TABLE 51 APHERESIS MARKET FOR ERYTHROCYTAPHERESIS, BY COUNTRY,
2017–2025 (USD MILLION) 108
TABLE 52 KEY PRODUCTS AVAILABLE FOR LEUKAPHERESIS 109
TABLE 53 APHERESIS MARKET FOR LEUKAPHERESIS, BY COUNTRY,
2017–2025 (USD MILLION) 109
TABLE 54 KEY PRODUCTS AVAILABLE FOR PHOTOPHERESIS 110
TABLE 55 APHERESIS MARKET FOR PHOTOPHERESIS, BY COUNTRY,
2017–2025 (USD MILLION) 110
TABLE 56 KEY PRODUCTS AVAILABLE FOR OTHER APPLICATIONS OF APHERESIS 111
TABLE 57 APHERESIS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2017–2025 (USD MILLION) 111
TABLE 58 APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 113
TABLE 59 APHERESIS MARKET FOR BLOOD COLLECTION CENTERS AND BLOOD
COMPONENT PROVIDERS, BY COUNTRY, 2017–2025 (USD MILLION) 114
TABLE 60 NUMBER OF HOSPITALS PERFORMING BLOOD TRANSFUSIONS, BY REGION, 2015 115
TABLE 61 APHERESIS MARKET FOR HOSPITALS AND TRANSFUSION CENTERS,
TABLE 62 APHERESIS MARKET FOR OTHER END USERS, BY COUNTRY,
2017–2025 (USD MILLION) 117
TABLE 63 APHERESIS MARKET, BY REGION, 2017–2025 (USD MILLION) 120
TABLE 64 NORTH AMERICA: HEMOPHILIA PATIENTS, 2013 VS. 2017 121
TABLE 65 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 122
12
TABLE 66 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 122
TABLE 67 NORTH AMERICA: APHERESIS DEVICES MARKET, BY TYPE,
2017–2025 (USD MILLION) 122
TABLE 68 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE,
2017–2025 (USD MILLION) 122
TABLE 69 NORTH AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 123
TABLE 70 NORTH AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET,
BY DISEASE TYPE, 2017–2025 (USD MILLION) 123
TABLE 71 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY,
2017–2025 (USD MILLION) 123
TABLE 72 NORTH AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 124
TABLE 73 NORTH AMERICA: APHERESIS MARKET, BY APPLICATION,
2017–2025 (USD MILLION) 124
TABLE 74 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 124
TABLE 75 US: KEY MACROINDICATORS FOR THE APHERESIS MARKET 126
TABLE 76 US: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 126
TABLE 77 US: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 126
TABLE 78 US: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 126
TABLE 79 US: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 127
TABLE 80 US: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 127
TABLE 81 US: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 127
TABLE 82 US: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION) 128
TABLE 83 US: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 128
TABLE 84 US: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 128
TABLE 85 CANADA: KEY MACROINDICATORS FOR THE APHERESIS MARKET 130
TABLE 86 CANADA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 130
TABLE 87 CANADA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 130
TABLE 88 CANADA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 131
TABLE 89 CANADA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 131
TABLE 90 CANADA: THERAPEUTIC APHERESIS DISPOSABLES MARKET,
TABLE 91 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 132
TABLE 92 CANADA: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 132
TABLE 93 CANADA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 132
TABLE 94 CANADA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 133
TABLE 95 COLLECTIONS OF BLOOD COMPONENTS USING APHERESIS ACROSS
EUROPEAN COUNTRIES IN 2013 133
TABLE 96 EUROPE: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 136
TABLE 97 EUROPE: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 136
TABLE 98 EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 136
TABLE 99 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 137
TABLE 100 EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 137
13
TABLE 101 EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE

TYPES, 2017–2025 (USD MILLION) 137
TABLE 102 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 138
TABLE 103 EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 138
TABLE 104 EUROPE: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 138
TABLE 105 EUROPE: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 139
TABLE 106 INCREASING HEALTHCARE EXPENDITURE IN GERMANY,
2015–2017 (USD MILLION) 139
TABLE 107 GERMANY: KEY MACROINDICATORS FOR THE APHERESIS MARKET 140
TABLE 108 GERMANY: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 140
TABLE 109 GERMANY: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 140
TABLE 110 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 141
TABLE 111 GERMANY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 141
TABLE 112 GERMANY: THERAPEUTIC APHERESIS DISPOSABLES MARKET,
TABLE 113 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 142
TABLE 114 GERMANY: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 142
TABLE 115 GERMANY: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 142
TABLE 116 GERMANY: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 143
TABLE 117 FRANCE: KEY MACROINDICATORS FOR THE APHERESIS MARKET 144
TABLE 118 FRANCE: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 144
TABLE 119 FRANCE: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 144
TABLE 120 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 144
TABLE 121 FRANCE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT
2017–2025 (USD MILLION) 145
TABLE 122 FRANCE: THERAPEUTIC APHERESIS DISPOSABLES MARKET,
TABLE 123 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 145
TABLE 124 FRANCE: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 146
TABLE 125 FRANCE: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 146
TABLE 126 FRANCE: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 146
TABLE 127 ITALY: KEY MACROINDICATORS FOR THE APHERESIS MARKET 147
TABLE 128 ITALY: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 148
TABLE 129 ITALY: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 148
TABLE 130 ITALY: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 148
TABLE 131 ITALY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 148
TABLE 132 ITALY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 149
TABLE 133 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 149
TABLE 134 ITALY: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 149
TABLE 135 ITALY: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 150
14
TABLE 136 ITALY: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 150
TABLE 137 UK: KEY MACROINDICATORS FOR THE APHERESIS MARKET 151
TABLE 138 UK: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 151
TABLE 139 UK: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 151
TABLE 140 UK: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 152
TABLE 141 UK: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 152
TABLE 142 UK: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 152
TABLE 143 UK: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 153
TABLE 144 UK: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION) 153
TABLE 145 UK: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 153
TABLE 146 UK: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 154
TABLE 147 SPAIN: KEY MACROINDICATORS FOR THE APHERESIS MARKET 155
TABLE 148 SPAIN: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 155
TABLE 149 SPAIN: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 155
TABLE 150 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 156
TABLE 151 SPAIN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 156
TABLE 152 SPAIN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 156
TABLE 153 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 157
TABLE 154 SPAIN: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 157
TABLE 155 SPAIN: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 157
TABLE 156 SPAIN: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 158
TABLE 157 ROE: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 158
TABLE 158 ROE: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 159
TABLE 159 ROE: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 159
TABLE 160 ROE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 159
TABLE 161 ROE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 160
TABLE 162 ROE: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 160
TABLE 163 ROE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION) 160
TABLE 164 ROE: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 161
TABLE 165 ROE: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 161
TABLE 166 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 163
TABLE 167 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 163
TABLE 168 ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 163
TABLE 169 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 163
TABLE 170 ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 164
TABLE 171 ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE
TYPE, 2017–2025 (USD MILLION) 164
TABLE 172 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 164
15
TABLE 173 ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE,

2017–2025 (USD MILLION) 165
TABLE 174 ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 165
TABLE 175 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 165
TABLE 176 CHINA: KEY MACROINDICATORS FOR THE APHERESIS MARKET 167
TABLE 177 CHINA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 167
TABLE 178 CHINA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 167
TABLE 179 CHINA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 167
TABLE 180 CHINA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 168
TABLE 181 CHINA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 168
TABLE 182 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 168
TABLE 183 CHINA: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 169
TABLE 184 CHINA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 169
TABLE 185 CHINA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 169
TABLE 186 BLOOD DONATIONS IN JAPAN, BY TYPE OF DONATION, 2015 170
TABLE 187 JAPAN: KEY MACROINDICATORS FOR THE APHERESIS MARKET 170
TABLE 188 JAPAN: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 171
TABLE 189 JAPAN: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 171
TABLE 190 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 171
TABLE 191 JAPAN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 171
TABLE 192 JAPAN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 172
TABLE 193 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 172
TABLE 194 JAPAN: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 172
TABLE 195 JAPAN: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 173
TABLE 196 JAPAN: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 173
TABLE 197 INDIA: KEY MACROINDICATORS FOR THE APHERESIS MARKET 174
TABLE 198 INDIA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 174
TABLE 199 INDIA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 175
TABLE 200 INDIA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 175
TABLE 201 INDIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 175
TABLE 202 INDIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 176
TABLE 203 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 176
TABLE 204 INDIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 176
TABLE 205 INDIA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 177
TABLE 206 INDIA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 177
TABLE 207 ROAPAC: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 178
TABLE 208 ROAPAC: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 178
TABLE 209 ROAPAC: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 178
16
TABLE 210 ROAPAC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,

2017–2025 (USD MILLION) 178
TABLE 211 ROAPAC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 179
TABLE 212 ROAPAC: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 179
TABLE 213 ROAPAC: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 179
TABLE 214 ROAPAC: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 180
TABLE 215 ROAPAC: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 180
TABLE 216 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 181
TABLE 217 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 181
TABLE 218 LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE,
2017–2025 (USD MILLION) 182
TABLE 219 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE,
2017–2025 (USD MILLION) 182
TABLE 220 LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 182
TABLE 221 LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET,
TABLE 222 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY,
2017–2025 (USD MILLION) 183
TABLE 223 LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 183
TABLE 224 LATIN AMERICA: APHERESIS MARKET, BY APPLICATION,
2017–2025 (USD MILLION) 184
TABLE 225 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 184
TABLE 226 BRAZIL: KEY MACROINDICATORS FOR THE APHERESIS MARKET 185
TABLE 227 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 185
TABLE 228 BRAZIL: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 185
TABLE 229 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 186
TABLE 230 BRAZIL: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 186
TABLE 231 BRAZIL: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 186
TABLE 232 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 187
TABLE 233 BRAZIL: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 187
TABLE 234 BRAZIL: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 187
TABLE 235 BRAZIL: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 188
TABLE 236 MEXICO: KEY MACROINDICATORS FOR THE APHERESIS MARKET 188
TABLE 237 MEXICO: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 189
TABLE 238 MEXICO: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 189
TABLE 239 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 189
TABLE 240 MEXICO: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 189
TABLE 241 MEXICO: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 190
TABLE 242 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 190
17
TABLE 243 MEXICO: CENTRIFUGATION APHERESIS MARKET, BY TYPE,

2017–2025 (USD MILLION) 190
TABLE 244 MEXICO: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 191
TABLE 245 MEXICO: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 191
TABLE 246 ROLA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 191
TABLE 247 ROLA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 192
TABLE 248 ROLA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 192
TABLE 249 ROLA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 192
TABLE 250 ROLA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 193
TABLE 251 ROLA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 193
TABLE 252 ROLA: CENTRIFUGATION APHERESIS MARKET, BY TYPE,
2017–2025 (USD MILLION) 193
TABLE 253 ROLA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 194
TABLE 254 ROLA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 194
TABLE 255 MEA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 195
TABLE 256 MEA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 195
TABLE 257 MEA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 196
TABLE 258 MEA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,
2017–2025 (USD MILLION) 196
TABLE 259 MEA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2017–2025 (USD MILLION) 196
TABLE 260 MEA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 197
TABLE 261 MEA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION) 197
TABLE 262 MEA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 197
TABLE 263 MEA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 198
TABLE 264 PRODUCT LAUNCHES & APPROVALS (2017–2019) 205
TABLE 265 EXPANSIONS (2017–2019) 205
TABLE 266 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2017–2019) 206
TABLE 267 ACQUISITIONS (2017) 207
TABLE 268 OTHER STRATEGIES (2018–2019) 207
18
LIST OF FIGURES
FIGURE 1 APHERESIS MARKET 25

FIGURE 2 RESEARCH DESIGN 28
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 31
FIGURE 4 BOTTOM-UP APPROACH 33
FIGURE 5 TOP-UP APPROACH 33
FIGURE 6 DATA TRIANGULATION METHODOLOGY 34
FIGURE 7 APHERESIS MARKET, BY PRODUCT, 2019 VS. 2025 (USD MILLION) 36
FIGURE 8 APHERESIS DEVICES MARKET, BY TYPE, 2019 VS. 2025 (USD MILLION) 37
FIGURE 9 APHERESIS MARKET, BY PROCEDURE, 2019 VS. 2025 (USD MILLION) 37
FIGURE 10 THERAPEUTIC APHERESIS PROCEDURES MARKET, BY PRODUCT,
2019 VS. 2025 (USD MILLION) 38
FIGURE 11 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
2019 VS. 2025 (USD MILLION) 38
FIGURE 12 APHERESIS MARKET, BY TECHNOLOGY, 2019 VS. 2025 (USD MILLION) 39
FIGURE 13 CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2019 VS. 2025 (USD MILLION) 40
FIGURE 14 APHERESIS MARKET, BY APPLICATION, 2019 VS. 2025 (USD MILLION) 40
FIGURE 15 APHERESIS MARKET, BY END USER, 2019 VS. 2025 (USD MILLION) 41
FIGURE 16 GEOGRAPHIC SNAPSHOT: APHERESIS MARKET 42
FIGURE 17 RISING PREVALENCE OF DISEASES AND THE GROWING NUMBER OF
TRAUMA AND INJURY CASES TO DRIVE MARKET GROWTH 43
FIGURE 18 PLASMAPHERESIS ACCOUNTED FOR THE LARGEST SHARE OF THE
EUROPEAN APHERESIS MARKET IN 2018 44
FIGURE 19 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2018 45
FIGURE 20 APAC TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 46
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE
FORECAST PERIOD 46
FIGURE 22 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN THE US,
1995–2030 (MILLION INDIVIDUALS) 48
FIGURE 23 TYPE OF PLASMA PROCESSED WORLDWIDE, 1990–2014 (MILLION LITERS) 49
FIGURE 24 PORTER’S FIVE FORCES ANALYSIS (2018): APHERESIS MARKET 58
FIGURE 25 APHERESIS DISPOSABLES TO DOMINATE THE APHERESIS MARKET
DURING THE FORECAST PERIOD 65
FIGURE 26 AUTOMATED BLOOD COLLECTION ACCOUNTED FOR THE LARGEST SHARE
OF THE APHERESIS MARKET DURING THE FORECAST PERIOD 74
FIGURE 27 THERAPEUTIC APHERESIS DISPOSABLES TO DOMINATE THE THERAPEUTIC
APHERESIS MARKET DURING THE FORECAST PERIOD 77
FIGURE 28 NEUROLOGICAL DISORDERS TO ACCOUNT FOR THE LARGEST SHARE OF THE
THERAPEUTIC APHERESIS DISPOSABLES MARKET DURING THE FORECAST PERIOD 79
FIGURE 29 CENTRIFUGATION SEGMENT TO DOMINATE THE APHERESIS MARKET
DURING THE FORECAST PERIOD 93
FIGURE 30 BLOOD COLLECTION CENTERS AND BLOOD COMPONENT PROVIDERS SEGMENT
TO DOMINATE THE APHERESIS MARKET DURING THE FORECAST PERIOD 113
FIGURE 31 APHERESIS MARKET: GEOGRAPHIC SNAPSHOT (2018) 119
FIGURE 32 NORTH AMERICA: APHERESIS MARKET SNAPSHOT 121
19
FIGURE 33 EUROPE: APHERESIS MARKET SNAPSHOT 135

FIGURE 34 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT 162
FIGURE 35 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2017 TO 2019 199
FIGURE 36 GLOBAL APHERESIS MARKET SHARE, BY KEY PLAYER, 2018 200
FIGURE 37 GLOBAL CENTRIFUGATION MARKET SHARE, BY KEY PLAYER, 2018 201
FIGURE 38 GLOBAL MEMBRANE SEPARATION MARKET SHARE, BY KEY PLAYER, 2018 202
FIGURE 39 APHERESIS MARKET: COMPETITIVE LEADERSHIP MAPPING (2018) 204
FIGURE 40 TERUMO BCT, INC.: COMPANY SNAPSHOT (2018) 208
FIGURE 41 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2018) 211
FIGURE 42 FRESENIUS KABI: COMPANY SNAPSHOT (2018) 212
FIGURE 43 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2019) 215
FIGURE 44 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2018) 218
FIGURE 45 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2018) 221
FIGURE 46 B. BRAUN: COMPANY SNAPSHOT (2018) 224
FIGURE 47 CERUS CORPORATION: COMPANY SNAPSHOT (2018) 226
FIGURE 48 KANEKA CORPORATION: COMPANY SNAPSHOT (2019) 229
FIGURE 49 KAWASUMI LABORATORIES: COMPANY SNAPSHOT (2019) 231
FIGURE 50 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2018) 233
FIGURE 51 OTSUKA HOLDINGS COMPANY LIMITED: COMPANY SNAPSHOT (2018) 238
FIGURE 52 MALLINCKRODT PLC : COMPANY SNAPSHOT (2018) 240
FIGURE 53 CYTOSORBENTS CORPORATION: COMPANY SNAPSHOT (2018) 246
FIGURE 54 TORAY MEDICAL CO. LTD.: COMPANY SNAPSHOT (2019) 249
20
LIST OF ABBREVIATIONS
ABBREVIATIONS FULL FORM
AABB American Association of Blood Banks
AACR American Association of Cancer Research
AAI American Association of Immunologists
ACS American Cancer Society
AMD Age-related Macular Degeneration
APAC Asia Pacific
ASBP Armed Service Blood Program
ASCO American Society of Clinical Oncology
ASFA American Society for Apheresis
BBTS British Blood Transfusion Society
BS Blood System
CAG Canadian Apheresis Group
CAGR Compound Annual Growth Rate
CBER Center for Biologics Evaluation and Research
CBS Canadian Blood Services
CDC Centers for Disease Control and Prevention
CFDA China’s Food and Drug Administration
CFR Code of Federal Regulations
CHD Coronary Heart Disease
CIDP Chronic Inflammatory Demyelinating Polyneuropathy
CKD Chronic Kidney Disease
CMS Centers for Medicare & Medicaid Services
CPR Canadian Plasma Resources
CROs Contract Research Organizations
CTCL Cutaneous T-cell Lymphomas
CVD Cardiovascular Disease
DALYs Disability-adjusted Life Years
DCGI Drug Controller General of India
ECI Extracorporeal Immunoadsorption
ECV Extracorporeal Volume
21
EFS Établissement Français du Sang
EHA European Hematology Association
EIU Economist Intelligence Unit
EMA European Medicines Agency
EPP Erythropoietic Protoporphyria
ESFH European Society for Hemapheresis
EU European Union
GBS Guillain-Barré Syndrome
G-CSF Granulocyte Colony-stimulating Factor
GLP Good Laboratory Practice
GMP Good Manufacturing Practice
GVHD Graft-Versus-Host Disease
H.E.L.P. Heparin-induced Extracorporeal LDL Precipitation
HDN Hemorrhagic Disease of the Newborn
HUS Hemolytic Uremic Syndrome
IFC Intermittent Flow Centrifugation
IPAW International Plasma Awareness Week
ISBT International Society of Blood Transfusion
ISFA International Society for Apheresis
ISG Indian Society for Apheresis
IVIG Intravenous Immunoglobulin
JIS Japanese Industrial Standards
JRC Japan Red Cross
KSA Kingdom of Saudi Arabia
KSFA Korean Society for Apheresis
LDL Low-density Lipoprotein
LLS Leukemia and Lymphoma Society
MAH Marketing Authorization Holder
MAPC Multipotent Adult Progenitor Cell
MDD Medical Device Directive
MDEL Medical Device Establishment License
MDS Myelodysplastic Syndromes
22
MG Myasthenia Gravis
MNCs Mononuclear Cells
NCBI National Center for Biotechnology Information
NIH National Institutes of Health
NTC National Transfusiology Center
NYBC New York Blood Center
OECD Organisation for Economic Co-operation and Development
PCS Plasma Collection System
PHS Public Health Service
PLOS Public Library of Science
PNH Paroxysmal Nocturnal Hemoglobinuria
PPTA Plasma Protein Therapeutics Association
PRT Pathogen Reduction Technologies
RBCs Red Blood Cells
RCBs Registered Certification Bodies
RoAPAC Rest of Asia Pacific
ROE Rest of Europe
RoLA Rest of Latin America
SFDA State Food and Drug Administration
TMP Transmembrane Pressure
TPE Therapeutic Plasma Exchange
TTP Thrombotic Thrombocytopenic Purpura
UK United Kingdom
US United States of America
USD United States Dollar
WAA World Apheresis Association
WBCs White Blood Cells
WFH World Federation of Hemophilia
WHO World Health Organization
23
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY

 To define, describe, segment, and forecast the global apheresis market by product, technology,
procedure, application, end user, and region
 To provide detailed information about the factors influencing market growth (such as drivers,
restraints, opportunities, and challenges)
 To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions
to the overall apheresis market
 To analyze market opportunities for stakeholders and provide details of the competitive
landscape for key players
 To forecast the size of the apheresis market in five main regions along with their respective key
countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East
& Africa
 To profile key players in the global apheresis market and comprehensively analyze their core
competencies2 and market shares
 To track and analyze competitive developments such as acquisitions; expansions, partnerships,
agreements, and collaborations; and product launches and approvals
 To benchmark players within the apheresis market using the "Competitive Leadership Mapping"
framework, which analyzes market players on various parameters within the broad categories of
business and product strategy
1.2 MARKET DEFINITION AND SCOPE

Apheresis is a process in which the blood of a donor/patient is passed through a medical device that
separates one or more components of the blood and returns the remaining with/without extracorporeal
treatment or the replacement of the separated component. Apheresis includes devices and disposables
that leverage centrifugation & membrane separation/filtration technologies to separate blood components.
PRODUCT INCLUSIONS EXCLUSIONS
Only apheresis devices and

Apheresis Devices & Reagents such as coagulation agents, saline, and
disposables have been
Disposables apheresis systems/software have not been considered
considered
____________
1. Micromarkets are defined as the further segments and subsegments of the global apheresis market included in the report.
2. Core competencies of companies are captured in terms of the key developments carried out and strategies adopted by them to sustain their positions in the
market.
24
1.2.1 MARKETS COVERED

FIGURE 1 APHERESIS MARKET
NETWORK SECURITY
APHERESIS
FIREWALLMARKET
MARKET
BY PRODUCT BY TECHNOLOGY BY END USER

 Apheresis Disposables  Centrifugation  Blood Collection Centers
 Apheresis Devices • Continuous Flow and Blood Component
• Centrifugal Apheresis Centrifugation Providers
Devices • Intermittent Flow  Hospitals and Transfusion
• Membrane Separators Centrifugation Centers
 Membrane Separation  Other End Users
BY PROCEDURE BY APPLICATION BY REGION

 Automated Blood Collection  Plasmapheresis  North America
(Donor Apheresis)  Plateletpheresis (US and Canada)
 Therapeutic Apheresis  Erythrocytapheresis  Europe
• By Type  Leukapheresis (Germany, France, Italy,
 Therapeutic Apheresis Devices UK, Spain, and RoE)
 Photopheresis
 Therapeutic Apheresis  Asia Pacific
 Other Applications
Disposables (Japan, China, India,
 By Disease Type and RoAPAC)
o Neurological Disorders  Latin America
o Blood Disorders (Brazil, Mexico, and RoLA)
o Renal Disorders  Middle East & Africa
o Autoimmune Disorders
o Metabolic Disorders
o Cardiovascular Disorders
o Other Disorders
Note 1: Other disorders include rheumatic disorders, malaria, and hyperviscosity syndrome.
Note 2: Other applications include lipidpheresis, lymphapheresis, immunoadsorption, and stem cell collection.
Note 3: Other end users include emergency medical service providers, acute care centers, and medical & academic institutes.
25
1.2.2 YEARS CONSIDERED FOR THE STUDY

2025
2019
2018
2017
HISTORICAL YEAR BASE YEAR ESTIMATED YEAR PROJECTED YEAR
Note: For market estimates, the calendar year has been considered; whereas, for company profiles, the fiscal year has been
considered.
1.3 CURRENCY
 The currency used in the report is the United States Dollar (USD), with market sizes indicated in
USD million/billion.
 For companies reporting their revenue in USD, the revenues were directly picked from their
annual reports and SEC filings.
 For companies reporting their revenues in other currencies, the average annual currency
conversion rate was used for that particular year to convert the value to USD.
EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
CURRENCY 2016 2017 2018
EUR 1.10671 1.129856 1.181109
Yen 0.009251 0.009028 0.009021
Source: USForex
1.4 LIMITATIONS
 Some companies in this market are privately owned, and their revenues are not available in the
public domain. Hence, revenues for these companies are not included in this report.
 Company developments that are not reported in the public domain are not included in this
report.
 Differences between table totals and segmental market sizes, in some instances in the report,
are due to rounding-off of numbers.
26
1.5 STAKEHOLDERS
 Apheresis devices manufacturers and distributors
 Hospitals and transfusion centers
 Therapeutic apheresis service providers
 Blood banks and blood collection centers
 Plasma fractionation companies
 Healthcare providers
 Academic research institutes
 Pharmaceutical companies
 Contract research organizations (CROs)
 Market research & consulting firms
27
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH

This research study involved the extensive usage of both primary and secondary sources. It involved the
study of various factors affecting the industry to identify the segmentation types; industry trends; key
players; the competitive landscape of the apheresis market; and key market dynamics such as drivers,
opportunities, challenges, restraints, and key market player strategies.
The following illustrative figure shows the market research methodology applied in making this report.
FIGURE 2 RESEARCH DESIGN
HISTORICAL DATA MARKET SHARE INDUSTRY TRENDS

OF THE APHERESIS KEY PLAYERS
MARKET COMPETITIVE
RECENT DEVELOPMENTS
LANDSCAPE
DRIVERS: RESTRAINTS: OPPORTUNITIES:

 Rising prevalence of  High cost of apheresis  Apheresis for leukemia
chronic diseases and devices & therapeutic and pediatric patients
growing number of apheresis procedures  Emerging economies
trauma and injury cases and installation of with increasing
 Increasing demand for apheresis devices investments from
source plasma from through rental model government bodies and
INFLUENCING biopharmaceutical  Fewer blood donations leading players
FACTORS companies using apheresis due to
(Market Trends  Rising demand for blood lack of awareness
& Dynamics) components and growing  Stringent donor CHALLENGES:
concerns regarding blood recruitment criteria  Recruitment of
safety voluntary non-
 Increase in the number of remunerated donors
complex surgical  Blood transfusion
procedures safety in developing
 Favorable reimbursement countries
for apheresis procedures
FORECAST PERIOD CAGR MARKET SIZE

(2019–2025)
2.1.1 SECONDARY RESEARCH

This research study involved the widespread use of secondary sources; directories; databases such as Dun
& Bradstreet, Bloomberg Businessweek, and Factiva; white papers; annual reports; and companies’ house
documents. Secondary research was used to identify and collect information for this extensive, technical,
market-oriented, and commercial study of the global apheresis market. It was also used to obtain
important information about the top players, market classification, and segmentation according to industry
trends to the bottom-most level, geographic markets, and key developments related to the market, and
technology perspectives. A database of the key industry leaders was also prepared using secondary
research.
28
Some of the key secondary sources referred for this study include:
 American Society for Apheresis (ASFA)

 American Society of Hematology (ASH)
 International Society for Apheresis (ISFA)
 World Apheresis Association (WAA)
 European Society for Hemapheresis (ESFH)
 Canadian Apheresis Group (CAG)
 Turkish Society of Apheresis
 Organisation for Economic Co-operation and Development (OECD)
 World Health Organization (WHO)
 Annual Reports/SEC Filings, Investor Presentations, and Press Releases of Key Players
 White Papers, Journals/Magazines, and News Articles
2.1.1.1 Key data from secondary sources

PARAMETER SOURCE
 Journals, Websites, and Press Releases
 Paid Databases
 World Apheresis Association (WAA)
 American Society for Apheresis (ASFA)
 International Society for Apheresis (ISFA)
 European Society for Hemapheresis (ESFH)
MARKET SIZE  Canadian Apheresis Group (CAG)
 Indian Society for Apheresis (ISFA)
 Centers for Disease Control and Prevention (CDC)
 World Health Organization (WHO)
 Company Financials
 Magazines & Journals
 MarketsandMarkets Data Repository
 Annual Reports and SEC Filings

 Company Websites and Press Releases
COMPANY REVENUES
 Public and Paid Databases
 MarketsandMarkets Data Repository
 Paid Databases
 Company Websites
QUALITATIVE INFORMATION
 Journals Based on Research Tools
 Annual Reports
29
2.1.2 PRIMARY RESEARCH

In the primary research process, various sources from both the supply and demand sides were interviewed
to obtain qualitative and quantitative information for this report. Primary sources from the supply side
include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation
directors, and related key executives from various key companies and organizations operating in the
apheresis market. Primary sources from the demand side include directors and presidents of hospitals &
blood centers, apheresis nurses from hospitals and blood collection & transfusion centers, and
scientists/researchers from academic & research institutes.
Primary research was conducted to validate the market segmentation, identify key players in the market,
and gather insights on key industry trends and key market dynamics.
2.1.2.1 Key data from primary sources

TYPE PARAMETER DATA
 The apheresis market was valued at

 Global market size in 2019
GLOBAL USD 1.6–1.8 billion in 2019.
 CAGR for the forecast
MARKET SIZE  The apheresis market is expected to grow at a
period (2019-2025)
CAGR of 7.0–9.0% during the forecast period.
 In 2018, apheresis disposables accounted for the

largest share of the apheresis market, by product.
 In 2018, the centrifugation segment accounted for
the largest share of the apheresis market, by
Apheresis Market Split: technology.
 Product  In 2018, the automated blood collection (donor
 Technology apheresis) segment accounted for the largest share of
MARKET SPLIT the apheresis market, by procedure.
 Procedure
 Application  In 2018, the plasmapheresis segment accounted for
 End User the largest share of the apheresis market, by
application.
 In 2018, the blood centers and blood component
providers segment accounted for the largest share of
the apheresis market, by end user.
 Overall market and

 North America accounted for 40–50% of the global
subsegments in 2018
GEOGRAPHICAL apheresis market in 2018.
 CAGR of each region in the
SPLIT  The APAC market is expected to grow at the highest
forecast period
rate during the forecast period.
(2019–2025)
30
2.1.2.2 Breakdown of primaries

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
BY COMPANY TYPE BY DESIGNATION BY REGION
5%
25% 10%
35%
40% 40%
45%
25%
30%
25% 20%
Tier 1 C-level North America

Tier 2 Director-level Europe
Tier 3 Others* Asia Pacific
Latin America
Middle East & Africa
*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue. As of 2018, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1
billion, and Tier 3 = <USD 500 million.
2.2 MARKET SIZE ESTIMATION

The report presents a detailed assessment of the apheresis market, along with qualitative inputs and
insights from MarketsandMarkets. Both top-down and bottom-up approaches were used to anticipate and
validate the size of the global apheresis market and estimate the size of various submarkets.
Total Market Size: Global Apheresis Market

The total market size for the apheresis market was arrived at by using revenue share analysis of leading
players in the market.
Bottom-up Approach Using Revenue Share Analysis

 Revenues of individual companies were gathered from public sources and databases.
 Shares of apheresis businesses (devices and disposables) of leading players were gathered
from secondary sources. In certain cases, shares of apheresis businesses were ascertained
after a detailed analysis of various parameters, including product portfolios, market positioning,
and geographic reach.
 Individual shares or revenue estimates were validated through expert interviews.
Growth Forecast
The growth forecast model was defined on the basis of the assessment of qualitative and quantitative
factors affecting market growth. These mainly included:
 Historic revenue growth trends of leading players in the market

 Growth trends of markets, such as the medical devices and plasma fractionation markets
 Demand-side factor assessment, including rising whole blood and blood component donations,
growth in the number of therapeutic apheresis procedures, and increasing plasmapheresis
procedures
31
 Impact assessment of historic competitive trends driving market growth, such as the number of
product launches, FDA approvals, strategic growth initiatives, innovation trends, and R&D
initiatives
 Impact assessment of regulatory guidelines/mandates on market growth over the forecast
period. For this, only defined regulatory guidelines at the point of the study period have been
considered. The impact of any future regulatory uncertainties on market growth is not
accounted for
SEGMENT ASSESSMENT (BY PRODUCT, TECHNOLOGY, PROCEDURE, APPLICATION, AND END USER)
The geographic assessment was done using the following approaches:
Approach for Products: Splits for segments were derived by studying the usage and pricing of various product
segments considered in the study.
Approach for Technologies: Splits for segments were derived by studying the adoption pattern of various types
of products and related technologies for various applications considered in the study.
Approach for Procedures: Splits for segments were derived by studying the number of procedures conducted
by different end users considered in the study.
Approach for Applications: Segments for applications being used have been arrived at by studying the type of
applications being adopted by end users. This information was validated through primary interviews.
Similarly, the adoption of various procedures and products for each application segment was assessed to
arrive at the percentage splits.
Approach for End Users: Splits for segments were derived by studying the adoption pattern of products and
disposables by different end users in the apheresis market.
GEOGRAPHIC MARKET ASSESSMENT (BY REGION & COUNTRY)

The geographic assessment was done using the following approaches:
 APPROACH 1: Geographic revenue contributions/splits of leading players in the market

(wherever available) and respective growth trends
 APPROACH 2: Geographic adoption trends for individual product segments by end users and
growth prospects for each of the segments (assumptions and indicative estimates validated
from primary interviews)
32
At each point, the assumptions and approaches were validated through industry experts contacted during
the course of primary research. Considering the limitations of data availability from secondary research,
revenue estimates for individual companies (for the overall apheresis market and for geographic market
assessment) were ascertained on the basis of detailed analyses of their respective product offerings,
geographic reach/strength (direct or through distributors or suppliers), and shares of the leading players in
a particular region or country.
FIGURE 4 BOTTOM-UP APPROACH
Total market size (USD million)
Extrapolated the market to 100% to arrive at the total size of the apheresis market
Mapping the revenue, by company, to the extent it covers 85–90% of the market
Mapping the revenue generated by the apheresis businesses (devices and disposables),
by company
Generating a list of players operating in the apheresis market BOTTOM-UP

APPROACH
FIGURE 5 TOP-UP APPROACH
Total apheresis market (USD million)
Percentage splits for the subsegments of the apheresis market, TOP-DOWN

APPROACH
by product
Geographical uptake of the apheresis market, by product, technology, procedure,

application, and end user
Regional and country-wise market for each subsegment
33
2.3 DATA TRIANGULATION APPROACH

To complete the overall market engineering process and arrive at the exact statistics for all segments and
subsegments, data triangulation and market breakdown procedures were employed wherever applicable.
The following figure shows the market validation sources structure and the data triangulation methodology
implemented in the market engineering process for making this report.
FIGURE 6 DATA TRIANGULATION METHODOLOGY
PRIMARY SOURCES SECONDARY SOURCES
INTERVIEWS WITH Annual Reports, Company Financial

PERSONNEL FORM : Statements, Presentations,
Websites, and Press Releases
DEMAND SIDE
 Hospitals, Blood Banks. of Top Players; News Articles;

Transfusion Centers, and Journals; and Paid Databases
Blood Collection Centers
 Organisation for Economic
Cooperation and Development
MnM KNOW* (OECD)
 World Apheresis Association
(WAA)
INTERVIEWS WITH:  American Society for Apheresis
DATA (ASFA)
 CEOs PRIMARY TRIANGULATION  International Society for
 Presidents and Vice SOURCES Apheresis (ISFA)
SUPPLY SIDE
Presidents  European Society for

 Marketing Managers SECONDARY
SOURCES Hemapheresis (ESFH)
 Business Managers  Canadian Apheresis Group (CAG)
 Product Managers  Indian Society for Apheresis
 Other Apheresis Market- (ISFA)
related Personnel  Centers for Disease Control and
Prevention (CDC)
INFORMATION SOURCED  World Health Organization (WHO)
Market Size (2019) and Market

Key Players Opportunities/Challenges
Share (2018)
Influencing Factors Competitive Landscape Geographical Analysis
*MnM KNOW stands for MarketsandMarkets’ “Knowledge Asset Management” framework. In this context, it stands for the existing
market research knowledge repository of over 5,000 granular markets, our flagship competitive intelligence and market research
platform “Knowledge Store," subject-matter experts, and independent consultants. MnM KNOW acts as an independent source that
helps us validate information gathered from primary and secondary sources.
34
2.4 MARKET SHARE ESTIMATION

The market shares for leading players in the apheresis market were arrived at after a detailed assessment
of their product offerings, average pricing, and revenue generated from products in the apheresis market
by secondary data available through paid and unpaid sources. Due to data limitations, in certain cases, the
revenue share was arrived at after a detailed assessment of the product offerings of major companies and
their respective sales performance. At each point, this data was validated through primary interviews with
various industry experts.
2.4.1 ASSUMPTIONS FOR THE STUDY

INDICATOR MNM ASSUMPTION IMPACT
The year-on-year revenue growth of companies has been considered to

Market Growth Rate High
estimate the growth rate of the overall market.
Growth in R&D spending in the medical devices and apheresis industries

and the technological advancements in this market space are the key
Market Trends factors driving the growth of the apheresis market. Between January 2017 High
and December 2019, a number of companies launched new products in
the global market. Similar trends are expected during the forecast period.
A stable and moderate government spending pattern has been assumed

Healthcare Spending Medium
between 2019 and 2025.
Niche Market Where accurate data of the respective timeline was not available, data for
Medium
Segments certain niche market segments was calculated using the trend-line analysis.
The CAGR for the forecast period is assumed to be normalized, and the
Regional Economic
effects of inflation, recession, economic downturns, and unforeseen
and Regulatory Low
regulatory or policy changes during the forecast period and other factors
Factors
are not considered.
The political environment is assumed to remain stable between 2019 and

Global Political 2025 in the US and Mexico. Political scenarios, in general, are not
Low
Outlook considered for the analysis of the parent market and are not expected to
have a great impact on the market.
35
3 EXECUTIVE SUMMARY
Apheresis is a process in which the blood of a donor/patient is passed through a medical device that
separates one or more components of the blood and returns the remaining with/without extracorporeal
treatment or the replacement of the separated component. Over the years, various types of cell separators
have been developed that efficiently separate red blood cells, white blood cells, platelets, and plasma,
either continuously or on an intermittent basis.
The apheresis market is projected to reach USD 2,709.2 million by 2025 from USD 1,699.2 million in
2019, at a CAGR of 8.1% during the forecast period (2019–2025). Growth in the market is largely driven
by the rising prevalence of chronic diseases and the growing number of trauma and injury cases, the
increasing demand for source plasma from biopharmaceutical companies, the rising demand for blood
components and growing concerns regarding blood safety, the increase in the number of complex surgical
procedures, and the favorable reimbursement for apheresis procedures. However, the high cost of
apheresis machines, lack of awareness about apheresis procedures, and scarcity of qualified donors limit
market growth to a certain extent.
The extended applications of apheresis in leukemia and pediatric patients, coupled with rapid growth in
emerging markets, offer significant growth opportunities for leading players in the apheresis market.
However, the recruitment of voluntary non-remunerated donors and blood transfusion safety in developing
countries is a key challenge for leading players.
In this report, the apheresis market is segmented by product, technology, procedure, application, end user,
and region.
FIGURE 7 APHERESIS MARKET, BY PRODUCT, 2019 VS. 2025 (USD MILLION)

2,500.0
Market Size (USD Million)
2,000.0
1,500.0
1,000.0
500.0
0.0
Apheresis Disposables Apheresis Devices
2019 1,389.5 309.7
2025 2,284.1 425.1
CAGR 8.6% 5.4%
Source: World Apheresis Association (WAA), American Society for Apheresis (ASFA), Journal of Clinical Apheresis, World Federation of
Hemophilia (WFH), Transfusion and Apheresis Science, Centers for Disease Control and Prevention (CDC), World Health Organization
(WHO), National Institutes of Health (NIH), US Census Bureau, European Commission, Organisation for Economic Co-operation and
Development (OECD), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA), World Bank, Annual
Reports, Company Websites, Investor Presentations, SEC Filings, Press Releases, Expert Interviews, and MarketsandMarkets Analysis
On the basis of product, the apheresis market is segmented into apheresis devices and disposables. In
2018, the disposables segment accounted for the highest share of 81.3% of the apheresis market. This
segment is expected to reach USD 2,284.1 million by 2025 from USD 1,389.5 million in 2019, at a CAGR
of 8.6%. The large share and high growth in this market can be attributed to its recurrent use, increasing
blood donations using apheresis devices, increasing number of therapeutic apheresis procedures, and
favorable reimbursement policies for apheresis procedures.
36
FIGURE 8 APHERESIS DEVICES MARKET, BY TYPE, 2019 VS. 2025 (USD MILLION)
400.0
350.0
300.0
250.0
200.0
150.0
100.0
50.0
0.0
Centrifugal Apheresis Devices Membrane Separators
2019 239.6 70.2
2025 337.7 87.4
CAGR 5.9% 3.7%
On the basis of type, the apheresis devices market is segmented into centrifugal apheresis devices and
membrane separators. In 2018, the centrifugal apheresis devices segment accounted for the largest share
of 77.0% of the apheresis market. This segment is expected to reach USD 337.7 million by 2025 from USD
239.6 million in 2019, at a CAGR of 5.9%. This can be attributed to the advantages offered by
centrifugation over membrane separation, such as the higher efficiency of centrifugation and the ability to
separate all types of blood components.
FIGURE 9 APHERESIS MARKET, BY PROCEDURE, 2019 VS. 2025 (USD MILLION)

2,500.0
2,000.0
1,500.0
1,000.0
500.0
0.0
Automated Blood Collection (Donor Apheresis) Therapeutic Apheresis
2019 1,301.0 398.3
2025 2,046.8 662.4
CAGR 7.8% 8.8%
On the basis of procedure, the apheresis market is segmented into automated blood collection (donor
apheresis) and therapeutic apheresis. The automated blood collection (donor apheresis) segment
accounted for the largest share of 76.7% of the global apheresis market in 2018. This segment is
projected to reach USD 2,046.8 million by 2025 from USD 1,301.0 million in 2019, at a CAGR of 7.8%
during the forecast period. The large share of this segment can be attributed to the increasing number of
blood component donations using apheresis devices and the increasing demand for source plasma from
biopharmaceutical companies.
37
FIGURE 10 THERAPEUTIC APHERESIS PROCEDURES MARKET, BY PRODUCT,

2019 VS. 2025 (USD MILLION)
700.0
600.0
500.0
400.0
300.0
200.0
100.0
0.0
Therapeutic Apheresis Disposables Therapeutic Apheresis Devices
2019 362.0 36.3
2025 615.3 47.1
CAGR 9.2% 4.4%
By product type, the therapeutic apheresis procedures market is further segmented into therapeutic
apheresis disposables and devices. Therapeutic apheresis disposables held the largest share of 90.5% of
the global therapeutic apheresis procedures market in 2018. It is also the fastest-growing segment of the
therapeutic apheresis procedures market. The large share and high growth in this segment are mainly due
to the recurrent purchase of disposables for the treatment of various diseases such as neurological, blood,
and renal diseases.
FIGURE 11 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

300.0
250.0
200.0
150.0
100.0
50.0
0.0
Neurological Blood Renal Autoimmune Metabolic Cardiovascula Other
Disorders Disorders Disorders Disorders disorders r Disorders Disorders
2019 145.4 109.6 42.2 22.8 16.2 15.4 10.3
2025 257.5 180.9 71.9 39.4 25.4 25.0 15.3
CAGR 10.0% 8.7% 9.3% 9.5% 7.8% 8.4% 6.7%
38
By disease type, the therapeutic apheresis disposables market is further segmented into neurological
disorders, blood disorders, cardiovascular disorders, renal disorders, autoimmune disorders, metabolic
disorders, and other disorders (rheumatic disorders, malaria, and hyperviscosity syndrome). Of these,
neurological disorders held the largest share of 39.9% of the global therapeutic apheresis procedures
market in 2018. It is also the fastest-growing segment of the therapeutic apheresis procedures market.
The large share and high growth in this segment are mainly due to the increasing pool of patients with
neurological disorders and the optimum results associated with therapeutic apheresis procedures for the
treatment of neurological diseases such as GBS.
FIGURE 12 APHERESIS MARKET, BY TECHNOLOGY, 2019 VS. 2025 (USD MILLION)

2,500.0
2,000.0
1,500.0
1,000.0
500.0
0.0
Centrifugation Membrane Separation
2019 1,328.8 370.5
2025 2,216.0 493.2
CAGR 8.9% 4.9%
On the basis of technology, the apheresis market is divided into centrifugation and membrane separation.
The centrifugation technology segment accounted for the largest share of 77.6% of the apheresis market
in 2018. This segment is projected to reach USD 2,216.0 million by 2025 from USD 1,328.8 million in
2019, at a CAGR of 8.9% during the forecast period. The large share of this segment can be attributed to
the advantages offered by centrifugation over membrane separation, such as its high efficiency and its
ability to separate all types of blood components.
39
FIGURE 13 CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2019 VS. 2025 (USD MILLION)
1,600.0
1,400.0
1,200.0
1,000.0
800.0
600.0
400.0
200.0
0.0
Continuous Flow Centrifugation Intermittent Flow Centrifugation
2019 836.5 492.3
2025 1,456.9 759.1
CAGR 9.7% 7.5%
On the basis of centrifugation technology, the apheresis market is divided into continuous flow
centrifugation and intermittent flow centrifugation technologies. The continuous flow centrifugation
segment accounted for the largest share of 62.5% of the apheresis market in 2018. This segment is
projected to reach USD 1,456.9 million by 2025 from USD 836.5 million in 2019, at a CAGR of 9.7%
during the forecast period. The continuous flow process is preferred in both blood collection and
therapeutic apheresis. In therapeutic apheresis, this technology is commonly used since it only needs a
small amount of ECV and is associated with a shorter procedural time and a relatively low volume of
anticoagulants. These factors are advantageous for both children and the elderly. Due to its advantages,
the demand for continuous flow apheresis products among hospitals and blood collection centers is on the
rise. This is expected to drive the growth of this segment during the forecast period.
FIGURE 14 APHERESIS MARKET, BY APPLICATION, 2019 VS. 2025 (USD MILLION)

1,400.0
1,200.0
1,000.0
800.0
600.0
400.0
200.0
0.0
Plasmapheresis Plateletpheresis Erythrocytapheresis Leukapheresis Photopheresis Other Applications
2019 790.9 565.6 236.8 52.4 22.2 31.3
2025 1,301.1 876.4 360.5 84.4 36.8 50.0
CAGR 8.6% 7.6% 7.3% 8.3% 8.7% 8.1%
40
Based on application, the global apheresis market is segmented into plasmapheresis, plateletpheresis,
erythrocytapheresis, leukapheresis, photopheresis, and other applications (lipidpheresis, lymphapheresis,
and immunoadsorption). The plasmapheresis segment accounted for the largest share of 46.3% of the
global apheresis market in 2018. The large share of this segment can be attributed to the high adoption of
plasmapheresis in the treatment of various neurological, immunological, and renal diseases and the high
and growing demand for plasma and its components among pharmaceutical and biopharmaceutical
companies.
The photopheresis segment is estimated to grow at the highest CAGR during the forecast period. This
segment is projected to reach USD 36.8 million by 2025 from USD 22.2 million in 2019, at a CAGR of 8.7%
during the forecast period. The growth of this market is driven by the increasing prevalence of blood
disorders and the rising demand for photopheresis in organ transplant rejection treatment.
FIGURE 15 APHERESIS MARKET, BY END USER, 2019 VS. 2025 (USD MILLION)
2,100.0
1,800.0
1,500.0
1,200.0
900.0
600.0
300.0
0.0
Blood Collection Centers and Hospitals and Transfusion
Other End Users
Blood Component Providers Centers
2019 1,141.6 473.9 83.8
2025 1,766.2 820.6 122.4
CAGR 7.5% 9.6% 6.5%
On the basis of end users, the market is segmented into blood collection centers and blood component
providers, hospitals and transfusion centers, and other end users. In 2018, collection centers and blood
component providers accounted for the largest share of 67.5% of the apheresis market. This segment is
expected to reach USD 1,766.2 million by 2025 from USD 1,141.6 million in 2019, at a CAGR of 7.5%. The
large share of this end-user segment is mainly due to the rising number of blood component donations, a
growing number of blood centers, and increasing awareness.
However, the hospitals and transfusion centers segment is estimated to grow at the highest CAGR of 9.6%
during the forecast period. The high growth of this segment can be attributed to the increasing adoption of
therapeutic apheresis in the treatment of various diseases, growing indications of therapeutic apheresis,
and rising awareness of apheresis as a therapy.
41
FIGURE 16 GEOGRAPHIC SNAPSHOT: APHERESIS MARKET
EUROPE
27.1%
NORTH AMERICA 7.1%
45.4% ASIA PACIFIC
7.6%
21.4%
10.0%
MIDDLE EAST & AFRICA

2.6%
LATIN AMERICA 7.7%
3.5%
9.1%
MARKET SHARE (2018) CAGR (2019–2025)
In 2018, North America accounted for the largest share of 45.4% of the apheresis market, followed by
Europe (27.1%), Asia Pacific (21.4%), Latin America (3.5%), and the Middle East & Africa (2.6%). The
market in North America is characterized by the easy accessibility to advanced technologies, the presence
of a large number of leading apheresis companies in this region, and an established healthcare
infrastructure.
The Asia Pacific market is expected to register the highest regional CAGR of 10.0% during the forecast
period owing to its large population and rising healthcare needs. Growth in this region can be attributed to
the rapid growth in the geriatric population, improving healthcare infrastructure, increasing per capita
income of the middle-class population in the region, rising focus of key market players on emerging APAC
countries, and the increasing accessibility to a range of products with leading players entering these
lucrative geographical regions.
The global apheresis market is consolidated, with the top players being Terumo BCT, Inc. (US), Fresenius
SE & Co. KGaA (Germany), and Haemonetics Corporation (US). These three players accounted for a
combined market share of 71.4% in 2018. The other prominent players in the global apheresis market
include Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc.
(US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso
Co., Ltd. (Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Otsuka Holdings Co. Ltd. (Japan),
Medica S.p.A. (Italy), Mallinckrodt plc (UK), Medicap Clinic GmbH (Germany), Lmb Technologies GmbH
(Germany), Bioelettronica (Italy), Infomed (Switzerland), Cytosorbents Corporation (US), and Toray Medical
Co. Ltd. (Japan). These companies adopted strategies such as acquisitions; partnerships, agreements, and
collaborations; expansions; and product launches & approvals to increase their presence in the apheresis
market.
42
4 PREMIUM INSIGHTS
4.1 APHERESIS MARKET OVERVIEW

FIGURE 17 RISING PREVALENCE OF DISEASES AND THE GROWING NUMBER OF TRAUMA
AND INJURY CASES TO DRIVE MARKET GROWTH
CAGR
8.1%
 The apheresis market is projected to reach USD 2,709.2 million by 2025, at
a CAGR of 8.1% during the forecast period.
 Market growth can be attributed to the rising prevalence of chronic diseases

and the growing number of trauma and injury cases, increasing demand for
USD USD source plasma from biopharmaceutical companies, rising demand for blood
1,699.2 2,709.2 components, and favorable reimbursement policies for apheresis
procedures.
Million Million
 Emerging countries such as India and China are expected to offer significant
growth opportunities for players operating in the apheresis market.
2019 2025
43
4.2 EUROPE: APHERESIS MARKET, BY APPLICATION

FIGURE 18 PLASMAPHERESIS ACCOUNTED FOR THE LARGEST SHARE OF THE EUROPEAN
APHERESIS MARKET IN 2018
EUROPE: APHERESIS MARKET, 2018

= USD 428.1 MILLION
BY APPLICATION BY COUNTRY
PLASMAPHERESIS GERMANY
46.2% 26.1%
PLATELETPHERESIS FRANCE
33.3% 19.3%
ERYTHROCYTAPHERESIS ITALY
14.1% 14.6%
LEUKAPHERESIS UK
3.0% 12.4%
PHOTOPHERESIS SPAIN
1.5% 7.0%
Note 1: Other applications are not included in this diagram. Hence, the market shares of the application segments do not sum up to
100%.
Note 2: The Rest of Europe is not included in this diagram. Hence, the market shares of the country segments do not sum up to
100%.
44
4.3 GEOGRAPHIC SNAPSHOT OF THE APHERESIS MARKET (2018)

FIGURE 19 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2018
Canada UK 7.1%
6.9%
8.4% Germany
France 8.2%
US 7.8% China 12.0%
Spain 5.8% Italy 8.8% Japan
11.1%
9.0%
India
Mexico 7.7%
9.5% Middle East &
Africa
Brazil
CAGR (2019–2025) <7.0% CAGR 7.0–9% CAGR >9% CAGR
45
4.4 GEOGRAPHIC MIX: APHERESIS MARKET,

2019–2025 (USD MILLION)
FIGURE 20 APAC TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
CAGR
(2019–2025)
3,000
7.7%
2,500 9.1%
8.1%
CAGR 10.0%
2,000
1,500
7.1%
1,000
500 7.6%
0
2017 2018 2019 2020 2021 2022 2023 2024 2025
North America Europe APAC Latin America Middle East & Africa
4.5 APHERESIS MARKET: DEVELOPING VS. DEVELOPED MARKETS,

FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING
THE FORECAST PERIOD
DEVELOPING COUNTRIES DEVELOPED COUNTRIES
1,200.0
1,000.0
800.0
600.0
400.0
200.0
0.0
China India Brazil US Germany UK
2019 123.7 38.1 24.6 668.2 120.9 56.6
2025 243.9 71.8 42.4 1,045.6 195.7 85.4
CAGR 12.0% 11.1% 9.5% 7.8% 8.4% 7.1%
46
5 MARKET OVERVIEW
5.1 INTRODUCTION
The global apheresis market is projected to reach USD 2,709.2 million by 2025 from an estimated USD
1,699.2 million in 2019, at a CAGR of 8.1% during the forecast period. Growth in the apheresis market is
largely driven by the rising prevalence of chronic diseases and the growing number of trauma and injury
cases, the increasing demand for source plasma from biopharmaceutical companies, the rising demand
for blood components and growing concerns regarding blood safety, the increase in the number of complex
surgical procedures, and the favorable reimbursement for apheresis procedures.
On the other hand, the high cost of apheresis devices & therapeutic apheresis procedures and installation
of apheresis devices through the rental model, fewer blood donations using apheresis due to lack of
awareness, and the stringent donor recruitment criteria are expected to limit market growth to a certain
extent in the coming years.
5.2 MARKET DYNAMICS: IMPACT ANALYSIS

IMPACT
MARKET
FACTOR
DYNAMICS 2–3 Years 3–5 Years 5–10 Years
Rising prevalence of chronic diseases and growing

High High High
number of trauma and injury cases
Increasing demand for source plasma from

Medium Medium Low
biopharmaceutical companies
Drivers Rising demand for blood components and growing

High High High
concerns regarding blood safety
Increase in the number of complex surgical

High High High
procedures
Favorable reimbursement for apheresis procedures High High Medium
High cost of apheresis devices & therapeutic

apheresis procedures and installation of apheresis High High Medium
devices through rental model
Restraints
Fewer blood donations using apheresis due to lack
High High Medium
of awareness
Stringent donor recruitment criteria High High High
Apheresis for leukemia and pediatric patients High High Medium

Opportunities
Emerging economies with increasing investments
High High High
from government bodies and leading players
Recruitment of voluntary non-remunerated donors High Medium Medium

Challenges
Blood transfusion safety in developing countries High Medium Medium
Source: Secondary Literature, Expert Interviews, and MarketsandMarkets Analysis
47
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of chronic diseases and growing number
of trauma and injury cases
Urbanization, changing lifestyles, and changing food habits have led to an increase in the number of
chronic diseases, such as cardiovascular disease (CVD), neurological disorders, diabetes, renal disorders,
and digestive diseases. Listed below are some of the major statistics related to these diseases:
 According to the Global Burden of Disease Study (published in 2017), CVD was a major cause of
death in 2016 and is expected to remain a leading cause until 2040.
 Globally, there were an estimated 422.7 million prevalent cases of CVD in 2015, and this
number is expected to increase (Source: NCBI).
 According to the American Heart Association, the prevalence of CVD in the US increased from
36.9% in 2010 to 38.7% by 2020 and is further expected to increase to 40.5% by 2030.
 According to the American Hospital Association, in 2015, approximately 149 million individuals
in the US suffered from at least one chronic illness, such as hypertension, heart disease, and
arthritis. By 2030, this number is expected to reach 171 million.
 The incidence of deaths caused by diabetes is increasing year-on-year. In 1990, diabetes
ranked as the ninth-leading leading cause of death, while in 2017, it was ranked as the fourth-
leading cause of death (Source: Global Burden of Diseases Study, published in 2017).
The growing prevalence of these diseases has driven the demand for accurate treatment in several
countries across the globe. As surgical interventions are effective treatment options in severe or
complicated cases, the increasing prevalence of chronic diseases is expected to increase the number of
surgical procedures performed annually. This will, in turn, drive the demand for blood transfusions and
positively impact the apheresis blood collection market.
FIGURE 22 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN THE US,

1995–2030 (MILLION INDIVIDUALS)
200
171
Number of Patients with Chronic
164
157
160 149
141
Diseases (Million)
133
125
118
120
80
40
0
1995 2000 2005 2010 2015 2020 2025 2030
Source: American Hospital Association (AHA)
48
The number of trauma and injury cases is also on the rise due to the growing number of road accidents,
fire incidents, and sports injuries, as well as the rapidly increasing aging population (the elderly are more
prone to falls and orthopedic injuries). In 2015, the National Trauma Institute estimated that severe
bleeding accounts for more than 35% of pre-hospital deaths and nearly 40% of trauma-related deaths
within the first 24 hours of injury, across the world. In most cases, blood transfusions are essential for the
treatment of severe trauma or injuries. Thus, the increasing incidence of trauma and injuries is expected to
create a greater demand for blood and, in turn, drive the demand for apheresis procedures.
5.2.1.2 Increasing demand for source plasma from bi opharmaceutical

companies
Source plasma is collected from healthy, voluntary donors through a process called plasmapheresis.
Biopharmaceutical companies produce plasma-derived products from collected raw plasma using
fractionation technology. Plasma-derived products, such as intravenous immunoglobulin (IVIG), albumin,
and factor VIII, are used for the treatment of various diseases such as hemophilia A and B, Von Willebrand
Disease, and other bleeding diseases.
In order to meet the growing demand for plasma-derived products, biopharmaceutical companies have
increased their processing/fractionation capacities in the past decade. According to the Plasma Protein
Therapeutics Association, globally, the volume of source plasma (collected through the plasmapheresis
procedure) processed by biopharmaceutical companies increased from 16.3 million liters in 2004 to 36.2
million liters in 2014. With the growing demand for source plasma in biopharmaceutical companies, the
adoption of plasmapheresis procedures is also expected to increase across the globe.
FIGURE 23 TYPE OF PLASMA PROCESSED WORLDWIDE, 1990–2014 (MILLION LITERS)

40.0 36.2
33.6
35.0
30.0 27.9
25.6
Million Liters
25.0
17.6 18.6 18.2
20.0 16.3
14.9
15.0 12.8
9.8
10.0
5.0 8.5 8.5 8.2 7.8 8.1 8.9 9.0 8.7
6.6 6.9 7.4
0.0
1990 1993 1996 1999 2002 2004 2007 2010 2012 2013 2014
Source Plasma Recovered Plasma
Source: Plasma Protein Therapeutics Association (PPTA)
5.2.1.3 Rising demand for blood components and growing concerns

regarding blood safety
The global demand for blood and blood components is on the rise. In the US alone, approximately 44,000
units of blood are required every day in hospitals and emergency treatment facilities for the treatment of
patients suffering from accident/trauma-related injuries, cancer, and other diseases.
Around 21 million units of blood components are transfused in the US every year; whereas, only 13.6
million units of whole blood and red blood cells are collected yearly in the country. This deficit in the
demand and supply can be met with the collection of blood components using the apheresis process. With
an efficient and automated apheresis process, physicians or blood banks can collect more units of any one
blood component during the collection process. Moreover, the frequency of blood donations allowed for
49
apheresis donors is higher in comparison to whole blood donors. Considering these advantages, the
apheresis process can help in addressing the issue of blood component shortages and be instrumental in
saving lives across the globe.
The automated apheresis process also reduces patient risks and enhances blood safety by reducing the
exposure to multiple donors for meeting their total blood requirements. Moreover, the hematocrit and
hemoglobin content of red cells collected through apheresis is much more consistent than that collected
after the processing of whole blood. Thus, the growing demand for blood and blood components, coupled
with the growing concerns regarding blood safety, is expected to contribute to the growth of the apheresis
market during the forecast period.
5.2.1.4 Increase in the number of complex surgical procedures

Over the years, the importance of blood components in treating certain diseases or conditions has been
recognized. Additionally, a huge volume of blood and its components are required to manage major blood
loss occurring due to hemorrhages from trauma or surgery.
Various chronic diseases, such as diabetes, kidney disorders, and respiratory diseases, have an associated
risk of organ failure in affected patients. Such critical cases of organ failure require organ transplant
surgeries. The number of such surgeries is expected to increase in the coming years as a result of the
growth in the prevalence of chronic diseases. This, in turn, is estimated to increase the demand for blood
and blood components during the forecast period.
TABLE 1 REQUIRED UNITS OF BLOOD AND BLOOD COMPONENTS, BY TYPE OF SURGERY
TYPE OF SURGERY/CONDITION REQUIRED UNITS OF BLOOD AND BLOOD COMPONENTS
Liver Transplant 6–10 units of red blood cells, 20 units of plasma, and 10 units of platelets
Kidney Transplant 1–2 units of red blood cells
Heart Transplant 2–6 units of red blood cells
Adult Open-heart Surgery 2–6 units of red blood cells, 2–4 units of plasma, and 1–10 units of platelets
Newborn Open-heart Surgery 1–4 units of red blood cells, 1–2 units of plasma, and 1–4 units of platelets
Prostate Cancer Surgery 2–4 units of red blood cells
Abdominal Aortic Aneurysm 4–6 units of red blood cells
1–2 units of red blood cells every other day for 2–4 weeks, and 6–8 units of
Bone Marrow Transplant
platelets daily for 4–6 weeks
Automobile Accident 4–40 units of red blood cells
Leukemia 2–6 units of red blood cells, and 6–8 units of platelets daily for 2–4 weeks
Sickle-cell Disease 10–15 units of red blood cells to treat severe complications
Premature Newborns 1–4 units of red blood cells while in intensive care
Source: The Lewin Group, Inc. cited Jeffrey McCullough, M.D., Center for Molecular and Cellular Therapy, University of Minnesota
50
5.2.1.5 Favorable reimbursement for apheresis procedures

Reimbursement policies governing apheresis procedures are quite favorable in developed countries such
as the US, Germany, Italy, and Japan. This is a major factor driving the growth of the apheresis market.
Insurance companies and governments are reforming these policies every year and increasing the
reimbursement cost for therapeutic apheresis procedures. According to the Centers for Medicare &
Medicaid Services (CMS) and American Society for Apheresis (ASFA), the reimbursement for various
apheresis procedures and devices was expected to increase by 5–7% in 2018 in many countries across
the globe. For example, the reimbursement for the apheresis of WBCs was proposed to be increased to
USD 1,222 in 2018 from USD 1,047.76 in 2016.
Reforms in reimbursement policies have further had a positive impact on the adoption of therapeutic
apheresis procedures in the treatment of various diseases, such as neurological diseases and
cardiovascular diseases. This is one of the major factors driving the demand and sales of apheresis
devices and related disposables.
TABLE 2 US: PAYMENT RATES FOR APHERESIS PROCEDURES, 2016–2018
HCPCS CODE DETAILS 2016 PAYMENT 2017 PAYMENT PROPOSED 2018 PAYMENT
36511 Apheresis WBC USD 1,047.76 USD 1,098.22 USD 1,222
36512 Apheresis RBC USD 1,047.76 USD 1,098.22 USD 1,222
36514 Apheresis Plasma USD 1,047.76 USD 1,098.22 USD 1,222
36515 Apheresis Adsorption/Reinfuse USD 3,015.06 USD 3,186.48 USD 3,700
36516 Apheresis Selective USD 3,015.06 USD 3,186.48 USD 3,700
36522 Photopheresis USD 3,015.06 USD 3,186.48 USD 3,700
Source: Centers for Medicare & Medicaid Services (CMS)
5.2.2 RESTRAINTS
5.2.2.1 High cost of apheresis devices & therapeutic apheresis
procedures and installation of apheresis devices
through rental model
The cost of apheresis devices is a critical factor in determining the adoption of apheresis by healthcare
providers and, ultimately, by patients. Apheresis devices are used by blood banks for blood component
collection, while hospitals use these devices for therapeutic apheresis procedures.
For blood banks, capital investments in apheresis collection are significantly higher in comparison to that
of whole blood collection. The average price of apheresis devices ranges from USD 20,000 to USD
150,000, which is just the initial investment for setting up the devices (Source: WHO). The cost of
disposable sets produced by manufacturers varies between USD 100 and USD 200 per procedure. Also,
replacement fluids (at an average volume of 2.8 liters), such as albumin or fresh frozen plasma, cost
around USD 125 to USD 600 per procedure. Considering these high costs, smaller blood banks and
hospitals with controlled budgets do not opt for this type of blood collection procedure. The high cost of
apheresis devices and disposables also increases the overall cost of apheresis procedures. For instance,
in the US, the cost of an apheresis procedure is ~USD 2,500 per treatment. Patients might not opt for
these procedures owing to their high cost.
51
A majority of the small and medium-sized hospitals in emerging countries, such as Brazil and India, avail
apheresis devices on the rental model. With this model, hospitals directly pay rent and the cost of
disposables per procedure to manufacturing companies, annually. The rent is decided based on the
number of procedures carried out by hospitals. Hospitals significantly reduce major capital investments
with the adoption of this model. In India, approximately 60% of apheresis devices are installed on a rental
basis by hospitals, and the rest are purchased by government hospitals and large hospitals. Owing to this,
most end users opt for procuring these devices through the rental mode instead of buying them. This
affects market growth to a certain extent.
5.2.2.2 Fewer blood donations using apheresis due to lack of awareness

The growth of the global apheresis market is largely challenged by the low awareness of apheresis
procedures among donors. In developed countries across North America and Europe, a higher number of
apheresis procedures are performed per year as compared to developing countries. In 2013, in high-
income countries, 21% of all donations were collected through apheresis, compared to 4% in upper-middle-
income countries, and 0.4% in lower-middle-income countries. The awareness about apheresis and donor
acceptance towards this process is still relatively lower in these countries as compared to the blood
donation process. As a general perception, many blood donors in developing countries believe that blood
donation through apheresis may lead to weakness and other diseases as the remaining blood is re-infused
to the donor after the collection of one or more blood components.
TABLE 3 ESTIMATED BLOOD DONATIONS BY WHO REGION, 2013
REGION ESTIMATED WHOLE-BLOOD DONATIONS (MILLION) ESTIMATED APHERESIS DONATIONS (MILLION)
Africa 5.6 0.03
Americas 20.4 2.0
Eastern Mediterranean 9.9 0.04
Europe 26.5 6.1
Southeast Africa 16.6 0.06
Western Pacific 21.3 3.7
Global (Rounded Total) 100.6 11.9
Source: Global Status Report on Blood Safety and Availability, Published in 2016 by WHO
Stakeholders such as several players in the apheresis market, blood collection centers, healthcare
organizations, and several NGOs have undertaken a number of initiatives and awareness campaigns to
educate people regarding the safety of apheresis and its importance. For instance, the Plasma Protein
Therapeutics Association (PPTA) and its member companies organized an International Plasma Awareness
Week (IPAW), held in October 2016, to spread awareness about the importance of plasma donation. Even
though such awareness campaigns are being conducted in various countries, the awareness of apheresis
is still low among prospective donors, and this is expected to affect market growth during the forecast
period.
52
5.2.2.3 Stringent donor recruitment criteria

Red Cross societies across the globe have issued certain guidelines and eligibility requirements for blood
donors to ensure the safety of blood donation for both donors and recipients. These requirements include
the ideal donor age, general health considerations, medical conditions, medical treatments, medications,
vaccinations, and lifestyle & life events, in addition to choices such as tattoos and piercings. The most
important eligibility criteria for donating leukocytes is human leukocyte antigen (HLA) typing. HLAs are
proteins and markers present in most cells. The human immune system uses these markers to distinguish
between its own cells and foreign ones. As a result, HLA typing is typically performed during collection to
ensure specificity and easy identification of leukocytes.
Owing to the above-mentioned stringent criteria, very few people qualify for blood component donation.
Furthermore, only a very small segment of this regularly donates blood. This scarcity of qualified, willing
blood donors is expected to restrict the growth of the apheresis market in the coming years.
TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS
BLOOD COMPONENT INTERVAL BETWEEN DONATIONS
Men: 56 Days
Whole Blood
Women: 84 Days
Plasma (by Apheresis) 6 Days
RBCs (by Apheresis) Double Donation: 112 Days
Platelets (by Apheresis) 14 Days
WBCs (by Apheresis) 10 Days
Source: Hema-Quebec
5.2.3 OPPORTUNITIES
5.2.3.1 Apheresis for leukemia and pediatric patients
The growing adoption of therapeutic apheresis for the treatment of various diseases is expected to offer
potential growth opportunities to market players in the coming years. Currently, the use of apheresis
products in leukemia therapeutics is low; however, it presents a huge opportunity in the near future.
According to the National Cancer Institute, in 2015, 405,815 people were suffering from leukemia in the
US, and the number of new cases of leukemia has increased on an average rate of 0.3% each year over
the last 10 years (from 2006 to 2015). The availability of effective treatment options (including
leukapheresis) has reduced the mortality rate of leukemia by 1.5% each year between 2006 and 2015.
Leukapheresis is mainly a supportive procedure in the case of hyperleukocytic leukemia and performed
prior to chemotherapy or radiotherapy. A single leukapheresis procedure can reduce the leukocyte count by
10–70%; a minimum of two to three procedures may be required to effectively minimize excessive
leukocytes. The use of apheresis procedures in pediatric patients is also very low. However, blood
component transfusions for pediatric patients are on the rise, primarily due to the growing success of
therapeutic apheresis in pediatric patients. Moreover, the growing applications of therapeutic apheresis in
autoimmune diseases, refractory chronic graft-versus-host disease (GVHD), lupus erythematosus,
hyperlipidemia, and atherosclerosis is also expected to offer growth opportunities to players operating in
the apheresis market.
53
5.2.3.2 Emerging economies with increasing investments from

government bodies and leading players
Emerging markets in the Asia Pacific (India and China) and Latin America (Brazil and Mexico) are expected
to offer significant growth opportunities for market players in the coming years. This can be attributed to
the rising prevalence of chronic diseases, improving healthcare infrastructure (as a result of the increasing
healthcare expenditure by respective governments), and the rising investments by leading players in
emerging countries. To address the increasing demand for better healthcare services, governments in
these countries are making significant investments for the modernization of their respective healthcare
infrastructures. Such investments are one of the major contributors to the growth of the apheresis market
in emerging economies. In November 2015, the government of China introduced the 13th five-year plan
(FYP) for the period of 2016 to 2020. Under this plan, the government aims to administer changes in areas
of healthcare services, healthcare insurance, and medications by mobilizing more medical resources to
rural areas, promoting the training of general practitioners, and developing telemedicine to address the
urban-rural gap in accessing healthcare. The plan also aims to construct a national basic insurance
network to expand catastrophic illness insurance coverage. Such initiatives are expected to strengthen the
country’s healthcare infrastructure, which will significantly improve the accessibility to quality healthcare in
the coming years.
Recently, many leading players in the apheresis market have made significant investments in emerging
markets.
 In April 2018, B. Braun opened five new medical production facilities in Penang, Malaysia. This
development helped the company increase its production of medical devices, including
apheresis devices and disposables.
 In 2015, Haemonetics Corporation (US) expanded its manufacturing unit in Malaysia.
 In July 2014, Terumo BCT (US) opened a manufacturing facility near Ho Chi Minh City, Vietnam.
This enabled the company to strengthen its presence in the APAC region.
Such investments by leading players and respective government bodies in emerging economies are
expected to create potential growth opportunities for market players in the coming years.
5.2.4 CHALLENGES
5.2.4.1 Recruitment of voluntary non-remunerated donors
The collection of blood and blood components only from voluntary, non-remunerated blood donors is an
important measure for ensuring the safety, quality, availability, and accessibility of blood for transfusion.
However, there is a severe shortage of safe blood and blood products in many countries, owing to which
blood transfusion is not available for a significant proportion of the patient population. To ensure the
supply of whole blood and its components for treatment, it is essential to create awareness among people
and encourage them to voluntarily donate blood.
Many government authorities and healthcare organizations are encouraging the establishment of blood
services based on full voluntary non-remunerated blood donations. According to the World Health
Organization, in 2016, only 62 countries got close to 100% of their national blood supply from voluntary
unpaid blood donations, with 34 countries still dependent on family donors and even paid donors for more
than 75% of their blood supply. In order to increase the number of voluntary non-remunerated blood
donors, in June 2016, the World Blood Donor Day was celebrated in the Netherlands to increase the
number of safe, voluntary, unpaid donors who give blood regularly. Similarly, in January 2017, the Ministry
of Health proposed a law that all Vietnamese citizens aged between 18 and 60 years have to make a blood
donation at least once every year.
54
However, the demand for blood and its components exceeds its supply, and blood services face the
challenge of making sufficient blood available. Some countries such as the US and Italy have donor
compensation practices available through which donors get compensation in various forms, such as movie
tickets, gift cards, and a paid day off at work after blood or plasma donation. However, the blood collected
only through voluntary donation cannot fulfill the requirement of producing life-saving therapies.
5.2.4.2 Safety of blood transfusion in developing countries

Blood transfusions have associated risks of transmission of infectious agents, such as HIV, HBV, HCV, and
malaria. Infection through the blood supply is a major issue, especially in developing countries, such as
India, China, Brazil, and Argentina, where economic constraints often limit safety considerations during
blood transfusion procedures.
Testing blood for HIV and hepatitis B viruses is an integral part of the blood transfusion process across the
globe; the necessity of this step is more pronounced in developing countries where the burden of these
diseases is higher. Even though authorities in various developing countries are currently ensuring blood
testing, it has been observed that between 8 and 16 million hepatitis B virus infections, 2 to 5 million
hepatitis C infections, and between 80 and 160,000 HIV infections are caused by unsafe blood
transfusions each year. In countries with greater malaria transmission, more than 30% of the blood donors
can carry malarial parasites, which can be transmitted by transfusion. Thus, ensuring blood safety is a
major challenge faced by blood and blood component suppliers in developing countries.
55
6 INDUSTRY INSIGHTS
6.1 INDUSTRY TRENDS

The growth in the apheresis market is mainly driven by the severity of blood shortage, growing concerns
regarding blood safety, increasing incidence and prevalence of various diseases, and rapid growth in the
aging population. Additionally, the increasing number of surgical procedures and emergency treatment
cases in hospitals across the world are also driving the overall growth of the apheresis market.
The apheresis industry is highly competitive, with the top five players accounting for a share of ~85–90%
of the market in 2018. The key players operating in this market have adopted various growth strategies
such as product launches, agreements, partnerships, and collaborations to enter new markets, develop
new applications, and expand their presence in emerging markets.
6.1.1 NEW INDICATIONS FOR PLASMA PRODUCTS

Plasma products are first-line therapies for a number of bleeding, hematological, and neurological
diseases. Moreover, the use of plasma products is still being evaluated for many diseases. The initial
results of such clinical trials have shown positive feedback indicating the successful application of plasma
products for new therapeutic conditions. From a manufacturer’s perspective, developing a new drug using
a plasma product is highly cost-intensive and, hence, manufacturers find it more feasible to study the
applications of existing products for new therapeutic indications.
Currently, intravenous immunoglobulin (IVIg) is being evaluated for a number of indications in clinical trials.
The use of IVIg is widely being studied for the treatment of Alzheimer’s, recurrent miscarriages, and chronic
regional pain syndrome. Other major therapeutic conditions where IVIg products have applications include
Guillain-Barré syndrome, polymyositis, dermatomyositis, multifocal motor neuropathy, stiff person
syndrome, relapsing-remitting multiple sclerosis, and pemphigus. However, these are not FDA-approved
indications of IVIg. Albumin is also used in the treatment of various liver diseases. The use of albumin for
new indications is mainly associated with its antioxidant activity and the effect of capillary integration.
Alpha-1-antitrypsin, a protease inhibitor, is also being evaluated across the globe in controlled clinical trials
for new indications such as type 1 and type 2 diabetes, acute myocardial infarction, graft-versus-host
disease, and cystic fibrosis. It has potential applications in other conditions such as stroke, vasculitis, and
organ and cell transplantation.
The increasing applications of plasma products for new indications are expected to result in an increase in
the demand for source plasma, which, in turn, increases the demand for apheresis. This surge, along with
the increasing uptake of plasma products across the globe, provides the potential for key players operating
in the apheresis market.
56
6.1.2 INCREASING NUMBER OF COLLABORATIONS, AGREEMENTS,

AND PARTNERSHIPS
The growth in the apheresis market is primarily driven by the growing incidence of chronic diseases such
as cancer, blood disorders, cardiovascular diseases & obesity, and the resultant increase in the number of
related surgical procedures. The growing demand for plasma from biopharmaceutical companies is also
contributing to the growth of the apheresis market.
Considering the steady growth in the market, key players are continuously focusing on increasing their
market shares through various growth strategies. Between 2016 and 2019, agreements, partnerships,
and collaborations were the key strategies adopted by a majority of the leading players to increase their
competitiveness and sustain their positions in the global apheresis market. These inorganic growth
strategies with similar or niche players have enabled these companies to combine their proprietary
technologies in order to create strong platforms for future growth by seeking opportunities in untapped
markets. Moreover, through agreements, market players also focus on geographic expansions, thus
strengthening their customer bases in high-growth emerging markets. Such strategic initiatives enable
companies to ensure long-term revenue growth in order to compete in the market.
Some of the recent agreements, partnerships, and collaborations in the apheresis market are listed below:
 In August 2019, Cerus Corporation entered into a distribution agreement with Kedrion
Biopharma (Italy) to distribute Cerus’s INTERCEPT blood system portfolio, including platelets,
plasma, and red blood cells in Italy. This will help Cerus to increase its market presence in
southern Europe.
 In August 2019, Terumo BCT provided a three-year grant to Abrale (Associação Brasileira de
Linfoma e Leucemia or the Brazilian Association of Lymphoma and Leukemia), a
nongovernmental organization working to democratize treatment and improve the quality of life
for patients with blood cancer in Brazil. With this funding activity, Terumo will increase its
presence in the Brazilian apheresis market.
 In August 2019, Cytosorbents Corporation (US) signed a distribution partnership with Fresenius
Medical Care (Germany) to distribute CytoSorb for acute care and other hospital applications in
Korea and Mexico.
 In February 2019, Mallinckrodt plc (UK) announced a research collaboration with Transimmune
AG (Germany) to further expand the understanding of the underlying mechanism of action for
extracorporeal photopheresis, and its application toward the development of potential next-
generation photopheresis technology, with plans to expand on Mallinckrodt's current Therakos
photopheresis platform through new clinical trials.
 In October 2018, Terumo BCT collaborated with UniCAR-Therapy Bio-Medicine Technology Co.
(China) to conduct research on CAR T-cell Therapies and Create a Center of Excellence in
Shanghai, China.
 In October 2017, Cerus Corporation entered into an agreement with Centro de Transfusión de
la Comunidad de Madrid (CTCM) to supply the INTERCEPT Blood System for platelets in Spain.
 In March 2017, Cytosorbents Corporation (US) signed a distribution partnership with Dr.
Reddy’s Laboratories (India).
57
6.2 PORTER’S FIVE FORCE ANALYSIS

The competitive environment prevailing in the apheresis market can be analyzed through Porter’s five
forces analysis framework.
FIGURE 24 PORTER’S FIVE FORCES ANALYSIS (2018): APHERESIS MARKET
THREAT FROM
SUBSTITUTES
(LOW)
BARGAINING POWER RIVALRY AMONG BARGAINING

OF SUPPLIERS EXISTING COMPETITORS POWER OF BUYERS
(MODERATE) (HIGH) (MODERATE)
THREAT FROM
NEW ENTRANTS
(LOW)
6.2.1 THREAT FROM NEW ENTRANTS

The threat from new entrants in the apheresis market is low, based on the following factors:
High Capital Requirement

Apheresis products are technology-intensive and require significant R&D investments from players that are
focused on entering this market. Existing market players strive to keep their product portfolios innovative
and unique, with investments focused on product development. In order to ensure profitable returns in this
highly competitive market, new players need to offer innovative products at low prices. This challenge
restricts the entry of new players in the apheresis market.
High Preference for Well-established Brands (Products) Provided by Existing Players

The apheresis market is marked by the presence of global players offering well-established brands. The
products offered by these players have been studied well and have previously been tested for their
performance. Owing to this, hospitals and blood centers across the world prefer branded products over
new ones. This creates an entry barrier for new players in the market.
58
The leading players in the apheresis market follow price bundling as a major strategy. This makes it
economical for end users to use apheresis machines from a dedicated provider. This strategy has played a
key role in defining the preferences of medical professionals for products from a given provider. Unless the
product offered by a new player is exceptional, hospitals and medical professionals will continue to opt for
products offered by existing players.
6.2.2 THREAT FROM SUBSTITUTES

The threat from substitutes in the apheresis market is low, based on the following factors:
Lack of Substitute Products

There are very few substitutes for apheresis products. In the blood collection industry, whole blood
collection acts as a substitute to apheresis blood collection; however, this does not separate blood
components and hence cannot threaten the apheresis industry. There are a few therapies that act as
substitutes to therapeutic apheresis, but they are not as effective as apheresis. Thus, the lack of high-
performing similar alternatives to existing apheresis products in this market reduces the threat of
substitutes.
6.2.3 BARGAINING POWER OF SUPPLIERS

The overall bargaining power of suppliers in the apheresis market is moderate, based on the following
factors:
Presence of a Large Number of Raw Material Suppliers

Apheresis products require raw materials that have certain specifications, due to which major players
prefer raw materials from specific vendors. Owing to this, the bargaining power of suppliers is moderate in
the apheresis market.
Supplier Switching Cost

Manufacturers can choose from a large number of raw material suppliers available in the apheresis
industry. These suppliers offer similar types of products with minute variations; therefore, manufacturers
can afford to switch to a product from a different company as brand loyalty is not a major concern. Owing
to such factors, the supplier switching cost is low to medium.
6.2.4 BARGAINING POWER OF BUYERS

In this market, the bargaining power of buyers is moderate, based on the following factors:
Few Companies Offering Premium Products at the Global Level

In the apheresis market, a limited number of players offer high-quality apheresis machines. This limits the
choice of products for buyers, which include hospitals, medical professionals, and blood centers, thereby
lowering their bargaining power. Moreover, hospitals prefer high-quality products that comply with the
standards set by regulatory authorities. This increases the switching cost for hospitals, which, in turn,
reduces their bargaining power against apheresis device manufacturers.
The growing environmental awareness and stringent safety standards at hospitals are further expected to
provide greater leverage to leading apheresis device manufacturers that offer high-quality products in the
market. This further lowers the bargaining power of buyers.
59
6.2.5 INTENSITY OF COMPETITIVE RIVALRY

The global apheresis market is marked by high competitive intensity, based on the following factors:
Increasing Demand for High-quality and Innovative Products

With increasing applications of apheresis products, the demand for high-quality and innovative products
from hospitals and blood centers is increasing. Companies are consistently focusing on R&D activities to
introduce technologically advanced and innovative products to cater to this increasing demand. As a result
of this, there is intense competitive rivalry among existing market players.
Lucrative Growth Potential in Emerging Markets

The apheresis market in the emerging Asia Pacific region is expected to grow at a higher rate in
comparison to other regions in the coming years. Due to this growth potential, vendors offering products in
these markets have greater opportunities. Existing players are focusing on expanding their presence in
these markets in order to capture the growth opportunities in the region. Thus, the lucrative growth
potential of the market triggers the entry of new players, which increases the intensity of competitive
rivalry.
6.3 REGULATORY ANALYSIS
6.3.1 NORTH AMERICA

6.3.1.1 US
The US Food and Drug Administration regulates the approval and marketing authorization of medical
devices in the US. Similar to other medical devices, apheresis devices are subject to premarket and post-
market approvals in the US. Apheresis blood collection and therapeutic apheresis devices are classified by
the FDA as Class II or III devices, depending on the technology used, such as centrifugation or filtration.
Devices that separate blood cells from the plasma through the filtration technology are classified as Class
III devices and have extensive regulations imposed by the FDA.
The 510(k) approval presents device manufacturers with two new optional approaches for obtaining
marketing clearance. These are as follows:
 Special 510(k) option for manufacturers who modify their legally marketed device
 Abbreviated 510(k) option when a guidance document exists, a special control has been
established, or the FDA has recognized a relevant consensus standard
The FDA approves apheresis blood collection devices intended for the collection of certain blood
components only. The intended uses of these devices include their use in the collection of single units of
red blood cells and plasma; single units of red blood cells and platelets; single units of red blood cells,
platelets, and plasma; or double units of red blood cells only.
Other proposed uses and other collection protocols of apheresis devices are evaluated by the Center for
Biologics Evaluation and Research (CBER).
60
6.3.1.2 Canada
In Canada, medical device manufacturers have to first register and obtain a license from Health Canada to
market their apheresis devices in the country. Under its jurisdiction, Health Canada has established a four-
tiered, risk-based classification system (Class I, II, III, and IV) for various apheresis products.
Class I apheresis manufacturers can sell their products directly to customers rather than through
distributors, after product approval. Manufacturers supplying their devices through distributors are
classified as Class II, III, and IV medical device manufacturers. In this case, distributors need to secure a
Medical Device Establishment License (MDEL). However, manufacturers of Class II, III, and IV apheresis
devices must comply with the ISO 13485 standard for quality management systems and need to ensure
compliance with the additional quality system requirements of the Canadian Medical Device Regulations
(CMDR).
6.3.2 EUROPE
The Medical Device Directive (93/42/EEC) regulates apheresis devices in Europe. In this region, medical
devices are not subject to premarket authorization by a regulatory body but need to go through a
conformity assessment process. This process is administered by the Medical Device Directive (MDD), a
European directive that details the pathway needed for a manufacturer to obtain CE Marking on devices,
which is a requirement for every medical device sold in Europe.
The European Union classifies medical devices into five major categories—Class I, IIa, IIb, and III devices.
These devices are classified on the basis of risk to patients. The risk classes for apheresis products (by
MDD) are as follows:
 Adsorption columns with material from animal origin: Class III

 Adsorption columns based on synthetic materials (such as dextran sulfate): Class IIb
 Plasma separation filters and plasma fraction filters: Class IIb
 Apheresis instruments: Class IIb
 Tube lines: Class IIa
According to the EU, apheresis devices are classified under Class III medical devices. These are regarded
as high-risk devices that control the circulatory system. Typically, the approval of Class III devices takes
nearly 6 to 9 months after the submission of a CE Marking application. Once approved, the CE Marking
certificate for these devices is valid for three years.
6.3.3 ASIA PACIFIC

6.3.3.1 Japan
Japan is one of the largest markets for medical devices across the globe. Imports account for a substantial
share of the medical devices market in the country. All healthcare products imported or marketed in the
country are regulated under the Japanese Pharmaceutical Affairs Law (PAL). As of November 2015, the
Japanese Pharmaceutical Affairs Law (PAL) has been revised, with its title changed to “Act on Securing
Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy
Products, Gene Therapy Products, and Cosmetics” (PMD Act).
In Japan, apheresis instruments are classified as orphan medical devices. Typically, less than 50,000
patients require these devices. Orphan medical devices are subjected to priority review and longer
reexamination periods (4 to 7 years) (Article 14(7) and 14-4(1) of PAL).
61
Japan’s medical device classification system is based on the Japanese Medical Device Nomenclature
codes, which differ from the classification schemes used in the US or the European Union. As of April
2005, third-party registered certification bodies (RCBs) are permitted to evaluate Class II devices and
conduct marketing certification required to sell medical devices in Japan legally. In order to be certified,
medical devices must demonstrate compliance with specified Japanese Industrial Standards (JIS), which
define product safety and performance requirements. RCBs are also permitted to evaluate Class III medical
devices and provide marketing certification services. In order to be certified, Class III medical devices must
demonstrate compliance with essential requirements, which have been harmonized to the Global
Harmonization Task Force (GHTF) documentation. Substantial equivalency to similar medical devices that
are already legally marketed in Japan is also required.
Manufacturers based outside Japan are required to appoint a marketing authorization holder (MAH), a
company based in Japan that is the legally responsible party for certified medical devices. The MAH and
registered manufacturing sites must establish and implement quality management systems based on the
Japanese QMS ordinance. In addition, companies must register their manufacturing sites located outside
of Japan and obtain a manufacturer registration from the PDMA, if the site performs either design or
development of medical devices or production and sterilization of medical devices.
6.3.3.2 China
In China, medical device manufacturers need to register their devices with China’s Food and Drug
Administration (CFDA), formerly known as the State Food and Drug Administration (SFDA). Although CFDA
guidelines have many similarities with registration requirements in the US and the European Union, it has
some important deviations from classification schemes in other countries.
The CFDA classifies medical devices into three categories based on their particular risk potential:
 Class I: For these medical devices, safety and effectiveness are confirmed through routine
supervision of these devices.
 Class II: These medical devices require device-specific details such as performance standards,
post-market surveillance, patient registries, special labeling requirements, and premarket data
requirements to ensure their safety and effectiveness.
 Class III: These devices are either implanted into the human body or used for life support or
sustenance, or pose potential risks to the human body, and thus must be strictly controlled with
respect to safety and effectiveness.
Apheresis devices are reviewed under Classes II and III. Class II and Class III medical device manufacturers
are also required to confirm that the country of origin has approved the device with documents such as CE
certificates, 510(k) letters, and PMA approvals, as well as compliance with ISO 13485; they may also be
required to submit clinical data in support of their application. In addition to these requirements, all
medical device manufacturers must include product information in the Chinese language on all packaging
and labeling, as detailed in SFDA Order No. 10.
The registration certificate from the CFDA is valid for a period of four years, post which, the holder of the
certificate shall apply for re-registration within six months before the certificate expires. In August 2014,
the CFDA issued a revised version of the guidance for the technical evaluation of disposable devices for
apheresis use. The new draft specifies that disposable devices for apheresis use are inactive medical
devices which are used together with active devices such as blood cell separators, blood collection
instrument, and automatic blood separators. Disposable devices listed in this new regulation include
disposable hemostix for machine use, disposable blood component separation pipelines, disposable
plasma separators, and disposable blood cell separators.
62
One of the key changes in the new draft is that registration applicants are required to provide an additional
copy of chronological post-market surveillance (PMS) reports. Imported medical devices registered in the
CFDA for the first time need to provide all existing PMS records and incident reports outside China, while
manufacturers of products that are already marketed in China need to provide those records both in China
and in other countries for future registration renewal.
6.3.3.3 India
The Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945, are the major laws that
regulate pharmaceuticals, medical devices, and diagnostic products in India. The Ministry of Health &
Family Welfare, through the Drug Controller General of India (DGCI), is the highest authority responsible for
the safety and improvement of public health by monitoring and regulating the quality, safety, and efficacy
of drugs & devices thorough examinations and investigations.
In order to improve the standards of blood and its components, the Indian government, through the DGCI,
has formulated comprehensive legislation to ensure better quality control systems on the collection,
storage, testing, and distribution of blood and its components. The existing requirements of blood banks
are regularly amended under the Drugs & Cosmetics Act, 1940, to meet the latest standards for blood and
its components collection. Consequent to a public litigation case, the Supreme Court of India directed the
government to enact comprehensive legislation on blood banks in the collection, storage, testing, and
distribution of blood and its components.
India is one of the larger medical device markets in Asia. Manufacturers intending to register their medical
devices in India must supply evidence of prior regulatory authorization in the US, Canada, Europe,
Australia, or Japan, as well as proof of approval in their home market. For apheresis licensing, blood banks
are required to seek special permission showing the equipment, space, and staff available for apheresis.
The Drugs and Cosmetic Act mentions only plateletpheresis, plasmapheresis, and leukapheresis on
donors, whereas it is the products, that is, single-donor (apheresis) platelets (SDP), plasma, and leukocytes
(granulocytes/mononuclear cells) that need licensing and not procedures.
63
7 APHERESIS MARKET, BY PRODUCT
KEY FINDINGS
 In 2018, the apheresis disposables segment accounted for the largest share of 81.3% of the
apheresis market. This segment is projected to reach USD 2,284.1 million by 2025 from USD
1,389.5 million in 2019, at a CAGR of 8.6% during the forecast period.
 The large share of the apheresis disposables segment is mainly due to its recurrent use,
increasing blood donations using apheresis devices, the increasing number of therapeutic
apheresis procedures, and favorable reimbursement policies.
 The apheresis devices segment is estimated to grow at a CAGR of 5.4% during the forecast
period.
 The centrifugal apheresis devices segment accounted for the largest share of 77.0% of the
apheresis devices market. This segment is projected to reach USD 337.7 million by 2025 from
USD 239.6 million in 2019, at a CAGR of 5.9% during the forecast period.
 The membrane separators segment is expected to reach USD 87.4 million by 2025 from USD
70.2 million in 2019, at a CAGR of 3.7% during the forecast period.
64
7.1 INTRODUCTION
On the basis of product, the apheresis market has been segmented into apheresis devices and
disposables. Of these two product segments, apheresis disposables accounted for a larger share of the
apheresis market. The large share of the apheresis disposables segment is mainly due to its recurrent use,
increasing blood donations using apheresis devices, the increasing number of therapeutic apheresis
procedures, and favorable reimbursement policies.
FIGURE 25 APHERESIS DISPOSABLES TO DOMINATE THE APHERESIS MARKET DURING

THE FORECAST PERIOD
2,500.0
2,000.0
1,500.0
1,000.0
500.0
0.0
Apheresis Disposables Apheresis Devices
2019 1,389.5 309.7
2025 2,284.1 425.1
CAGR 8.6% 5.4%
TABLE 5 APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Apheresis Disposables 1,186.0 1,282.6 1,389.5 2,284.1 8.6%
Apheresis Devices 280.8 294.6 309.7 425.1 5.4%
Total 1,466.8 1,577.3 1,699.2 2,709.2 8.1%
In 2018, the apheresis disposables segment accounted for the largest share of 81.3% of the global
apheresis market. This segment is projected to reach USD 2,284.1 million by 2025 from USD 1,389.5
million in 2019, at a CAGR of 8.6% during the forecast period. The large share and high growth in this
market can be attributed to its recurrent use, increasing blood donations using apheresis devices,
increasing number of therapeutic apheresis procedures, and favorable reimbursement policies for
apheresis procedures.
65
7.2 APHERESIS DISPOSABLES
7.2.1 RECURRENT USE OF APHERESIS DISPOSABLES TO DRIVE GROWTH

IN THIS MARKET SEGMENT
The disposables used in apheresis procedures include various types of columns (immunoadsorption
columns, plasma perfusion columns, and hemoperfusion columns), filters, absorbers, administration sets,
catheters, tubing sets/pipeline systems, needle sets, plasma transfer sets, seal safe systems, filter sets,
and single- & double-needle kits. These products are available as preassembled closed sets (with all
components and products) or as open sets that usually do not include the solutions. These disposables are
used for both automated blood collection and therapeutic apheresis.
In 2018, the apheresis disposables segment accounted for the largest share of 81.3% of the apheresis
market. The large share of this market segment can be attributed to the recurrent use of these products,
the increasing number of therapeutic apheresis procedures, and favorable reimbursement policies for
TABLE 6 APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
Country/Region 2017 2018 2019 2025 CAGR (2019–2025)
US 467.2 504.2 544.8 879.1 8.3%
Canada 71.4 76.4 81.9 126.0 7.4%
Germany 84.2 91.3 99.3 165.6 8.9%
France 61.7 66.9 72.6 120.4 8.8%
Italy 47.7 50.7 53.9 79.5 6.7%
UK 40.0 42.9 46.1 71.7 7.6%
Spain 23.0 24.4 25.9 37.4 6.3%
China 80.5 90.3 101.4 206.2 12.6%
Japan 79.9 87.1 95.0 162.6 9.4%
India 25.2 28.0 31.2 60.6 11.7%
Brazil 16.7 18.3 20.1 35.8 10.1%
Mexico 14.7 16.0 17.5 30.2 9.5%
Middle East & Africa 30.7 33.1 35.7 57.4 8.2%
Others 143.1 153.1 163.9 251.5 7.4%
Total 1,186.0 1,282.6 1,389.5 2,284.1 8.6%
66
7.3 APHERESIS DEVICES

Apheresis devices are machines/systems that are used to separate blood components either for the
collection of one or more specific blood components or the therapeutic treatment of blood disorders
through therapeutic apheresis procedures. In 2018, the apheresis devices segment accounted for a share
of 18.7% of the apheresis market. This segment is projected to reach USD 425.1 million by 2025 from
USD 309.7 million in 2019, at a CAGR of 5.4% during the forecast period.
Market growth can largely be attributed to the increasing number of installations of technologically
updated apheresis devices, increasing number of apheresis procedures for blood donations and
therapeutic purposes, increasing demand for plasma from biopharmaceutical companies for use in plasma
fractionation, and rising demand for apheresis devices in blood banks in emerging countries.
Apheresis is performed using centrifugation or membrane separation/filtration. There are a few devices
based on the combination of these two technologies that are used for automated blood collection
procedures as well as for therapeutic treatment. For example, the KPS8800Ce system (manufactured by
Sanyo Electronic Industries Co., Ltd.) and Aurora (Autopheresis-C) (manufactured by Fresenius Kabi) use
both technologies.
Fresenius (Germany), Terumo BCT, Inc. (US), and Haemonetics Corporation (US) are the leading providers
of apheresis devices. These players are primarily focused on expanding the application areas of their
existing products. They also focus on partnerships and collaborations with other companies, along with
enhancing their manufacturing capacities and presence on a global scale. For instance, in October 2018,
Terumo BCT (US) collaborated with UniCAR-Therapy Bio-Medicine Technology Co. (China) to advance CAR T-
Cell therapies using Terumo’s apheresis products.
The apheresis devices market is further segmented into centrifugal apheresis devices and membrane
separators.
TABLE 7 APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugal Apheresis Devices 215.1 226.8 239.6 337.7 5.9%
Membrane Separators 65.6 67.8 70.2 87.4 3.7%
Total 280.8 294.6 309.7 425.1 5.4%
The centrifugal apheresis devices segment accounted for a share of 77.0% of the apheresis devices
market in 2018. This segment is projected to reach USD 337.7 million by 2025 from USD 239.6 million in
2019, at a CAGR of 5.9% during the forecast period. This can be attributed to the advantages offered by
centrifugation over membrane separation, such as the higher efficiency of centrifugation and the ability to
separate all types of blood components.
67
TABLE 8 APHERESIS DEVICES MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
US 112.2 117.5 123.3 166.6 5.1%
Canada 16.9 17.5 18.2 23.5 4.3%
Germany 19.5 20.5 21.6 30.1 5.7%
France 15.1 15.9 16.7 23.2 5.6%
Italy 11.6 12.0 12.3 15.2 3.6%
UK 9.7 10.1 10.5 13.7 4.5%
Spain 5.5 5.7 5.9 7.1 3.2%
China 18.8 20.4 22.2 37.7 9.2%
Japan 18.1 19.2 20.3 28.9 6.1%
India 5.9 6.4 6.9 11.1 8.4%
Brazil 3.9 4.1 4.4 6.6 6.8%
Mexico 3.4 3.6 3.8 5.5 6.2%
Others 33.2 34.4 35.7 45.7 4.2%
Total 280.8 294.6 309.7 425.1 5.4%
7.3.1 CENTRIFUGAL APHERESIS DEVICES

7.3.1.1 Increasing installation of centrifugal apheresis devi ces in
hospitals for therapeutic apheresis drives market growth
Centrifugal apheresis devices are designed to separate plasma or blood components from whole blood.
Centrifugation can be done in two ways—continuous flow and intermittent/discontinuous flow. The
centrifugation procedure typically includes the following steps:
 Rotary peristaltic pumps, a major component of centrifugal devices, draw whole blood from a
patient or donor, and centrifuge the blood. Based on density, the centrifugal force separates the
blood into its components.
 Optical sensors detect the plasma-cell interfaces to minimize contamination from other
components. These devices have inlet and outlet ports and compartments to keep components
separated.
 Pumps move the blood products into collection bags and add citrate (an anticoagulant agent)
and reinfused fluids.
 Replacement fluids such as albumin, plasma, saline, serum albumin, plasma protein fraction,
and fresh frozen plasma are infused into the patient to maintain the appropriate intravascular
volume and pressure.
Centrifugal apheresis devices are widely used for blood collection, automated blood component
separation, therapeutic plasma exchange, leukapheresis, and erythrocytapheresis.
68
The increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis, favorable
reimbursement policies for therapeutic apheresis, and the increasing use of centrifugal apheresis for blood
component donations by blood centers and hospitals are the major factors driving the growth of centrifugal
apheresis devices market. However, the higher cost of continuous apheresis in comparison with
membrane separation limits market growth to a certain extent.
TABLE 9 LIST OF CENTRIFUGAL APHERESIS DEVICES AVAILABLE IN THE MARKET
COMPANY NAME PRODUCT TYPE OF APHERESIS PROCEDURE
 PCS-2/ PCS 300  Donor Apheresis and Therapeutic Apheresis
Haemonetics  MCS+ 8150 and 9000  Donor Apheresis and Therapeutic Apheresis
Corporation (US)  Cymbal  Donor Apheresis and Therapeutic Apheresis
 NexSys PCS plasmapheresis system  Donor Apheresis and Therapeutic Apheresis
Therakos, Inc.  UVAR-XTS  Therapeutic Apheresis

(US)  Cellex Photopheresis System  Therapeutic Apheresis
 COBE Spectra  Donor Apheresis and Therapeutic Apheresis
Terumo BCT (US)  Trima Accel  Donor Apheresis

 Spectra Optia  Donor Apheresis and Therapeutic Apheresis
 Amicus Cell Separator  Donor Apheresis and Therapeutic Apheresis

 Alyx  Donor Apheresis and Therapeutic Apheresis
Fresenius Kabi  AS 104  Donor Apheresis and Therapeutic Apheresis

(Germany)  Com.Tec  Donor Apheresis and Therapeutic Apheresis
 Aurora  Donor Apheresis and Therapeutic Apheresis
 Auto-C  Donor Apheresis and Therapeutic Apheresis
Source: Company Websites, Investor Presentations, and MarketsandMarkets Analysis
69
TABLE 10 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
US 87.9 92.5 97.5 135.0 5.6%
Canada 12.9 13.5 14.1 18.6 4.7%
Germany 14.5 15.4 16.3 23.4 6.2%
France 11.7 12.3 13.1 18.6 6.1%
Italy 9.0 9.3 9.7 12.3 4.0%
UK 7.7 8.0 8.4 11.2 4.9%
Spain 4.3 4.5 4.6 5.7 3.7%
China 14.0 15.3 16.8 29.3 9.7%
Japan 13.2 14.0 14.9 21.9 6.6%
India 4.5 4.9 5.3 8.8 8.9%
Brazil 2.9 3.1 3.4 5.1 7.3%
Mexico 2.5 2.7 2.9 4.3 6.8%
Others 24.8 25.8 27.0 35.6 4.7%
Total 215.1 226.8 239.6 337.7 5.9%
7.3.2 MEMBRANE SEPARATORS

7.3.2.1 Difficulties in separating huge volumes of plasma from
milliliters of whole blood—a key factor limiting the
adoption of these devices
In 2018, the membrane separators segment accounted for a share of 23.0% of the apheresis devices
market. This segment is projected to reach USD 87.4 million by 2025 from USD 70.2 million in 2019, at a
CAGR of 3.7% during the forecast period.
Membrane separators are used to separate plasma from whole blood with the help of filters. Separation is
achieved based on the molecular size of blood cells. These devices are available as hollow-fiber
membranes with pore diameters of 0.2 to 0.6 µm. The procedure for these devices closely resembles a
continuous dialysis procedure run in an isolated ultrafiltration mode. Membrane separators separate and
discard plasma, along with its pathogenic substances, and replace it with fluids such as albumin or
plasma.
Plasma separation from whole raw blood is required for various conditions such as HIV viral load testing,
autoimmune diseases, and others. HIV viral load testing plays a crucial role in clinical decision-making for
HIV diagnosis. Thus, the growing number of people living with HIV worldwide will increase the demand for
plasma separators during the forecast period.
Furthermore, it is very difficult to separate comparatively huge volumes of plasma from milliliters of whole
blood through these plasma separators. This is a key factor limiting the adoption of these devices. The
inability of these devices to perform cytapheresis is also expected to restrain market growth during the
forecast period.
70
TABLE 11 LIST OF MEMBRANE SEPARATORS AVAILABLE IN THE MARKET
COMPANY NAME PRODUCT TYPE OF APHERESIS PROCEDURE
B. Braun (Germany)  Plasmat Futura Apheresis System  Therapeutic Apheresis
Baxter International  PrismaFlex System  Therapeutic Apheresis

(US)  PRISMAX System  Therapeutic Apheresis
 Cellsorba EX  Therapeutic Apheresis

 Plasauto EZ  Therapeutic Apheresis
 Cascadeflo EC  Therapeutic Apheresis
 Plasmaflo OP  Therapeutic Apheresis
 IMMUSORBA TR  Therapeutic Apheresis
 IMMUSORBA PH  Therapeutic Apheresis
Asahi Kasei (Japan)  PLASORBA BR  Therapeutic Apheresis

 Rheofilter  Therapeutic Apheresis
 CUREFLO  Therapeutic Apheresis
 Cellsorba EX  Therapeutic Apheresis
 Sepacell RZ-2000  Donor Apheresis and Therapeutic Apheresis
 Sepacell R-S11  Donor Apheresis and Therapeutic Apheresis
 Sepacell PLX-5  Donor Apheresis and Therapeutic Apheresis
 LEUKOsmart  Therapeutic Apheresis

Medica S.p.A (Italy)
 PLASMART Plasmafilters  Therapeutic Apheresis
 Plasmacure PE  Donor Apheresis and Therapeutic Apheresis

Kawasumi  Evaflux  Donor Apheresis and Therapeutic Apheresis
Laboratories (Japan)
 Evacure/Evaclio  Donor Apheresis and Therapeutic Apheresis
 LDL–APHERESIS SYSTEM
Kaneka Corporation (Liposorber LA-15, And Liposorber  Therapeutic Apheresis
(Japan) LA-40S)
71
TABLE 12 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
US 24.32 25.06 25.86 31.57 3.4%
Canada 3.97 4.06 4.16 4.84 2.6%
Germany 4.96 5.14 5.33 6.73 4.0%
France 3.41 3.53 3.66 4.59 3.9%
Italy 2.56 2.60 2.65 2.95 1.8%
UK 2.01 2.06 2.11 2.48 2.7%
Spain 1.20 1.21 1.23 1.34 1.5%
China 4.77 5.11 5.48 8.43 7.4%
Japan 4.95 5.15 5.37 6.95 4.4%
India 1.41 1.50 1.60 2.35 6.6%
Brazil 0.97 1.02 1.07 1.44 5.1%
Mexico 0.86 0.90 0.94 1.23 4.5%
Others 8.38 8.55 8.74 10.11 2.5%
Total 65.63 67.80 70.15 87.41 3.7%
72
8 APHERESIS MARKET, BY PROCEDURE
KEY FINDINGS
 In 2018, the automated blood collection segment accounted for the largest share of 76.7% of
the apheresis market. This segment is projected to reach USD 2,046.8 million by 2025 from
USD 1,301.0 million in 2019, at a CAGR of 7.8% during the forecast period.
 The large share of this segment can mainly be attributed to the increasing demand for safer
blood components for transfusion, increasing demand for source plasma from
biopharmaceutical companies, and rising need to improve blood center efficiency.
 The therapeutic apheresis segment is estimated to grow at a CAGR of 8.8% during the forecast
period. Growth in this segment can be attributed to the increasing prevalence of blood
disorders.
 The therapeutic apheresis segment is projected to reach USD 662.4 million by 2025 from USD
398.3 million in 2019.
73
8.1 INTRODUCTION
On the basis of procedure, the apheresis market has been segmented into automated blood collection
(donor apheresis) and therapeutic apheresis. Of these two segments, the automated blood collection
(donor apheresis) segment commanded the large share of the market in 2018. The large share of this
segment can mainly be attributed to the increasing demand for safer blood components for transfusion,
increasing demand for source plasma from biopharmaceutical companies, and rising need to improve
blood center efficiency.
FIGURE 26 AUTOMATED BLOOD COLLECTION ACCOUNTED FOR THE LARGEST SHARE

OF THE APHERESIS MARKET DURING THE FORECAST PERIOD
2,500.0
2,000.0
1,500.0
1,000.0
500.0
0.0
Automated Blood Collection (Donor Apheresis) Therapeutic Apheresis
2019 1,301.0 398.3
2025 2,046.8 662.4
CAGR 7.8% 8.8%
TABLE 13 APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

Automated Blood Collection
1,127.8 1,210.2 1,301.0 2,046.8 7.8%
(Donor Apheresis)
Therapeutic Apheresis 338.9 367.1 398.3 662.4 8.8%
Total 1,466.8 1,577.3 1,699.2 2,709.2 8.1%
In 2018, the automated blood collection (donor apheresis) segment accounted for the largest share of
76.7% of the global apheresis market. This segment is projected to reach USD 2,046.8 million by 2025
from USD 1,301.0 million in 2019, at a CAGR of 7.8% during the forecast period. The large share of this
segment can be attributed to the increasing number of blood component donations using apheresis
devices and the increasing demand for source plasma from biopharmaceutical companies.
However, the therapeutic apheresis segment is estimated to grow at the highest CAGR of 8.8% during the
forecast period. Growth in this segment can be attributed to the increasing adoption of apheresis
procedures for the treatment of various neurological, blood, and renal diseases; the increasing prevalence
of blood disorders; and favorable reimbursement policies for apheresis procedures.
74
8.2 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS)
8.2.1 INCREASING NUMBER OF BLOOD COMPONENT DONATIONS USING

APHERESIS DEVICES TO SUPPORT MARKET GROWTH
Automated/apheresis blood collection or donor apheresis refers to the process of collecting specific blood
components such as platelets, plasma, or red blood cells from a donor. In this process, the donor’s blood is
drawn into an automated blood collection machine through sterile tubing. Blood components are
separated in this machine, with the required component being collected in a bag, while the remaining
blood is reinfused into the donor’s circulatory system. Centrifugation-based apheresis devices are majorly
used for automated blood collection or donor apheresis procedures. Automation enables blood collectors
to obtain more units of blood components from a single donor, thereby increasing the efficiency of blood
collection.
The medical industry faces a blood shortage for accident victims and the treatment of patients with various
blood disorders, trauma, and medical conditions. The growth in this segment is mainly driven by the
increasing demand for safer blood components for transfusion and the rising need to improve blood center
efficiency. Similarly, technological advancements such as the development of blood bags with inbuilt
filters, blood collection monitors, and tube sealers are driving market growth.
Currently, the US is a major market for apheresis blood collection. In 2016, there were more than 600
blood collection centers in the country (Source: America's Blood Centers). The adoption of advanced blood
collection technologies such as apheresis by blood collection centers and greater awareness among
donors account for the large share of this country in the global market.
The growth in the European market segment will be driven by the advantages of apheresis collection over
whole blood collection, increasing prevalence of chronic diseases such as cancer or autoimmune diseases,
a rising supply of platelets owing to a growing number of platelet donors, infrastructural developments in
healthcare facilities, and the growing demand for plasma by biopharmaceutical companies.
However, the lack of awareness about automated blood collection, especially in emerging markets, is one
of the key factors restraining the growth of this market. Additionally, the lack of availability of regular and
qualified donors for apheresis procedures poses a challenge to the growth of this market.
TABLE 14 APHERESIS DEVICES USED FOR AUTOMATED BLOOD COLLECTION PROCEDURES
COMPANY PRODUCT
 Trima Accel Automated Blood Collection System

 COBE Spectra/Spectra Optia Apheresis System for Mononuclear Cell
Terumo BCT, Inc. (US)
Collection, Continuous Mononuclear Cell Collection, And Granulocyte
Collection
 Fenwal Alyx Component Collection System

Fresenius Kabi (Germany)
 Fenwal Amicus Cell Separator for Collection of Blood Components
 MCS+ 9000 Mobile Platelet Collection System

 MCS+ 8150 Multicomponent Collection System
Haemonetics Corporation (US)
 NexSys PCS
 PCS-2/PCS 300 Plasma Collection System
Cerus Corporation (US)  INTERCEPT System for Plasma Collection
75
TABLE 15 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS) MARKET, BY COUNTRY,

US 443.5 474.9 509.2 786.3 7.5%
Canada 67.9 72.1 76.7 112.9 6.7%
Germany 80.2 86.4 93.1 148.7 8.1%
France 58.4 62.8 67.6 107.3 8.0%
Italy 45.2 47.6 50.3 70.9 5.9%
UK 38.0 40.4 43.1 64.1 6.8%
Spain 21.9 23.0 24.2 33.5 5.6%
China 76.7 85.3 95.0 184.8 11.7%
Japan 76.4 82.6 89.4 146.5 8.6%
India 24.0 26.5 29.3 54.5 10.9%
Brazil 15.9 17.3 18.9 32.2 9.3%
Mexico 14.0 15.2 16.4 27.2 8.7%
Others 136.6 144.9 154.0 226.3 6.6%
Total 1127.8 1210.2 1301.0 2046.8 7.8%
8.3 THERAPEUTIC APHERESIS

The therapeutic apheresis segment accounted for a share of 23.3% of the global apheresis market in
2018. This segment is expected to reach USD 662.4 million by 2025 from USD 398.3 million in 2019, at a
Therapeutic apheresis is a process in which the patient's blood is passed through a system to remove
defective blood components/cells or disease-provoking elements from the blood. The defective component
is removed, while the remaining blood is reinfused back into the patient.
Therapeutic apheresis can be used to treat many diseases. The American Society for Apheresis (ASFA)
publishes guidelines on the use of therapeutic apheresis every three years. The 2016 (7th edition) ASFA
Guidelines contain 87 diseases (up from 78 in the 6th edition) and 179 indications such as neurological
disorders, renal diseases, leukemia, and metabolic disorders. The increasing indications of therapeutic
apheresis and the optimum results associated with these procedures are driving the growth of the
therapeutic apheresis procedures market.
A significant rise in the number of photopheresis procedures across the globe for the treatment of various
autoimmune diseases is also expected to drive market growth on a global scale. However, as compared to
donor apheresis, therapeutic apheresis is an expensive treatment option for blood and other disorders.
This is a key factor responsible for its limited adoption among patients. Furthermore, a lack of awareness
among patients, especially in emerging markets, and a reluctance to adopt this therapy due to stringent
regulations are some of the other factors restraining market growth to a certain extent.
76
Based on the type of products used, the therapeutic apheresis market is subsegmented into therapeutic
apheresis devices and therapeutic apheresis disposables. The devices required for the treatment of
various therapies are based on centrifugation and membrane separation technologies. Depending on the
type of disease and the patient’s clinical condition, physicians select the type of technology for treatment.
FIGURE 27 THERAPEUTIC APHERESIS DISPOSABLES TO DOMINATE THE THERAPEUTIC

APHERESIS MARKET DURING THE FORECAST PERIOD
700.0
600.0
500.0
400.0
300.0
200.0
100.0
0.0
Therapeutic Apheresis Disposables Therapeutic Apheresis Devices
2019 362.0 36.3
2025 615.3 47.1
CAGR 9.2% 4.4%
TABLE 16 THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Therapeutic Apheresis Disposables 305.4 332.2 362.0 615.3 9.2%
Therapeutic Apheresis Devices 33.5 34.9 36.3 47.1 4.4%
Total 338.9 367.1 398.3 662.4 8.8%
In 2018, the therapeutic apheresis disposables segment commanded the largest share of 90.5% of the
global therapeutic apheresis market. The large share of this segment is mainly due to the recurrent
purchase of disposables for the treatment of various diseases such as neurological, blood, and renal
diseases.
77
TABLE 17 THERAPEUTIC APHERESIS MARKET BY COUNTRY, 2017–2025 (USD MILLION)
US 135.9 146.8 158.9 259.3 8.5%
Canada 20.4 21.9 23.5 36.6 7.7%
Germany 23.4 25.5 27.8 47.0 9.2%
France 18.4 20.0 21.7 36.3 9.0%
Italy 14.1 15.0 16.0 23.8 6.8%
UK 11.7 12.6 13.5 21.3 7.8%
Spain 6.7 7.1 7.5 11.0 6.5%
China 22.6 25.4 28.6 59.1 12.8%
Japan 21.7 23.7 25.9 45.0 9.7%
India 7.1 7.9 8.8 17.3 11.9%
Brazil 4.7 5.1 5.7 10.2 10.3%
Mexico 4.1 4.5 4.9 8.5 9.8%
Others 39.7 42.6 45.7 71.0 7.6%
Total 338.9 367.1 398.3 662.4 8.8%
8.3.1 THERAPEUTIC APHERESIS DISPOSABLES

The disposables used in therapeutic apheresis procedures are products used to access blood vessels.
They include apheresis catheters, filters, absorbers, columns, tubing sets/pipeline systems, needle sets,
centrifuge bowls, and others.
With the increase in awareness of apheresis and growing research on apheresis procedures for
therapeutic purposes, the number of therapeutic apheresis procedures is expected to increase. This, in
turn, will result in an increase in the recurrent purchase of disposables, thus driving market growth.
Disposables vary depending on the type of disease to be treated and the apheresis technology used.
Based on disease type, the therapeutic apheresis disposables market is further segmented into
neurological disorders, blood disorders, cardiovascular disorders, renal disorders, autoimmune disorders,
metabolic disorders, and other disorders (rheumatic disorders, malaria, and hyperviscosity syndrome).
78
FIGURE 28 NEUROLOGICAL DISORDERS TO ACCOUNT FOR THE LARGEST SHARE OF

THE THERAPEUTIC APHERESIS DISPOSABLES MARKET DURING THE
FORECAST PERIOD
300.0
250.0
200.0
150.0
100.0
50.0
0.0
Neurological Blood Renal Autoimmune Metabolic Cardiovascul Other
Disorders Disorders Disorders Disorders disorders ar Disorders Disorders
2019 145.4 109.6 42.2 22.8 16.2 15.4 10.3
2025 257.5 180.9 71.9 39.4 25.4 25.0 15.3
CAGR 10.0% 8.7% 9.3% 9.5% 7.8% 8.4% 6.7%
TABLE 18 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Disease Type 2017 2018 2019 2025 CAGR (2019–2025)
Neurological Disorders 121.0 132.5 145.4 257.5 10.0%
Blood Disorders 93.4 101.1 109.6 180.9 8.7%
Renal Disorders 35.6 38.7 42.2 71.9 9.3%
Autoimmune Disorders 19.1 20.9 22.8 39.4 9.5%
Metabolic Disorders 14.0 15.1 16.2 25.4 7.8%
Cardiovascular Disorders 13.2 14.3 15.4 25.0 8.4%
Other Disorders 9.1 9.7 10.3 15.3 6.7%
Total 305.4 332.2 362.0 615.3 9.2%
In 2018, the neurological disorders segment commanded the largest share of 39.9% of the global
therapeutic apheresis disposables market, followed by blood disorders and renal disorders with respective
shares of 30.4% and 11.7%. During the forecast period, the neurological disorders segment is projected to
grow at a CAGR of 10.0% to reach USD 257.5 million by 2025 from USD 145.4 million in 2019. Growth in
this segment is mainly due to the increasing pool of patients with neurological disorders and the optimum
results associated with therapeutic apheresis procedures for the treatment of neurological diseases such
as GBS.
79
TABLE 19 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY,

US 121.9 132.3 143.8 240.0 8.9%
Canada 18.4 19.8 21.3 34.0 8.1%
Germany 21.3 23.2 25.4 43.9 9.5%
France 16.4 17.8 19.5 33.4 9.4%
Italy 12.6 13.4 14.4 21.9 7.3%
UK 10.5 11.3 12.2 19.6 8.2%
Spain 6.0 6.4 6.8 10.2 6.9%
China 20.5 23.1 26.2 55.1 13.2%
Japan 19.8 21.7 23.9 42.3 10.0%
India 6.4 7.2 8.0 16.1 12.3%
Brazil 4.2 4.7 5.2 9.5 10.7%
Mexico 3.7 4.1 4.5 8.0 10.1%
Others 36.1 38.8 41.8 66.3 8.0%
Total 305.4 332.2 362.0 615.3 9.2%
8.3.1.1 Neurological disorders
8.3.1.1.1 Neurological disorders hold a major share in the therapeutic

apheresis disposables market
Plasma exchange is a well-established therapeutic apheresis procedure commonly used in many
neurological disorders of autoimmune etiology. Therapeutic plasma exchange (TPE) is a process in which
plasma containing antibodies, immune complexes, inflammatory moderators, paraproteins, and other
toxins, which are believed to be the cause of the disease, is removed from a patient. Cytokines, including
chemokines8 and complement9, are other potentially injurious molecules that can be removed by
plasmapheresis.
TPE is the first-line treatment in all forms of acute inflammatory demyelinating polyradiculoneuropathy
diseases (axonal, demyelinating, and miller-fisher variant) as well as in acute myasthenic crisis, chronic
inflammatory demyelinating polyradiculoneuropathy, and paraproteinemic neuropathies (category I, level
1B). Terumo’s Spectra Optia system is the first and only device in the European market that is approved to
treat the Guillain-Barré syndrome (GBS) and Myasthenia Gravis (MG) using TPE.
80
TABLE 20 NEUROLOGICAL DISORDERS TREATED USING THERAPEUTIC APHERESIS
DISEASES/DISORDERS COMPONENTS REMOVED
Myasthenia Gravis Antiacetylcholine receptor Ab, cryoglobulins
Multiple Sclerosis Antimyelin Ab
Guillain-Barré Syndrome Antimyelin Ab
Polyneuropathy Cryoglobulins, macroglobulins
Polyradiculoneuropathy Antibodies
Lambert-Eaton Syndrome Antibodies
Source: World Apheresis Association, Journal of Apheresis, World Health Organization (WHO), Centers for Disease Control and
Prevention (CDC), and National Institutes of Health (NIH)
In 2018, the neurological disorders segment accounted for the largest share of 39.9% of the therapeutic
apheresis disposables market. This segment is projected to reach USD 257.5 million by 2025 from USD
145.4 million in 2019, at a CAGR of 10.0% during the forecast period. Growth in this market is majorly
driven by the rising prevalence and incidence of neurological diseases in the geriatric population,
increasing patient awareness about the treatment of neurological diseases using apheresis, and rising
investments by key players for R&D on the new application areas of therapeutic apheresis in neurological
disorder treatment.
According to a WHO report, neurological disorders accounted for nearly 6.3% of the global disease burden
in 2005 [Disability Adjusted Life Years (DALYs)] and is projected to reach 6.4% and 6.8%, respectively, in
2015 and 2030. According to the Neurological Alliance, there are about 10 million people in the UK living
with neurological conditions, and ~600,000 people are newly diagnosed with a neurological condition
every year. The growing incidence of neurological disorders and the resultant rising demand for various
therapeutic options is one of the key factors contributing to the growth of the neurological disorders
segment.
TABLE 21 NEUROLOGICAL DISORDERS: ESTIMATED DALYS, BY REGION, 2015 VS. 2030
Region 2015 2030
US 36,651,648 39,714,418
Europe 27,406,286 25,800,469
Africa 24,029,510 31,855,133
Eastern Mediterranean 18,888,382 22,406,409
Southeast Asia 58,494,744 64,288,213
Western Pacific 49,722,122 49,016,595
Source: World Health Organization (WHO)
Government funding to promote research for the identification of new treatment options in reference to
various neurological disorders is also expected to support market growth. For instance, the National
Institutes of Health (NIH) allocated a budget of USD 1,608 million in 2015 to the National Institute of
Neurological Disorders and Stroke (US). However, poor reimbursement policies for therapeutic apheresis
procedures and tough taxation policies in the US and Europe are the key factors restraining the growth of
the therapeutic apheresis market for neurological disorders.
81
TABLE 22 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR NEUROLOGICAL DISORDERS,

BY COUNTRY, 2017–2025 (USD MILLION)
US 48.3 52.8 57.8 100.4 9.6%
Canada 7.4 8.0 8.7 14.4 8.8%
Germany 8.7 9.5 10.5 18.8 10.3%
France 6.4 7.0 7.7 13.8 10.1%
Italy 4.9 5.3 5.7 9.0 8.0%
UK 4.1 4.5 4.9 8.1 9.0%
Spain 2.3 2.5 2.7 4.2 7.6%
China 8.6 9.7 11.1 24.2 13.9%
Japan 7.9 8.7 9.6 17.7 10.7%
India 2.5 2.8 3.1 6.6 13.1%
Brazil 1.6 1.8 2.0 3.8 11.4%
Mexico 1.4 1.6 1.7 3.2 10.9%
Others 13.9 15.1 16.4 27.1 8.7%
Total 121.0 132.5 145.4 257.5 10.0%
8.3.1.2 Blood disorders
8.3.1.2.1 Increasing prevalence and incidence of hematologic and

genetic disorders will boost the demand for therapeutic
apheresis disposables
Thrombotic thrombocytopenic purpura (TTP), leukemia, sickle-cell disease, hemophilia, idiopathic
thrombocytopenic purpura, AIDS-HIV, autoimmune hemolytic anemia, Rh incompatibility, cryoglobulinemia,
hyperviscosity syndrome, Waldenstrom’s syndrome, paraproteinemia, and thrombocythemia are some
commonly treated blood disorders using therapeutic apheresis procedures. In addition to these diseases,
hemophagocytic syndrome, hemolysis, elevated liver enzymes, and low platelet syndrome can also be
treated by therapeutic apheresis procedures.
In 2018, the blood disorders segment accounted for a share of 30.4% of the therapeutic apheresis
disposables market. This segment is projected to reach USD 180.9 million by 2025 from USD 109.6
million in 2019, at a CAGR of 8.7% during the forecast period. Growth in this market is mainly due to the
increasing prevalence and incidence of hematologic and genetic disorders and the rising R&D investments
by players in search of new applications of therapeutic apheresis procedures for the treatment of various
blood disorders.
82
TABLE 23 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR BLOOD DISORDERS, BY COUNTRY,

US 36.2 39.1 42.3 68.7 8.4%
Canada 5.5 5.9 6.4 9.9 7.5%
Germany 6.3 6.9 7.5 12.5 9.0%
France 5.0 5.5 5.9 9.9 8.9%
Italy 3.9 4.2 4.4 6.6 6.8%
UK 3.3 3.5 3.8 5.9 7.7%
Spain 1.9 2.0 2.2 3.2 6.4%
China 5.9 6.6 7.4 15.2 12.7%
Japan 6.2 6.7 7.4 12.7 9.5%
India 2.1 2.3 2.6 5.0 11.8%
Brazil 1.4 1.5 1.7 3.0 10.2%
Mexico 1.2 1.3 1.5 2.5 9.6%
Others 11.9 12.7 13.6 21.0 7.5%
Total 93.4 101.1 109.6 180.9 8.7%
8.3.1.3 Renal disorders
8.3.1.3.1 Therapeutic plasma exchange is regarded as one of the most

useful treatment options for several renal disorders
Hemolytic uremic syndrome (HUS), Goodpasture’s syndrome, glomerulonephritis, lupus nephritis,
transplant rejection, renal vasculitis, thrombotic microangiopathies, and paraproteinemia are some of the
common kidney disorders that can be treated using therapeutic apheresis. Therapeutic plasma exchange
(TPE) is regarded as one of the most useful treatment options for several renal disorders.
The treatment of renal diseases can be achieved in the following ways:
 Cascade filtration and double filtration: Used for the removal of particles with a high molecular
weight
 Immunoadsorption: Used for the separation and removal of antibodies and protein complexes
 Plasma adsorption: Used for the removal of lipoproteins and large particles such as fibrinogen
and C-reactive protein
 Cryofiltration: Used to isolate cryoglobulins
 Cytapheresis: Used to isolate lymphocytes, granulocytes, or active platelets
83
According to a report published in the American Journal of Kidney Diseases, the number of adults aged 30
or older suffering from chronic kidney disease (CKD) is projected to increase from 13.2% in 2015 to 14.4%
in 2020 and to ~16.7% in 2030 in the US. This increasing incidence and prevalence of renal diseases
boost the growth of the therapeutic apheresis market for renal disorders.
In 2018, the renal disorders segment accounted for a share of 11.7% of the therapeutic apheresis
disposables market. This segment is projected to reach USD 71.9 million by 2025 from USD 42.2 million in
2019, at a CAGR of 9.3% during the forecast period.
TABLE 24 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR RENAL DISORDERS, BY COUNTRY,

US 14.39 15.62 16.99 28.41 8.9%
Canada 2.13 2.30 2.48 3.95 8.1%
Germany 2.49 2.72 2.98 5.15 9.6%
France 1.90 2.08 2.27 3.90 9.5%
Italy 1.45 1.55 1.67 2.54 7.3%
UK 1.21 1.30 1.41 2.27 8.3%
Spain 0.69 0.74 0.79 1.18 7.0%
China 2.42 2.73 3.09 6.50 13.2%
Japan 2.30 2.53 2.77 4.92 10.0%
India 0.73 0.82 0.92 1.85 12.4%
Brazil 0.49 0.54 0.60 1.10 10.7%
Mexico 0.42 0.47 0.51 0.91 10.2%
Others 4.06 4.37 4.71 7.48 8.0%
Total 35.56 38.70 42.19 71.88 9.3%
8.3.1.4 Autoimmune disorders
8.3.1.4.1 With the introduction of novel and effective biologic agents

for the treatment of various autoimmune disorders,
therapeutic apheresis is indicated only in severe cases
Autoimmune diseases include a broad spectrum of pathologies, compromising diverse organs, tissues,
systems, or, in some cases, systemic involvement. Autoimmune diseases affect up to 7% of the population
worldwide. Systemic autoimmune diseases based on immune pathogenesis produce autoantibodies and
circulate immune complexes, which can cause inflammation in the tissues of various organs. In most
cases, these diseases have a bad prognosis, when not treated. Therapeutic apheresis can be used as
supportive therapy in the treatment of autoimmune diseases such as systemic lupus erythematosus,
antiphospholipid syndrome, rheumatoid arthritis, and inflammatory eye disease.
84
With the introduction of novel and effective biologic agents for the treatment of various autoimmune
disorders, therapeutic apheresis is indicated only in severe cases such as in the rapid progression of
disease despite immunosuppressive therapy and/or biologic agents, and in patients with renal
involvement, acute generalized vasculitis, thrombocytopenia, leucopenia, pulmonary, cardiac, or cerebral
involvement.
In 2018, the autoimmune disorders segment accounted for a share of 6.3% of the therapeutic apheresis
TABLE 25 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR AUTOIMMUNE DISORDERS,


US 7.86 8.55 9.32 15.81 9.2%
Canada 1.18 1.27 1.37 2.22 8.3%
Germany 1.35 1.48 1.62 2.84 9.8%
France 1.02 1.12 1.22 2.13 9.7%
Italy 0.77 0.83 0.89 1.37 7.6%
UK 0.63 0.68 0.74 1.21 8.5%
Spain 0.35 0.38 0.40 0.61 7.2%
China 1.30 1.47 1.66 3.56 13.5%
Japan 1.19 1.31 1.44 2.59 10.3%
India 0.40 0.45 0.50 1.03 12.6%
Brazil 0.27 0.30 0.33 0.61 11.0%
Mexico 0.23 0.25 0.28 0.50 10.4%
Others 2.12 2.28 2.47 3.98 8.3%
Total 19.12 20.86 22.79 39.38 9.5%
8.3.1.5 Metabolic disorders
8.3.1.5.1 Increasing adoption of plasmapheresis for the treatment of

diabetes and other metabolic disorders drives the growth of
this segment
Erythropoietic protoporphyria (EPP), ulcerative colitis, Addison’s disease, chronic ulcerative colitis, diabetes
mellitus, Hashimoto’s disease, hypercholesterolemia, and hyperlipidemia are some of the most common
metabolic disorders that are treated using therapeutic apheresis.
Diabetes is the most common metabolic disease globally. According to the International Diabetes
Federation, in 2019, approximately 463 million people were suffering from diabetes on a global scale. This
figure is expected to reach ~700 million by 2045. Growth in this market is primarily driven by the growing
incidence of metabolic disorders and the increasing awareness about the application of therapeutic
apheresis in the treatment of these disorders.
85
In 2018, the metabolic disorders segment accounted for a share of 4.5% of the therapeutic apheresis
TABLE 26 METABOLIC DISORDERS: ESTIMATED DALYS BY REGION, 2015 VS. 2030 (THOUSANDS)
Region 2015 2030
US 5,115,426 5,583,949
Europe 5,321,843 4,239,432
Africa 5,765,911 6,186,305
Southeast Asia 10,615,627 8,150,086
Western Pacific 6,246,349 4,699,685
TABLE 27 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR METABOLIC DISORDERS,

US 5.85 6.26 6.71 10.33 7.4%
Canada 0.86 0.92 0.98 1.43 6.6%
Germany 1.00 1.08 1.16 1.85 8.0%
France 0.75 0.81 0.88 1.38 7.9%
Italy 0.57 0.60 0.63 0.89 5.8%
UK 0.46 0.49 0.53 0.78 6.8%
Spain 0.26 0.27 0.29 0.40 5.5%
China 0.97 1.08 1.21 2.34 11.7%
Japan 0.82 0.89 0.96 1.57 8.5%
India 0.28 0.31 0.34 0.63 10.8%
Brazil 0.18 0.20 0.22 0.37 9.2%
Mexico 0.16 0.17 0.18 0.30 8.7%
Others 1.54 1.64 1.74 2.55 6.6%
Total 14.03 15.06 16.19 25.37 7.8%
86
8.3.1.6 Cardiovascular disorders
8.3.1.6.1 Low-density lipoprotein (LDL) apheresis is mainly used in the

treatment of cardiovascular disorders
Therapeutic apheresis is a very useful treatment option for major cardiovascular diseases and for all types
of cardiac dysfunctions generated by autoimmune or metabolic disorders. Familial hypercholesterolemia
and hyperviscosity syndrome are well-established indications of therapeutic apheresis. In addition to these
indications, dilated cardiomyopathy, cardiac failure, and some specific disorders of severe dysfunction
occurring after heart transplantations are commonly treated using therapeutic apheresis procedures.
According to the American Heart Association (AHA), approximately 11.5% (27.6 million) of adults in the US
are suffering from heart disease. The AHA has estimated that by 2035, 45.1% of the US population will
have some form of heart disease. The important risk factors of cardiovascular disease (CVD) include high
blood pressure, smoking, and high cholesterol, and 47% of Americans have at least one of these risk
factors.
Low-density lipoprotein apheresis is an efficient, safe, and suitable treatment for lowering cholesterol
levels. This procedure is used for the treatment of various cardiovascular disorders. Similarly, plasma
exchange has been demonstrated as an efficient tool for reducing blood viscosity and the risk of a
consequent cardiac dysfunction in cardiac disorders, such as Waldenström macroglobulinemia and other
hyperviscosity syndromes.
In 2018, the cardiovascular disorders segment accounted for a share of 4.3% of the therapeutic apheresis
TABLE 28 CARDIOVASCULAR DISORDERS: ESTIMATED DALYS BY REGION,

2015 VS. 2030 (THOUSANDS)
Region 2015 2030
US 16,218,168 18,570,340
Europe 30,438,707 26,048,005
Africa 16,881,296 22,532,571
Southeast Asia 46,495,768 54,107,664
Western Pacific 32,861,681 36,756,322
87
TABLE 29 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR CARDIOVASCULAR DISORDERS,

US 5.53 5.95 6.42 10.23 8.1%
Canada 0.74 0.79 0.85 1.29 7.2%
Germany 0.89 0.96 1.05 1.72 8.7%
France 0.70 0.76 0.82 1.35 8.6%
Italy 0.55 0.58 0.61 0.89 6.4%
UK 0.43 0.46 0.50 0.76 7.4%
Spain 0.24 0.26 0.27 0.39 6.1%
China 0.83 0.92 1.04 2.08 12.3%
Japan 0.90 0.98 1.07 1.80 9.1%
India 0.28 0.32 0.35 0.67 11.4%
Brazil 0.19 0.20 0.22 0.39 9.8%
Mexico 0.16 0.17 0.19 0.32 9.3%
Others 1.47 1.57 1.68 2.56 7.2%
Total 13.22 14.27 15.43 25.02 8.4%
8.3.1.7 Other disorders

The other diseases treated with therapeutic apheresis procedures include rheumatic disorders, malaria,
and hyperviscosity syndrome. Rapid growth in the aging population and the rising incidence of these
diseases are primarily driving the growth of this segment. However, the high cost of therapeutic apheresis
procedures and the lack of awareness about such procedures are the key challenges restraining the
greater adoption of apheresis in the treatment of these disorders.
In 2018, the other disorders segment accounted for a share of 2.9% of the therapeutic apheresis
88
TABLE 30 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR OTHER DISORDERS, BY COUNTRY,

US 3.701 3.928 4.176 6.089 6.5%
Canada 0.525 0.553 0.584 0.811 5.6%
Germany 0.570 0.609 0.651 0.981 7.1%
France 0.542 0.578 0.617 0.925 7.0%
Italy 0.427 0.447 0.468 0.623 4.9%
UK 0.352 0.371 0.392 0.551 5.8%
Spain 0.199 0.207 0.216 0.282 4.6%
China 0.549 0.606 0.669 1.229 10.7%
Japan 0.567 0.608 0.653 1.010 7.5%
India 0.172 0.188 0.206 0.361 9.8%
Brazil 0.131 0.141 0.153 0.246 8.2%
Mexico 0.100 0.107 0.115 0.179 7.7%
Others 1.071 1.125 1.184 1.630 5.5%
Total 9.113 9.687 10.315 15.256 6.7%
8.3.2 THERAPEUTIC APHERESIS DEVICES

8.3.2.1 Centrifugation-based devices are one of the most commonly
adopted therapeutic apheresis devices
In 2018, the therapeutic apheresis devices segment accounted for a share of 9.5% of the therapeutic
apheresis market. This segment is projected to reach USD 47.1 million by 2025 from USD 36.3 million in
Therapeutic apheresis devices are specialized devices used to remove selected blood constituents
(plasma, leukocytes, platelets, or cells) from whole blood. Therapeutic apheresis is an autologous process;
i.e., blood is taken from the patient, handled, and reinfused in the patient as a part of a continuous
procedure. Hospitals are the primary users of therapeutic apheresis equipment and solutions.
Centrifugation and membrane separation are two technologies used for the separation of blood
components from whole blood.
89
TABLE 31 KEY PRODUCTS AVAILABLE IN THE MARKET FOR THERAPEUTIC APHERESIS
COMPANY NAME PRODUCT TECHNOLOGY INDICATOR
 Severe Lipometabolic
B. Braun  Plasmat Futura System  Disorders
Membrane Separation
(Germany)
 Cardiovascular diseases
 IMMUSORBA TR
Asahi Kasei
Corporation  IMMUSORBA PH Membrane Separation  Autoimmune Disorders
(Japan)  Cellsorba EX
Baxter  PRISMAFLEX System

International Inc. Membrane Separation  Acute Kidney Injury (AKI)
 PRISMAX System
(US)
 Glomerular Disease
 Guillain-Barré Syndrome
Terumo BCT, Inc.  COBE Spectra/Spectra (GBS)
Optia Apheresis System Centrifugation
(US)
 Myasthenia Gravis (MG)
 Leukemia
Asahi Kasei
Corporation  CUREFLO Membrane Separation  Renal Failure
(Japan)
 DALI Lipoprotein
Fresenius Apheresis
Membrane Separation  Cardiovascular Diseases
(Germany)  MONET Lipoprotein
Apheresis
Miltenyi Biotec  TheraSorb Therapeutic  Cardiovascular Diseases

Apheresis System Membrane Separation
(Germany)  Autoimmune Diseases
 UVAR-XTS Photopheresis  Cutaneous T-cell Lymphoma

Therakos, Inc. Systems (CTCL)
Centrifugation
(US)  THERAKOS CELLEX  Cutaneous T-cell Lymphoma
Photopheresis System (CTCL)
90
TABLE 32 THERAPEUTIC APHERESIS DEVICES MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
US 14.05 14.58 15.15 19.34 4.1%
Canada 2.01 2.07 2.14 2.60 3.3%
Germany 2.15 2.24 2.34 3.09 4.7%
France 2.03 2.12 2.21 2.90 4.6%
Italy 1.52 1.56 1.59 1.86 2.6%
UK 1.24 1.28 1.32 1.63 3.5%
Spain 0.69 0.71 0.72 0.82 2.3%
China 2.13 2.29 2.48 3.98 8.2%
Japan 1.83 1.92 2.01 2.73 5.2%
India 0.67 0.71 0.76 1.17 7.4%
Brazil 0.44 0.47 0.49 0.69 5.8%
Mexico 0.37 0.39 0.41 0.56 5.3%
Others 3.65 3.75 3.86 4.67 3.2%
Total 33.54 34.87 36.32 47.07 4.4%
91
9 APHERESIS MARKET, BY TECHNOLOGY
KEY FINDINGS
 In 2018, the centrifugation technology segment accounted for the largest share of 77.6% of the
1,328.8 million in 2019, at the highest CAGR of 8.9% during the forecast period.
 The high growth and large share of the centrifugation segment can be attributed to the
increasing adoption of centrifugation for automated blood collection owing to its high efficiency
and large amounts of blood components recovered from a single procedure.
 The continuous flow centrifugation segment accounted for the largest share of 62.5% of the
centrifugation technology market in 2018.
92
9.1 INTRODUCTION
On the basis of technology, the apheresis market has been segmented into centrifugation and membrane
separation.
TABLE 33 CENTRIFUGATION VS. MEMBRANE SEPARATION
CENTRIFUGATION TECHNOLOGY MEMBRANE SEPARATION TECHNOLOGY
Widely adopted method of apheresis in North America Minimal availability in the US
Useful for multiple procedures for the separation of

Limited to only plasma exchange—plasmapheresis
cellular blood components—cytapheresis
Efficiently provides cellular therapies Less efficient than centrifugation
Faster than centrifugation, with a blood flow speed of

Speed of blood flow is 10–100ml/min
150 ml/minute
Plasma removal efficiency is 80% Plasma removal efficiency is 30%
Time-consuming set-up process Faster set-up process than centrifugation
Uses citrate as an anticoagulant Commonly uses heparin as an anticoagulant
Source: Principles of Apheresis Technology, ASFA 2014
FIGURE 29 CENTRIFUGATION SEGMENT TO DOMINATE THE APHERESIS MARKET DURING

THE FORECAST PERIOD
2,500.0
2,000.0
1,500.0
1,000.0
500.0
0.0
Centrifugation Membrane Separation
2019 1,328.8 370.5
2025 2,216.0 493.2
CAGR 8.9% 4.9%
93
TABLE 34 APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 1,127.8 1,223.2 1,328.8 2,216.0 8.9%
Membrane Separation 338.9 354.1 370.5 493.2 4.9%
Total 1,466.8 1,577.3 1,699.2 2,709.2 8.1%
In 2018, the centrifugation technology segment accounted for the largest share of 77.6% of the apheresis
market. This segment is projected to reach USD 2,216.0 million by 2025 from USD 1,328.8 million in
2019, at a CAGR of 8.9% during the forecast period. The large share of this segment can be attributed to
the advantages offered by centrifugation over membrane separation, such as its high efficiency and its
ability to separate all types of blood components
9.2 CENTRIFUGATION
Centrifugation devices are commonly used by blood banks, blood collection centers, and hospitals for
blood component collection and therapeutic apheresis. These devices are used to separate plasma, white
blood cells, red blood cells, and platelets. In centrifugation, blood cells are separated by specific gravity,
based on the difference in densities of various blood components. Owing to their wide adoption,
centrifugation-based apheresis products hold the largest share of the apheresis market.
Growth in this segment is mainly driven by the increasing use of centrifugation devices, especially by blood
banks. One of the major advantages of centrifugation technology is that it is used for the apheresis of any
blood component. However, setting up a centrifugal interface is more time-consuming than that of
membrane filtration-based devices.
There are two kinds of centrifugation methods—intermittent flow and continuous flow.
TABLE 35 CONTINUOUS FLOW CENTRIFUGATION VS. INTERMITTENT FLOW CENTRIFUGATION
CONTINUOUS FLOW INTERMITTENT FLOW
Blood is processed and separated in a continuous Blood is processed in batches of a size that can be tolerated
manner by the subject
Once the tubing set is primed, the separation Once blood separation is completed, the separation chamber
chamber is not emptied till the end of the process must be emptied to repeat the process (cycle) again
Less extracorporeal volume (ECV) is used during

This method requires larger ECV
the procedure
Pediatric tubing sets are not necessary; instead, Pediatric tubing sets (with smaller ECVs) must be used with
blood priming is performed with younger patients younger patients
Rapid process Long procedure time
Requires two sites of vascular access Uses single-site venous access
Source: Principles of Apheresis Technology, ASFA 2014
94
TABLE 36 CENTRIFUGATION MARKET: KEY PLAYERS AND PRODUCTS
COMPANY NAME PRODUCT FLOW TYPE
 PCS-2/PCS 300  Intermittent Flow
Haemonetics  MCS+ 8150 and 9000  Intermittent Flow

Corporation (US)  Cymbal  Intermittent Flow
 NexSys PCS plasmapheresis system  Intermittent Flow
 UVAR-XTS  Intermittent Flow

Therakos, Inc. (US)
 Cellex Photopheresis System  Continuous Flow
 COBE Spectra/ Spectra Optia  Continuous Flow

Terumo BCT (US)
 Trima Accel  Continuous Flow
 Amicus Cell Separator  Continuous Flow

 Alyx.  Continuous Flow
Fresenius Kabi  AS 104  Continuous Flow
(Germany)
 Com.Tec  Continuous Flow
 Aurora  Continuous Flow
TABLE 37 CENTRIFUGATION MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Continuous Flow 699.2 764.2 836.5 1,456.9 9.7%
Intermittent Flow 428.6 459.0 492.3 759.1 7.5%
Total 1,127.8 1,223.2 1,328.8 2,216.0 8.9%
In 2018, the continuous flow centrifugation segment accounted for the largest share of 62.5% of the
centrifugation market. This segment is projected to reach USD 1,456.9 million by 2025 from USD 836.5
million in 2019, at a CAGR of 9.7% during the forecast period.
The large share of this segment can be attributed to the advantages of continuous flow centrifugation over
intermittent flow centrifugation, such as its rapidity and the need for fewer amounts of extracorporeal
volume (ECV).
95
TABLE 38 CENTRIFUGATION MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
US 447.9 485.0 525.9 864.1 8.6%
Canada 67.7 72.7 78.2 122.3 7.7%
Germany 78.5 85.4 93.1 157.8 9.2%
France 60.5 65.8 71.6 120.6 9.1%
Italy 46.5 49.6 52.9 79.1 6.9%
UK 38.9 41.8 45.0 70.8 7.8%
Spain 22.3 23.6 25.1 36.7 6.5%
China 75.4 84.9 95.6 197.7 12.9%
Japan 73.5 80.3 87.8 152.1 9.6%
India 23.8 26.5 29.6 58.1 11.9%
Brazil 15.8 17.3 19.1 34.3 10.3%
Mexico 13.8 15.1 16.5 28.8 9.7%
Others 134.6 144.2 154.7 239.2 7.5%
Total 1,127.8 1,223.2 1,328.8 2,216.0 8.9%
9.2.1 CONTINUOUS FLOW CENTRIFUGATION

9.2.1.1 Continuous flow is preferred in both blood collection and
therapeutic apheresis procedures
In 2018, the continuous flow centrifugation segment accounted for the largest share of 62.5% of the
centrifugation market. This segment is projected to reach USD 1,456.9 million by 2025 from USD 836.5
The continuous flow process involves the blood being separated and processed at a continuous pace. It
also requires two access sites in the donor/patient—one to draw blood and the other to return blood.
However, some newer systems are also associated with single-site access.
The continuous flow process is preferred in both blood collection and therapeutic apheresis. In therapeutic
apheresis, this technology is commonly used since it only needs a small amount of ECV and is associated
with a shorter procedural time and a relatively low volume of anticoagulants. These factors are
advantageous for both children and the elderly. Due to its advantages, the demand for continuous flow
apheresis products among hospitals and blood collection centers is on the rise. This is expected to drive
the growth of this segment during the forecast period.
96
TABLE 39 CONTINUOUS FLOW CENTRIFUGATION MARKET, BY COUNTRY,

US 290.3 316.5 345.6 590.8 9.3%
Canada 43.2 46.7 50.6 82.4 8.5%
Germany 49.2 54.0 59.3 104.8 10.0%
France 37.3 40.9 44.9 78.8 9.9%
Italy 28.2 30.3 32.6 50.9 7.7%
UK 23.2 25.1 27.3 44.9 8.7%
Spain 13.0 14.0 15.0 22.9 7.4%
China 48.1 54.5 61.8 133.2 13.6%
Japan 43.8 48.2 53.2 96.5 10.4%
India 13.9 15.7 17.6 36.2 12.8%
Brazil 9.2 10.2 11.3 21.2 11.1%
Mexico 7.9 8.8 9.7 17.7 10.6%
Others 75.8 81.9 88.6 143.9 8.4%
Total 699.2 764.2 836.5 1456.9 9.7%
9.2.2 INTERMITTENT FLOW CENTRIFUGATION

9.2.2.1 The need for a single venipuncture site is a major factor driving
the demand for intermittent flow centrifugation
In 2018, the intermittent flow centrifugation segment accounted for a share of 37.5% of the centrifugation
market. This segment is projected to reach USD 759.1 million by 2025 from USD 492.3 million in 2019, at
a CAGR of 7.5% during the forecast period.
In the intermittent flow process, blood is processed and separated in batches, and only one access site in
the donor/patient is required. The blood is pumped from the body into the apheresis instrument; hence,
the anticoagulant is automatically mixed with the blood to prevent coagulation. The major advantage of
this system is the requirement of a single venipuncture site, in comparison to the double-access sites used
in continuous flow centrifugation. However, the probability of fluctuations in hemodynamics and the
requirement of more ECV are the major reasons restraining the growth of this segment during the forecast
period.
97
TABLE 40 INTERMITTENT FLOW CENTRIFUGATION MARKET, BY COUNTRY,

US 157.6 168.4 180.3 273.3 7.2%
Canada 24.5 26.0 27.6 39.9 6.3%
Germany 29.3 31.4 33.8 53.0 7.8%
France 23.2 24.9 26.8 41.7 7.7%
Italy 18.3 19.3 20.3 28.1 5.6%
UK 15.7 16.7 17.8 25.9 6.5%
Spain 9.2 9.7 10.2 13.8 5.2%
China 27.3 30.4 33.8 64.5 11.4%
Japan 29.7 32.0 34.6 55.7 8.2%
India 9.8 10.9 12.0 21.8 10.5%
Brazil 6.6 7.2 7.8 13.1 8.9%
Mexico 5.9 6.3 6.8 11.1 8.4%
Others 58.8 62.3 66.1 95.3 6.3%
Total 428.6 459.0 492.3 759.1 7.5%
9.3 MEMBRANE SEPARATION
9.3.1 HIGHER EFFICACY OF THIS TECHNOLOGY ACCOUNTS FOR ITS HIGH

USAGE IN DEVELOPED WESTERN EUROPEAN COUNTRIES AND JAPAN
The membrane separation technology segment accounted for 22.4% of the apheresis market in 2018. This
segment is expected to reach USD 493.2 million by 2025 from USD 370.5 million in 2019, at a CAGR of
4.9% during the forecast period. Factors such as the increasing applications of membrane filtration
technology in therapeutic apheresis and the lower cost of membrane filtration as compared to
centrifugation are driving market growth.
In membrane separation (also known as filtration technology), blood is pumped through a membrane with
pores, allowing plasma to pass through while retaining blood cells. The blood components are separated
on the basis of the particle size difference. Membrane separators include filter or hollow-fiber membranes
with pore diameters ranging from 0.2 to 0.6 µm.
98
TABLE 41 SIZE OF BLOOD COMPONENTS
BLOOD COMPONENT SIZE
Red Blood Cells 8 µm
White Blood Cells – Leucocytes 25 µm
White Blood Cells – Lymphocytes 10 µm
Platelets Very small (about 2 µm)
Plasma Smallest (can pass through a capillary wall)
Source: World Apheresis Association and Journal of Apheresis
Membrane filters are used sequentially in a process known as double or cascade filtration, enabling the
removal of specific plasma pathogens without the need for replacement fluids. The higher efficacy of this
technology accounts for its high usage in developed Western European countries and Japan.
In this specific type of apheresis technology, a number of parameters need to be closely controlled.
Transmembrane pressure (TMP) is a critical factor for a successful apheresis procedure. Optimal TMP is
required for the good separation of blood components. Low TMP can reduce the chances of successful
separation, while high TMP can result in hemolysis. Moreover, the technology is not suitable for patients
with hyperviscosity syndrome due to the risk of paraproteinemia or cryoglobulinemia. Additionally, the
separation of blood components in this process is limited by the separation efficiency, which is referred to
as the sieving coefficient of plasma solutes. These factors limit the adoption of membrane separation
among end users to a certain extent.
TABLE 42 MEMBRANE SEPARATION MARKET: KEY PLAYERS AND PRODUCTS
COMPANY NAME PRODUCT
B. Braun (Germany)  Plasmat Futura Apheresis System
 PrismaFlex System
Baxter International (US)
 PRISMAX System
 Cellsorba EX
 Plasauto EZ
 Cascadeflo EC
 Plasmaflo OP
 IMMUSORBA TR
 IMMUSORBA PH
Asahi Kasei (Japan)  PLASORBA BR

 Rheofilter
 CUREFLO
 Cellsorba EX
 Sepacell RZ-2000
 Sepacell R-S11
 Sepacell PLX-5
99
 LEUKOsmart
Medica S.p.A (Italy)
 PLASMART Plasmafilters
 Plasmacure PE
Kawasumi Laboratories (Japan)  Evaflux

 Evacure/Evaclio
Kaneka Corporation (Japan)  LDL–APHERESIS SYSTEM (Liposorber LA-15 and Liposorber LA-40S)
TABLE 43 MEMBRANE SEPARATION MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
US 131.5 136.7 142.2 181.5 4.1%
Canada 20.6 21.3 22.0 27.1 3.6%
Germany 25.2 26.4 27.8 37.9 5.3%
Italy 12.7 13.0 13.3 15.6 2.7%
UK 10.8 11.2 11.6 14.5 3.8%
Spain 6.3 6.4 6.6 7.8 2.7%
China 23.9 25.9 28.1 46.2 8.7%
Japan 24.6 26.0 27.5 39.4 6.2%
India 7.3 7.9 8.5 13.7 8.2%
Brazil 4.8 5.1 5.5 8.1 6.7%
Mexico 4.3 4.5 4.8 6.9 6.3%
Others 41.7 43.2 45.0 58.0 4.3%
Total 338.9 354.1 370.5 493.2 4.9%
100
10 APHERESIS MARKET, BY APPLICATION
KEY FINDINGS
 In 2018, the plasmapheresis segment accounted for the largest share of 46.3% of the
 The increasing demand for plasma from biopharmaceutical companies and the use of
plasmapheresis as a key therapeutic apheresis procedure are the primary factors driving the
growth of the plasmapheresis market
 The photopheresis segment is estimated to grow at a CAGR of 8.7% during the forecast period.
The high growth of this segment can be attributed to the increasing prevalence of blood
disorders and the rising demand for photopheresis in organ transplant rejection treatments.
 The plateletpheresis segment accounted for a share of 33.4% of the apheresis market in 2018.
This segment is projected to reach USD 876.4 million by 2025 from USD 565.6 million in 2019,
at a CAGR of 7.6% during the forecast period.
 The erythrocytapheresis segment is expected to reach USD 360.5 million by 2025 from USD
101
10.1 INTRODUCTION
On the basis of application, the apheresis market has been segmented into plasmapheresis,
plateletpheresis, erythrocytapheresis, leukapheresis, photopheresis, and other applications. In 2018, the
plasmapheresis segment accounted for the largest share of 46.3% of this market, majorly due to the high
adoption of plasmapheresis in the treatment of various neurological, immunological, and renal diseases
and the high and growing demand for plasma and its components among pharmaceutical and
biopharmaceutical companies.
TABLE 44 APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Application 2017 2018 2019 2025 CAGR (2019–2025)
Plasmapheresis 675.5 730.3 790.9 1,301.1 8.6%
Plateletpheresis 492.8 527.4 565.6 876.4 7.6%
Erythrocytapheresis 207.5 221.4 236.8 360.5 7.3%
Leukapheresis 45.1 48.6 52.4 84.4 8.3%
Photopheresis 18.9 20.5 22.2 36.8 8.7%
Other Applications 27.0 29.0 31.3 50.0 8.1%
Total 1,466.8 1,577.3 1,699.2 2,709.2 8.1%
10.2 PLASMAPHERESIS
10.2.1 PLASMAPHERESIS IS THE LARGEST APPLICATION SEGMENT

IN THE APHERESIS MARKET
Plasmapheresis is the process of separation of plasma from the cellular components of blood using
centrifugation or membrane separation to collect plasma. This process is carried out for two major
purposes—for the collection of source plasma and for therapeutic plasmapheresis [i.e., therapeutic plasma
exchange (TPE)].
The American Society for Apheresis (ASFA) has listed the various indications for the use of apheresis as a
treatment. TPE is an ideal indication for the treatment of neurological conditions (such as Guillain-Barre
Syndrome and chronic inflammatory demyelinating polyneuropathy), non-neurologic conditions (such as
myasthenia gravis, hyperviscosity syndrome, thrombotic thrombocytopenic purpura, hemolytic uremic
syndrome, and idiopathic thrombocytopenia), renal diseases, and rheumatologic diseases.
TPE is also indicated for the following conditions:
 Antiglomerular basement membrane disease (Goodpasture syndrome)
 Paraproteinemic demyelinating polyneuropathy (IgG/IgA or IgM)
 ANCA-associated rapidly progressive glomerulonephritis
 Recurrent focal segmental glomerulosclerosis in transplanted kidneys
 Desensitization for ABOi living donor liver transplantation
 Desensitization for ABOi or ABO living donor kidney transplantation or antibody-mediated
rejection
102
 NMDA antibody encephalitis

 Progressive multifocal leukoencephalopathy, post-Natalizumab
 Acute liver failure
 Wilson’s disease (fulminant)
Rheopheresis is a form of therapeutic plasmapheresis designed to remove species circulating in the blood
that are larger than 25 nm (about 500 kilodaltons) using a double-staged membrane filtration system. The
rationale behind the use of rheopheresis is that high-molecular-weight molecules that have been
associated with the risk of age-related macular degeneration (AMD) (e.g., fibrinogen, LDL-cholesterol,
fibronectin, Von Willebrand factor) are removed from the patient’s plasma. This results in a reduction in
blood and plasma viscosity, platelet and red cell aggregation, and enhanced red cell membrane flexibility.
In donor plasmapheresis, the collected source plasma is transfused directly to patients, or further plasma
proteins are separated from source plasma. These plasma-derived proteins are used in various therapies.
The growth of this application segment is mainly driven by the rising demand for plasma from
biopharmaceutical companies, increasing source plasma collection across the globe, and increasing
application areas of plasma fractionation products. Intravenous immunoglobulin (IVIG), albumin, and factor
VIII are the key plasma-derived products that are used for the treatment of various conditions, such as
hemostasis disorders. Owing to this, the market for these products is expected to grow at a high CAGR
during the forecast period. Biopharmaceutical companies need raw plasma for the production of plasma-
derived products from the plasma fractionation process. Therefore, it creates a demand for plasma for
fractionation and drives the plasmapheresis market.
TABLE 45 TOTAL SOURCE PLASMA COLLECTION IN THE US & EUROPE,

2007–2017 (MILLION LITERS)
Year US Europe
2007 15.33 1.7
2008 18.82 2
2009 22.03 2.3
2010 19.81 2.4
2011 23.57 2.6
2012 26.21 2.7
2013 29.39 2.8
2014 32.55 3.1
2015 35.46 3.2
2016 38.3 3.3
2017 42.4 NA
Source: Plasma Protein Therapeutics Association (2016) and Bank of America Merrill Lynch Global Research, 2017.
In recent years, plasmapheresis is increasingly used as a method of detoxification in clinical toxicology and
in acute self-limited diseases (such as Guillain-Barré syndrome) to acutely lower circulating pathogenic
substances. This is a major factor driving the growth of this application segment in developing countries.
103
TABLE 46 KEY PRODUCTS AVAILABLE FOR PLASMAPHERESIS AND THERAPEUTIC

PLASMA EXCHANGE
 PCS 2/ PCS 300 Plasma Collection System - For plasmapheresis

 NexSys PCS Plasmapheresis System
 Amicus Cell Separator for Plasmapheresis and TPE

 Autopheresis-C Plasmapheresis System
Fresenius Kabi (Germany)  Aurora and Aurora Xi Plasmapheresis System

 NxStage System One for TPE
 Alyx for Plasma collection
Terumo BCT (US)  COBE Spectra/Spectra Optia for TPE
 PRISMAFLEX System for TPE

Baxter International (US)
 PRISMAX System for TPE
 Plasma Separator Plasmacure PE
Kawasumi Laboratories (Japan)  Plasma Separator Evacure/Evaclio (EC-4C, EC-2C)

 Plasma Separator Evaflux (2A, 3A, 4A, 5A)
Cerus Corporation (US)  INTERCEPT System for Plasma Collection
 Rheofilter ER for Rheopheresis

 Plasmaflo OP for Plasmapheresis
 Cascadeflo EC for Plasmapheresis
Asahi Kasei Corporation (Japan)  IMMUSORBA TR for Plasmapheresis

 IMMUSORBA PH for Plasmapheresis
 PLASORBA BR for Plasmapheresis
 PlasautoΣ for Plasmapheresis
Kaneka Corporation (Japan)  PLASMA LIPOSORBER LA-15
104
TABLE 47 APHERESIS MARKET FOR PLASMAPHERESIS, BY COUNTRY, 2017–2025 (USD MILLION)
US 258.6 279.0 301.5 487.2 8.3%
Canada 40.6 43.4 46.5 71.6 7.4%
Germany 47.6 51.6 56.0 93.5 8.9%
France 34.4 37.3 40.5 67.1 8.8%
Italy 26.8 28.5 30.3 44.6 6.7%
UK 22.8 24.4 26.2 40.7 7.6%
Spain 13.4 14.2 15.0 21.7 6.3%
China 47.2 52.8 59.3 120.4 12.5%
Japan 47.0 51.2 55.9 95.5 9.4%
India 14.8 16.4 18.3 35.4 11.6%
Brazil 9.8 10.8 11.8 21.0 10.0%
Mexico 8.9 9.7 10.6 18.3 9.5%
Others 86.0 91.9 98.4 150.9 7.4%
Total 675.5 730.3 790.9 1,301.1 8.6%
10.3 PLATELETPHERESIS
10.3.1 INCREASING DEMAND FOR PLATELETS IN TRANSFUSIONS TO DRIVE

MARKET GROWTH
The plateletpheresis segment accounted for 33.4% of the apheresis market in 2018. This segment is
expected to reach USD 876.4 million by 2025 from USD 565.6 million in 2019, at a CAGR of 7.6% during
the forecast period.
Plateletpheresis is a procedure in which platelets are separated from other blood components, for either
platelet transfusion or therapeutic purposes. Platelets are responsible for clot formation to stop bleeding in
an injury. People with low platelet counts suffer from thrombocytopenia. Thrombocytopenia can occur due
to various medical conditions & diseases, including rare bone marrow diseases [such as aplastic anemia,
myelodysplastic syndromes (MDS), and Paroxysmal nocturnal hemoglobinuria (PNH)], drug treatment for
leukemia, platelet destruction, and dengue. A plateletpheresis procedure performed to collect platelets
takes 90 to 120 minutes. Therapeutic plateletpheresis procedures are performed on patients with
myeloproliferative disorders and hemorrhage or thrombosis associated with an increase in circulating
platelets.
105
The growing demand for platelets and therapeutic plateletpheresis in developed European countries, the
US, and Japan; improved blood collection efficiencies; and the increasing awareness about apheresis
blood collection in emerging economies are driving the growth of this market. Additionally, the growing
number of critical surgeries and organ transplant procedures across the globe will increase the demand for
plateletpheresis procedures during the forecast period.
However, the shortage of platelets is a critical factor in the plateletpheresis market; the short life cycle and
a limited number of donations are hampering the growth of the plateletpheresis market.
TABLE 48 KEY PRODUCTS AVAILABLE FOR PLATELETPHERESIS
Terumo BCT (US) COBE Spectra/Spectra Optia for Platelet Depletion
Cerus Corporation (US) INTERCEPT System for Plasma and Platelets
Haemonetics Corporation (US) MCS+ 9000 Mobile Platelet Collection System
 Fenwal Amicus Cell Separator for Plateletpheresis
Fresenius Kabi (Germany)  AmiCORE Platelet Apheresis System

 Com.TEC
Asahi Kasei Corporation (Japan) Platelet Filtration Sepacell PLX-5
TABLE 49 APHERESIS MARKET FOR PLATELETPHERESIS, BY COUNTRY, 2017–2025 (USD MILLION)
US 197.18 210.58 225.27 342.67 7.2%
Canada 29.56 31.31 33.23 48.20 6.4%
Germany 34.45 36.99 39.80 62.60 7.8%
France 26.10 28.00 30.09 47.06 7.7%
Italy 20.10 21.15 22.29 30.97 5.6%
UK 16.73 17.75 18.87 27.66 6.6%
Spain 9.53 9.99 10.50 14.30 5.3%
China 33.15 36.80 40.91 78.42 11.5%
Japan 32.11 34.63 37.42 60.38 8.3%
India 10.71 11.79 13.01 23.80 10.6%
Brazil 6.77 7.35 7.99 13.40 9.0%
Mexico 5.81 6.28 6.79 11.05 8.4%
Others 57.69 61.04 64.71 93.59 6.3%
Total 492.77 527.43 565.59 876.36 7.6%
106
10.4 ERYTHROCYTAPHERESIS
10.4.1 INCREASING DEMAND FOR RED BLOOD CELLS FOR TRANSFUSION IN

SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
In 2018, the erythrocytapheresis segment accounted for a share of 14.0% of the apheresis market. This
segment is projected to reach USD 360.5 million by 2025 from USD 236.8 million in 2019, at a CAGR of
7.3% during the forecast period.
Erythrocytapheresis is a procedure where red blood cells (RBCs) are separated from other blood
components for either blood component collection or therapeutic purposes. Red cell apheresis is used to
improve the ratio of normal to abnormal red cells in hemoglobinopathies and protozoan disease, and to
remove excess red cells, red cell-associated toxins, or excess iron from the body.
Also, therapeutic erythrocytapheresis is performed on patients with damaged erythrocytes because of

organ failure (the kidneys), sickle-cell anemia, severe malaria, hemorrhagic disease of the newborn (HDN),
polycythemia vera, paroxysmal nocturnal hemoglobinuria (PNH), and arsenic poisoning. During therapeutic
erythrocytapheresis procedures, defective RBCs of patients are removed, and the remaining blood
components along with the RBCs collected from donors are reinfused into the circulatory system.
Growth in the erythrocytapheresis segment is driven by the rising demand for RBCs for transfusion in
various surgical procedures. The demand for therapeutic erythrocytapheresis procedures is driven by the
growing prevalence of diseases that damage RBCs.
TABLE 50 KEY PRODUCTS AVAILABLE FOR ERYTHROCYTAPHERESIS
Terumo BCT (US) COBE Spectra/Spectra Optia for Red Blood Cell Exchange
 Fenwal Amicus Cell Separator for Red Blood Cell Collection

Fresenius Kabi (Germany)
 Alyx for RBC Collection
Asahi Kasei Corporation (Japan) RBC Filtration Sepacell R-S11
107
TABLE 51 APHERESIS MARKET FOR ERYTHROCYTAPHERESIS, BY COUNTRY,

US 85.4 91.0 97.0 145.4 7.0%
Canada 12.5 13.2 13.9 19.9 6.1%
Germany 14.7 15.7 16.9 26.1 7.6%
France 11.2 12.0 12.9 19.8 7.5%
Italy 8.5 9.0 9.4 12.9 5.4%
UK 7.1 7.5 7.9 11.4 6.3%
Spain 4.0 4.2 4.4 5.8 5.0%
China 13.2 14.6 16.2 30.6 11.2%
Japan 13.3 14.4 15.5 24.6 8.0%
India 3.6 3.9 4.3 7.8 10.3%
Brazil 2.7 3.0 3.2 5.3 8.7%
Mexico 2.4 2.6 2.8 4.4 8.2%
Others 23.7 25.0 26.5 37.6 6.0%
Total 207.5 221.4 236.8 360.5 7.3%
10.5 LEUKAPHERESIS
10.5.1 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA

TO DRIVE THE LEUKAPHERESIS MARKET
In 2018, the leukapheresis segment accounted for a share of 3.1% of the apheresis market. This segment
is projected to reach USD 84.4 million by 2025 from USD 52.4 million in 2019, at a CAGR of 8.3% during
Leukapheresis is a procedure in which white blood cells (WBCs) (including leukemia cells) are separated
from whole blood. Leukapheresis is a therapeutic apheresis procedure, mostly used to treat patients with
acute leukemia.
Leukapheresis techniques reduce the leucocyte count by 20% to 50%, based on the sedimentation
properties of the particular blast cell population. Leukapheresis is a procedure that quickly reduces the
number of leukemia cells, but without further treatment of the patient (with either chemotherapy,
monoclonal antibodies, or targeted therapy), the leukemia cell count may increase again.
108
TABLE 52 KEY PRODUCTS AVAILABLE FOR LEUKAPHERESIS
COBE Spectra/Spectra Optia for White Blood Cell Depletion and Granulocyte
Terumo BCT (US)
Collection
Otsuka Pharmaceuticals (Japan) Adacolumn System
Fresenius Kabi (Germany) Fenwal Amicus Cell Separator for Mononuclear Cells
Medica SpA (Italy) Leukapheresis Machine LA25
TABLE 53 APHERESIS MARKET FOR LEUKAPHERESIS, BY COUNTRY, 2017–2025 (USD MILLION)
US 18.95 20.36 21.92 34.58 7.9%
Canada 2.79 2.98 3.18 4.78 7.0%
Germany 3.31 3.58 3.87 6.32 8.5%
France 2.43 2.62 2.83 4.60 8.4%
Italy 1.86 1.97 2.09 3.01 6.3%
UK 1.40 1.50 1.60 2.43 7.2%
Spain 0.76 0.80 0.84 1.19 5.9%
China 3.03 3.39 3.79 7.54 12.1%
Japan 2.94 3.19 3.47 5.80 9.0%
India 1.19 1.31 1.46 2.77 11.3%
Brazil 0.72 0.79 0.87 1.50 9.7%
Mexico 0.58 0.63 0.68 1.15 9.1%
Others 4.16 4.42 4.71 6.98 6.8%
Total 45.10 48.58 52.43 84.41 8.3%
10.6 PHOTOPHERESIS
10.6.1 PHOTOPHERESIS IS EXPECTED TO GROW AT THE HIGHEST CAGR

DURING THE FORECAST PERIOD
In 2018, the photopheresis segment accounted for a share of 1.3% of the apheresis market. This segment
is projected to reach USD 36.8 million by 2025 from USD 22.2 million in 2019, at a CAGR of 8.7% during
Photopheresis is a process in which white blood cells (WBCs) are separated from the blood and exposed to
ultraviolet light, which assists in the complete removal of the diseased cells. Photopheresis is also called
as extracorporeal photopheresis or extracorporeal photochemotherapy. Currently, photopheresis is
109
indicated to reduce skin problems associated with cutaneous T-cell lymphomas (CTCL), such as mycosis
fungoides or Sezary syndrome. Photopheresis has also been used effectively in the treatment of
epidermolysis bullosa acquisita; in the treatment of conditions such as graft-versus-host disease (GVHD); in
conditions such as organ transplant rejection, including that of heart, lung, and kidneys; and in the
treatment of bronchiolitis obiterans, scleroderma, and other autoimmune diseases.
The growth of this market is driven by the increasing prevalence of blood disorders and the rising demand
for photopheresis in organ transplant rejection treatment.
TABLE 54 KEY PRODUCTS AVAILABLE FOR PHOTOPHERESIS
 UVAR-XTS Photopheresis Systems

Therakos (US)
 THERAKOS CELLEX Photopheresis System
TABLE 55 APHERESIS MARKET FOR PHOTOPHERESIS, BY COUNTRY, 2017–2025 (USD MILLION)
US 7.45 8.05 8.71 14.18 8.5%
Canada 1.20 1.29 1.39 2.15 7.6%
Germany 1.95 2.12 2.31 3.89 9.1%
France 1.00 1.09 1.18 1.98 9.0%
Italy 0.82 0.88 0.93 1.39 6.8%
UK 0.92 0.99 1.06 1.66 7.8%
Spain 0.39 0.42 0.44 0.65 6.5%
China 1.07 1.21 1.36 2.78 12.7%
Japan 1.30 1.42 1.55 2.68 9.5%
India 0.42 0.47 0.52 1.02 11.9%
Brazil 0.20 0.22 0.25 0.44 10.2%
Mexico 0.13 0.14 0.16 0.27 9.7%
Others 1.77 1.89 2.03 3.10 7.3%
Total 18.95 20.50 22.23 36.76 8.7%
110
10.7 OTHER APPLICATIONS

Other applications include lipidpheresis, lymphapheresis, immunoadsorption, and stem cell collection.
Among these, immunoadsorption is the most widely used apheresis technique.
LDL apheresis selectively removes low-density lipoproteins from the blood while returning the remaining
components. A variety of instruments are available which remove LDL cholesterol based on charge
(dextran sulfate and polyacrylate), size (double-membrane filtration), precipitation at low pH (HELP), or
immunoadsorption with anti-Apo B-100 antibodies.
In immunoadsorption, the plasma of patients is passed over a specific adsorption column (protein A
column) that removes immunoglobulin G and circulates immune complexes from the plasma. The
therapeutic apheresis process usually takes several hours and is performed in an outpatient facility.
TABLE 56 KEY PRODUCTS AVAILABLE FOR OTHER APPLICATIONS OF APHERESIS
COMPANY NAME PRODUCT APPLICATION
 H.E.L.P. (heparin-induced extracorporeal LDL

B. Braun (Germany) Plasmat Futura System
 Precipitation) Apheresis - LDL Apheresis
TABLE 57 APHERESIS MARKET FOR OTHER APPLICATIONS, BY COUNTRY,

US 11.91 12.79 13.76 21.70 7.9%
Canada 1.65 1.75 1.87 2.82 7.0%
Germany 1.73 1.87 2.03 3.30 8.5%
France 1.60 1.73 1.87 3.03 8.4%
Italy 1.13 1.19 1.26 1.82 6.3%
UK 0.86 0.91 0.98 1.48 7.2%
Spain 0.54 0.57 0.60 0.85 5.9%
China 1.67 1.86 2.08 4.14 12.1%
Japan 1.29 1.40 1.52 2.55 9.0%
India 0.42 0.46 0.51 0.97 11.3%
Brazil 0.35 0.38 0.41 0.72 9.6%
Mexico 0.27 0.30 0.32 0.54 9.1%
Others 3.00 3.19 3.40 5.06 6.9%
Total 26.97 29.02 31.28 50.02 8.1%
111
11 APHERESIS MARKET, BY END USER
KEY FINDINGS
 In 2018, the blood collection centers and blood component providers segment accounted for
the largest share of 67.5% of the apheresis market. This segment is projected to reach USD
1,766.2 million by 2025 from USD 1,141.6 million in 2019, at a CAGR of 7.5% during the
forecast period.
 The large share of this segment is attributed to the increasing number of blood component
donations and growing awareness, among other factors.
 The hospitals and transfusion centers segment is estimated to grow at the highest CAGR of
 The other end users segment is expected to reach USD 122.4 million by 2025 from USD 83.8
112
11.1 INTRODUCTION
On the basis of end user, the apheresis market has been segmented into blood collection centers and
blood component providers, hospitals and transfusion centers, and other end users.
FIGURE 30 BLOOD COLLECTION CENTERS AND BLOOD COMPONENT PROVIDERS SEGMENT

TO DOMINATE THE APHERESIS MARKET DURING THE FORECAST PERIOD
2,100.0
1,800.0
1,500.0
1,200.0
900.0
600.0
300.0
0.0
Blood Collection Centers and Hospitals and Transfusion
Other End Users
Blood Component Providers Centers
2019 1,141.6 473.9 83.8
2025 1,766.2 820.6 122.4
CAGR 7.5% 9.6% 6.5%
TABLE 58 APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

Blood Collection Centers and Blood
994.7 1,064.7 1,141.6 1,766.2 7.5%
Component Providers
Hospitals and Transfusion Centers 397.7 433.7 473.9 820.6 9.6%
Other End Users 74.4 78.9 83.8 122.4 6.5%
Total 1,466.8 1,577.3 1,699.2 2,709.2 8.1%
In 2018, the blood collection centers and blood component providers segment accounted for the largest
share of 67.5% of the global apheresis market. The large share of this end-user segment is mainly
attributed to the rising number of blood component donations, a growing number of blood centers, and
increasing awareness.
However, the hospitals and transfusion centers segment is estimated to grow at the highest CAGR of 9.6%
during the forecast period. The high growth of this segment can be attributed to the increasing adoption of
therapeutic apheresis in the treatment of various diseases, growing indications of therapeutic apheresis,
and rising awareness of apheresis as a therapy.
113
11.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS
11.2.1 BLOOD COLLECTION CENTERS AND BLOOD COMPONENT PROVIDERS

HOLD A MAJOR SHARE OF THE APHERESIS MARKET
In 2018, the blood collection centers & blood component providers segment accounted for the largest
share of 67.5% of the apheresis market. This segment is projected to reach USD 1,766.2 million by 2025
from USD 1,141.6 million in 2019, at a CAGR of 7.5% during the forecast period. The large share of this
segment is mainly attributed to the increasing demand for apheresis devices and related disposables &
reagents in this segment. This, in turn, is driven by the growing number of blood donations, increasing
demand for blood components in clinical conditions, and rising awareness.
This end-user segment includes blood management companies, collection centers (private and public),
component providers, and blood banks. Cellular apheresis donations for platelets and WBCs are mainly
performed in blood banks, while collection centers use centrifugation-based apheresis devices for the
separation and collection of various components of blood.
TABLE 59 APHERESIS MARKET FOR BLOOD COLLECTION CENTERS AND BLOOD COMPONENT
PROVIDERS, BY COUNTRY, 2017–2025 (USD MILLION)
US 384.0 410.0 438.4 664.7 7.2%
Canada 59.6 63.1 67.0 96.9 6.3%
Germany 69.4 74.5 80.2 126.0 7.8%
France 50.5 54.1 58.1 90.4 7.6%
Italy 39.6 41.7 43.9 60.7 5.6%
UK 33.8 35.9 38.1 55.7 6.5%
Spain 19.4 20.4 21.4 29.1 5.3%
China 65.6 72.8 80.9 154.6 11.4%
Japan 69.0 74.5 80.5 130.3 8.4%
India 22.4 24.7 27.3 50.0 10.6%
Brazil 14.2 15.5 16.8 28.2 9.0%
Mexico 12.7 13.7 14.8 24.1 8.5%
Others 127.8 135.4 143.7 209.3 6.5%
Total 994.7 1,064.7 1,141.6 1,766.2 7.5%
114
11.3 HOSPITALS AND TRANSFUSION CENTERS
11.3.1 HOSPITALS AND TRANSFUSION CENTERS SEGMENT IS EXPECTED TO

GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
In 2018, the hospitals and transfusion centers segment accounted for a share of 27.5% of the apheresis
market. This segment is projected to reach USD 820.6 million by 2025 from USD 473.9 million in 2019, at
a CAGR of 9.6% during the forecast period. This segment also includes cancer treatment centers.
Medium-sized and large hospitals use centrifugation-based apheresis devices for donor apheresis and
therapeutic apheresis. Among hospitals and cancer treatment centers, the ability to pay for the high cost of
centrifugation-based apheresis devices, the availability of larger office spaces, and a larger patient pool are
the major driving factors for the adoption of centrifugation-based apheresis devices. Small hospitals with
fewer patients adopt membrane filtration-based apheresis.
The number of organ transplant surgeries has increased over the last decade. According to the US
Department of Health and Human Services, the number of organ transplant surgeries increased from
28,100 in 2005 to 30,973 in 2015. This growth is also expected to drive the market for therapeutic
apheresis in hospitals, as patients are prone to more blood loss during these procedures.
The increasing demand for blood components used in the treatment of various neurological, renal,
autoimmune, and oncological diseases; rising number of complex surgical procedures; and growth in the
number of hospitals performing transfusions are the major factors driving the growth of hospitals and
transfusion centers.
TABLE 60 NUMBER OF HOSPITALS PERFORMING BLOOD TRANSFUSIONS, BY REGION, 2015
REGION NUMBER OF HOSPITALS PERFORMING BLOOD TRANSFUSIONS
Western Pacific 11,619
North America and Latin America 9,084
Europe 5,529
Africa 4,507
Southeast Asia 3,662
Eastern Mediterranean 2,233
Source: WHO
115
TABLE 61 APHERESIS MARKET FOR HOSPITALS AND TRANSFUSION CENTERS, BY COUNTRY,

US 163.6 178.0 194.0 329.8 9.2%
Canada 24.3 26.3 28.4 46.0 8.4%
Germany 28.2 30.8 33.8 59.4 9.9%
France 22.0 24.1 26.3 46.0 9.8%
Italy 16.7 17.9 19.2 29.8 7.6%
UK 13.7 14.8 16.1 26.3 8.6%
Spain 7.7 8.2 8.8 13.4 7.3%
China 28.3 32.0 36.2 77.6 13.5%
Japan 24.4 26.8 29.5 53.1 10.3%
India 7.5 8.4 9.5 19.3 12.7%
Brazil 5.4 6.0 6.6 12.4 11.0%
Mexico 4.6 5.1 5.6 10.2 10.5%
Others 42.0 45.2 48.8 78.3 8.2%
Total 397.7 433.7 473.9 820.6 9.6%
11.4 OTHER END USERS

In 2018, the other end users segment accounted for a share of 5.0% of the apheresis market. This
segment is projected to reach USD 122.4 million by 2025 from USD 83.8 million in 2019, at a CAGR of
6.5% during the forecast period. Other end users include emergency medical service providers, acute care
centers, and medical & academic institutes.
Acute care centers and emergency medical service providers use centrifugation and membrane filtration
technology to perform therapeutic apheresis. TPE is mostly indicated in emergencies for the management
of life-threatening conditions, for which emergency therapeutic apheresis (24 hours a day) is the primary
mode of acute treatment. These conditions include:
 Thrombotic thrombocytopenic purpura (TTP)

 Acute chest syndrome in sickle-cell disease
 Thrombocytosis
 Hyperleukocytosis
 Hyperviscosity
116
High costs and the need for sufficient office space for these machines make it difficult for care centers to
purchase apheresis machines. In addition to this, fewer patients visit these centers as compared to other
end users; this further hampers the adoption of apheresis instruments.
TABLE 62 APHERESIS MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2025 (USD MILLION)
US 31.88 33.72 35.72 51.18 6.2%
Canada 4.33 4.54 4.77 6.52 5.3%
Germany 6.13 6.52 6.94 10.28 6.8%
France 4.29 4.56 4.85 7.14 6.7%
Italy 2.96 3.09 3.22 4.22 4.6%
UK 2.20 2.31 2.43 3.36 5.5%
Spain 1.41 1.47 1.53 1.96 4.2%
China 5.36 5.89 6.49 11.71 10.3%
Japan 4.67 4.99 5.34 8.12 7.2%
India 1.17 1.28 1.40 2.41 9.5%
Brazil 1.00 1.08 1.16 1.83 7.9%
Mexico 0.78 0.83 0.89 1.36 7.4%
Others 6.59 6.89 7.22 9.72 5.1%
Total 74.39 78.86 83.76 122.39 6.5%
117
12 APHERESIS MARKET, BY REGION
KEY FINDINGS
 In 2018, North America accounted for the largest share of 45.4% of the apheresis market,
followed by Europe, accounting for 27.1%.
 The US accounted for the largest share of 86.9% of the apheresis market in North America in
2018. This market is projected to reach USD 1,045.6 million by 2025 from USD 668.2 million
in 2019, at a CAGR of 7.8%.
 Germany held the largest share of 26.1% of the European apheresis market in 2018.
 The Asia Pacific market is estimated to grow at the highest CAGR of 10.0% during the forecast
period. This can be attributed to the rising incidence of blood disorders/diseases among the
growing population, increasing demand for blood owing to the growth in the number of surgical
procedures, government support for healthcare infrastructure development, and the rising
number of government-licensed and accredited blood banks.
 The apheresis market in Latin America is projected to reach USD 102.7 million by 2025 from
USD 60.8 million in 2019, at a CAGR of 9.1%.
118
12.1 INTRODUCTION
The apheresis market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle
East & Africa. In 2018, North America accounted for the largest share of 45.4% of the apheresis market.
The large share of this region can be attributed to the easier accessibility to advanced blood collection
technologies, the presence of an established healthcare infrastructure, and the increasing presence of
leading apheresis companies in the region.
Europe is the second-largest market for apheresis. It is mainly characterized by the increasing demand for
apheresis collection, growth in the scope of therapeutic apheresis & its applications, and the presence of
leading players in this region.
A majority of the market growth is expected from emerging countries across the Asia Pacific and Latin
America. The APAC is expected to be the fastest-growing regional market, with India and China projected to
witness strong growth in the coming years.
FIGURE 31 APHERESIS MARKET: GEOGRAPHIC SNAPSHOT (2018)
UK
Canada 7.1% China
6.9% Germany 12.0%
France 8.4%
US 8.2% Italy
7.8% Japan
6.1%
8.8%
Spain
Mexico 5.8%
9.0%
Brazil India
9.5% Middle East & Africa 11.1%
7.7%
<6.5% 6.5–8.5% >8.5%

Growth Growth Growth
119
TABLE 63 APHERESIS MARKET, BY REGION, 2017–2025 (USD MILLION)
North America 667.7 715.6 768.3 1,195.1 7.6%
Europe 401.7 428.1 457.1 689.5 7.1%
APAC 308.3 337.2 369.6 654.1 10.0%
Latin America 51.4 55.8 60.8 102.7 9.1%
Total 1,466.8 1,577.3 1,699.2 2,709.2 8.1%
North America accounted for the largest share of 45.4% of the global apheresis market in 2018. This can
be attributed to the easier accessibility to advanced blood collection technologies, the presence of a large
number of leading apheresis companies in this region, and an established healthcare infrastructure. This
market is projected to reach USD 1,195.1 million by 2025 from USD 768.3 million in 2019, at a CAGR of
The Asia Pacific market is expected to register the highest growth during the forecast period, primarily due
to the increasing necessity of apheresis for the treatment of various diseases. Additionally, a larger patient
population in the emerging markets of India and China also contributes to growth in this region. As a result,
a majority of the leading global companies continuously focus on developing and expanding their
manufacturing capabilities & distribution networks in the Asia Pacific region.
12.2 NORTH AMERICA

North America, comprising the US and Canada, held a share of 45.4% of the apheresis market in 2018.
This market is projected to reach USD 1,195.1 million by 2025 from USD 768.3 million in 2019, at a CAGR
of 7.6% during the forecast period.
The US accounted for the largest share of 86.9% of the North American apheresis market in 2018, while
Canada accounted for the remaining 13.1%. A number of factors such as the increasing prevalence of
cardiovascular & neurological diseases, rising number of accident & trauma cases, and growing instances
of surgical procedures are increasing the demand for blood components for transfusion. This, in turn,
drives the automated blood component collection market to overcome blood shortages. Similarly, financial
access to therapeutic apheresis therapies; the availability of reimbursement for these procedures; FDA-
approved therapeutic apheresis procedures for various diseases; and the availability of hospitals,
transfusion centers, and cancer centers for therapeutic apheresis are the leading factors driving the
growth of the therapeutic apheresis market in the North American region.
In addition to this, the increasing applications of apheresis products in plasma collection and fractionation,
rising demand for plasma-derived products for therapeutic applications, and technological developments in
the US plasma collection industry are also driving the growth of the North American apheresis market. The
growing number of hemophilic patients will also lead to an increase in the adoption of apheresis
procedures in North America.
120
TABLE 64 NORTH AMERICA: HEMOPHILIA PATIENTS, 2013 VS. 2017
Country 2013 2017 Change %
US 17,073 17,750 4.0%
Canada 3,704 4,023 8.6%
Total 20,777 21,773 4.8%
Source: World Federation of Hemophilia
However, the high cost of apheresis therapeutic procedures is restraining the growth of this market. The
greatest challenge for the wide-scale adoption of apheresis procedures is primarily recruiting donors for
apheresis collection.
FIGURE 32 NORTH AMERICA: APHERESIS MARKET SNAPSHOT
NORTH AMERICA
7.6% CAGR USD 768.3 Million 45.4%

Share of the Region in the Global
(2019–2025) Market Size in 2019
Market in 2018
BY PRODUCT, 2019 (USD MILLION) BY END USER, 2019 (USD MILLION)
Blood Collection Centers and

Apheresis 505.4
626.8 Blood Component Providers
Disposables
Hospitals and Transfusion
222.4
Centers
Apheresis Devices 141.6
Other End Users 40.5
BY COUNTRY FACTORS DRIVING MARKET GROWTH
MARKET SIZE, CAGR  Rising incidence of chronic diseases and blood

COUNTRY disorders in the US
2019 (USD MILLION) (2019–2025)
 Presence of a well-established healthcare market
US 668.2 7.8%
 Rise in demand for source plasma from
Canada 100.2 6.9% biopharmaceutical companies
121
TABLE 65 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
Country 2017 2018 2019 2025 CAGR (2019–2025)
US 579.4 621.7 668.2 1,045.6 7.8%
Canada 88.3 93.9 100.2 149.5 6.9%
Total 667.7 715.6 768.3 1,195.1 7.6%
TABLE 66 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Apheresis Disposables 538.6 580.6 626.8 1,005.1 8.2%
Total 667.7 715.6 768.3 1,195.1 7.6%
TABLE 67 NORTH AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 129.1 135.1 141.6 190.0 5.0%
TABLE 68 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

511.4 546.9 585.9 899.2 7.4%
(Donor Apheresis)
Total 667.7 715.6 768.3 1,195.1 7.6%
122
TABLE 69 NORTH AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,

Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 156.3 168.7 182.4 295.9 8.4%
TABLE 70 NORTH AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 41.7 45.1 48.7 78.5 8.3%
Renal Disorders 16.5 17.9 19.5 32.4 8.8%
Other Disorders 4.2 4.5 4.8 6.9 6.4%
Total 140.2 152.0 165.1 274.0 8.8%
TABLE 71 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 515.6 557.7 604.1 986.4 8.5%
Total 667.7 715.6 768.3 1,195.1 7.6%
123
TABLE 72 NORTH AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE,

Type 2017 2018 2019 2025 CAGR (2019–2025)
Continuous Flow Centrifugation 333.4 363.2 396.2 673.3 9.2%
Intermittent Flow Centrifugation 182.1 194.4 207.9 313.2 7.1%
Total 515.6 557.7 604.1 986.4 8.5%
TABLE 73 NORTH AMERICA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 299.1 322.4 348.0 558.7 8.2%
Leukapheresis 21.7 23.3 25.1 39.4 7.8%
Photopheresis 8.7 9.3 10.1 16.3 8.4%
Total 667.7 715.6 768.3 1,195.1 7.6%
TABLE 74 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

443.6 473.1 505.4 761.6 7.1%
Component Providers
Other End Users 36.2 38.3 40.5 57.7 6.1%
Total 667.7 715.6 768.3 1,195.1 7.6%
124
12.2.1 US
12.2.1.1 The US dominates the North American apheresis market
The US held the largest share of 86.9% of the North American apheresis market in 2018. It is expected to
reach USD 1,045.6 million by 2025 from USD 668.2 million in 2019, at a CAGR of 7.8% during the
forecast period. The large share of this segment can be attributed to factors such as the high healthcare
expenditure in the country, the presence of an advanced healthcare infrastructure, and rising patient
awareness about various apheresis technologies.
During the forecast period, a majority of the growth in the US apheresis market will be driven by the
availability of advanced blood collection technologies and a huge demand for source plasma from
biopharmaceutical companies for the production of plasma-derived medicines/therapies. The US is a
leading plasma supplier to biopharmaceutical companies for further processing of plasma. Plasma
collection in the US is increasing year-on-year. According to the Plasma Protein Therapeutic Association, in
2015, 530 plasma collection centers collected 35.46 million liters of source plasma, and in 2017, 327
plasma collection centers collected 42.39 million liters of source plasma.
In the US, plasma is collected either from non-remunerated donors or through plasmapheresis; a major
portion of the collection is attributed to paid donors. Paid donors receive financial benefits from plasma
donation centers. For instance, CSL Plasma (US) pays up to USD 400 to plasma donors (for frequent
donations) per month, while BioLife Plasma Services (US) offers USD 20 for the first donation and USD 50
for the second donation within a week. Paid plasma donation services are expected to increase the total
volume of plasma collected, thus meeting the growing demand for plasma-derived products through
plasmapheresis procedures in the US.
In the US, the demand for blood components is on the rise. Growing disease prevalence and an increasing
number of surgical procedures in the country are resulting in increasing government initiatives for blood
safety. According to the Armed Service Blood Program (ASBP), in 2016, the US Department of Health and
Human Services funded more than USD 48 million to Cerus Corporation and Terumo Corporation. This was
aimed at funding Pathogen Reduction Technologies (PRT) to reduce the transmission of the Zika virus
along with other blood-borne pathogens that are transmitted through the blood supply. This initiative
improved blood safety for both military and civilian blood programs and helped reduce transfusion-
transmitted infections (TTIs).
The US has favorable reimbursement policies for various apheresis procedures. Moreover, reforms in
reimbursement policies are expected to have a positive impact on the adoption of therapeutic apheresis
treatments in the country. For instance, according to the Centers for Medicare & Medicaid Services (CMS),
the reimbursement payment rate for leukapheresis, erythrocytapheresis, and plasmapheresis procedures
has increased from USD 1,047.6 in 2016 to USD 1,222 in 2018. This favorable reimbursement scenario is
one of the major factors driving the growth of the apheresis disposables market in the country.
125
TABLE 75 US: KEY MACROINDICATORS FOR THE APHERESIS MARKET
INDICATOR YEAR VALUE
Total Population (Million) 2018 327.17
Aging Population (Share of the Total the Population) 2015 15%
GDP (USD Trillion) 2018 20.54
Healthcare Expenditure (Percentage of GDP) 2016 17.2%
Number of Hospitals 2014 5,686
Number of Blood Donation Centers 2016 More than 600
Number of Blood Donations 2016 13.6 Million Units
Source: US Census Bureau, World Bank Data, and OECD
TABLE 76 US: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)

Apheresis Disposables 467.2 504.2 544.8 879.1 8.3%
Total 579.4 621.7 668.2 1,045.6 7.8%
TABLE 77 US: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 112.2 117.5 123.3 166.6 5.1%
TABLE 78 US: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

443.5 474.9 509.2 786.3 7.5%
(Donor Apheresis)
Total 579.4 621.7 668.2 1,045.6 7.8%
126
TABLE 79 US: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 135.9 146.8 158.9 259.3 8.5%
TABLE 80 US: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 36.2 39.1 42.3 68.7 8.4%
Renal Disorders 14.4 15.6 17.0 28.4 8.9%
Other Disorders 3.7 3.9 4.2 6.1 6.5%
Total 121.9 132.3 143.8 240.0 8.9%
TABLE 81 US: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 447.9 485.0 525.9 864.1 8.6%
Total 579.4 621.7 668.2 1,045.6 7.8%
127
TABLE 82 US: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 447.9 485.0 525.9 864.1 8.6%
TABLE 83 US: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 258.6 279.0 301.5 487.2 8.3%
Leukapheresis 19.0 20.4 21.9 34.6 7.9%
Photopheresis 7.5 8.0 8.7 14.2 8.5%
Total 579.4 621.7 668.2 1,045.6 7.8%
TABLE 84 US: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

384.0 410.0 438.4 664.7 7.2%
Component Providers
Other End Users 31.9 33.7 35.7 51.2 6.2%
Total 579.4 621.7 668.2 1,045.6 7.8%
128
12.2.2 CANADA
12.2.2.1 The demand for plasma protein products in Canada is on the
rise, which is a key factor driving market growth
In 2018, Canada accounted for a share of 13.1% of the apheresis market in North America. This market is
projected to reach USD 149.5 million by 2025 from USD 100.2 million in 2019, at a CAGR of 6.9% during
In Canada, various private and not-for-profit organizations, such as Canadian Blood Services (CBS), collect
blood and its components for hospitals and healthcare facilities. CBS collects about 195,000 liters of
plasma each year. Canadian Plasma Resources (CPR), a pharmaceutical manufacturer licensed by Health
Canada, collects quality plasma for the production of plasma-derived products and offers USD 25 to 35 per
donation to donors. The volume of plasma supplied for fractionation by Héma-Québec, a non-profit
organization that manages the blood supply for the Canadian province of Quebec, increased from 55,201
liters in 2013 to 105,160 liters in 2017.
According to a report published on the Canadian Blood System (by the Blood Safety and Supply Committee
of the Canadian Hemophilia Society), in November 2017, Héma‐Québec reported a decrease in the
delivery of blood components as the demand for fresh blood components reduced. Héma‐Québec reported
a decrease of 13%, 5%, and 32% in the delivery of red blood cells, platelets, and plasma for transfusion,
respectively. CBS and Héma‐Québec were successful in filling hospital orders for red blood cells, platelets,
and plasma during 2016-2017. CBS reports that it filled orders for 99.4% of red cells, 98.3% of platelets,
and 99.6% of plasma within one day. Demand for red blood cells is higher since it used for the treatment
of sickle cell anemia. Hence, the number of erythrocytapheresis procedures is more than other apheresis
procedures in the country.
The demand for plasma protein products in the country is on the rise. For instance, immunoglobulins used
for the treatment of immune deficiencies and neurological conditions have increased by more than 6% per
year for the last four years. These plasma protein products are manufactured by American and European
pharmaceutical companies from recovered plasma and source plasma, collected through plasmapheresis
donations. This increase in the demand for plasma-derived products necessitates the collection of source
plasma through plasmapheresis. This, in turn, is expected to drive the growth of the apheresis devices
market in Canada.
During 2016–17, CBS and Héma‐Québec collected only 15% and 21% of the plasma needed for the
manufacture of immune globulins, respectively. The remaining required plasma is supplied by
compensated donors in the US. CBS has proposed to the Provinces and Territories a business plan to
increase the volume of plasma collected from non‐compensated Canadian donors from 180,000 liters per
year to 600,000 liters per year (866,000 donations), which would meet 50 percent of the demand for
plasma for immune globulin production. In recent years, Héma‐Québec has opened three PLASMAVIE
centers to exclusively collect plasma. The expansion of this program aims to increase plasma volume from
100,000 liters currently to 150,000 liters by 2020, which would result in a level of plasma sufficiency of
30%. This activity is expected to increase the demand for apheresis products for the collection of source
plasma using plasmapheresis.
The Canadian Apheresis Group (CAG) is a national volunteer organization of physicians and nurses who
have a special interest in evaluating the appropriate application of therapeutic apheresis (TA). The CAG
was the first group to organize a national database. Since 1981, the organization has collected data from
42 apheresis units throughout Canada and more than 140,000 plasma exchange procedures (Source;
NCBI). The number of plasma exchange procedures in the country is increasing with the rise in the
indications of TPE and increasing patient awareness. This also drives the growth of the therapeutic
apheresis market in the country.
129
However, the high cost of apheresis procedures and the rising cost-containment pressures are expected to
restrain the growth of this market. The Canadian apheresis market is expected to witness lower growth
than the US market in the forecast period, mainly due to the slower development of the healthcare sector
in the country over the past decade.
TABLE 85 CANADA: KEY MACROINDICATORS FOR THE APHERESIS MARKET
Total Population (Million) 2018 37. 06
Number of Hospitals 2014 944
36 Permanent Collection Centers

Number of Blood Collection Centers 2015
and More than 14,000 Clinics
Source: US Census Bureau, World Bank Data, WHO, and OECD
TABLE 86 CANADA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 88.3 93.9 100.2 149.5 6.9%
TABLE 87 CANADA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 16.9 17.5 18.2 23.5 4.3%
130
TABLE 88 CANADA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

67.9 72.1 76.7 112.9 6.7%
(Donor Apheresis)
Total 88.3 93.9 100.2 149.5 6.9%
TABLE 89 CANADA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 20.4 21.9 23.5 36.6 7.7%
TABLE 90 CANADA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 5.55 5.95 6.38 9.87 7.5%
Renal Disorders 2.13 2.30 2.48 3.95 8.1%
Other Disorders 0.53 0.55 0.58 0.81 5.6%
Total 18.38 19.79 21.34 33.99 8.1%
131
TABLE 91 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 67.7 72.7 78.2 122.3 7.7%
Total 88.3 93.9 100.2 149.5 6.9%
TABLE 92 CANADA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 67.7 72.7 78.2 122.3 7.7%
TABLE 93 CANADA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 40.6 43.4 46.5 71.6 7.4%
Leukapheresis 2.8 3.0 3.2 4.8 7.0%
Photopheresis 1.2 1.3 1.4 2.2 7.6%
Total 88.3 93.9 100.2 149.5 6.9%
132
TABLE 94 CANADA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

59.6 63.1 67.0 96.9 6.3%
Component Providers
Other End Users 4.3 4.5 4.8 6.5 5.3%
Total 88.3 93.9 100.2 149.5 6.9%
12.3 EUROPE
In 2018, Europe accounted for 27.1% of the apheresis market. This regional segment is estimated to
reach USD 689.5 million by 2025 from USD 457.1 million in 2019, at a CAGR of 7.1%. The large share of
this market can be attributed to factors such as the increasing demand for apheresis collection, increase
in the incidence of chronic lifestyle diseases and blood disorders, growth in the scope of therapeutic
apheresis and its applications, the presence of a well-established healthcare industry, and the presence of
leading players in this region.
The European blood industry is divided into two sectors—commercial and not-for-profit. The not-for-profit
sector in Europe was established under the supervision of various national blood services and Red Cross
societies. In most European countries, only Red Cross societies are authorized to collect blood and plasma.
Germany and the Netherlands have the highest rates of plasma donations by apheresis (per million
inhabitants).
TABLE 95 COLLECTIONS OF BLOOD COMPONENTS USING APHERESIS ACROSS EUROPEAN

COUNTRIES IN 2013
NUMBER OF PLASMA
NUMBER OF PLATELETS
COUNTRY DONATIONS BY OTHER DONATIONS BY APHERESIS
DONATIONS BY APHERESIS
APHERESIS
Belgium 104.545 13,471 6,078
Bulgaria 232 2,714 -
Croatia 0 2,646 118
Cyprus 1.507 272 261
Czech Republic 617.617 18,271 -
Denmark 3.086 1,232 -
Estonia 1.028 105 804
Finland 4.127 483 -
32,643 (128 Erythrocytapheresis +

France 487.804 131,875 909 Combined Apheresis
Procedures)
133
35,245 (Erythrocytes: 14,699

Germany 2.445.918 196,106 Granulocytes: 629 Multicomponents:
19,917)
Greece 2.146 18,123 -
Hungary NA 3,573 825
Ireland 0 12,023 -
Italy 403.554 80,051 26,147
Latvia 3,461 -
Lithuania 11 1,049 2,221
Luxembourg 3.132 679
Malta 0 469
The Netherlands 321.184 4,723
Norway 4.693 51,000 4,654
Poland 21.042 34,133 600
Portugal 0 4,568 346
Romania 1 6,830 1,037
Slovakia 152 6,257
Slovenia 623 2,343 125
24,728 (128 erythrocytapheresis+

Spain 22.564 7,880
909 combined apheresis procedures)
UK 0 148,012
Source: C-C/EAHC-EU Commission-EU overview of the landscape of blood and plasma /Creative Ceutical report
In the forecast period, a majority of the growth in the European apheresis market will be driven by the
advantages of apheresis collection over whole blood collection, rising demand for blood plasma in blood
fractionation, and the growing research into new applications of therapeutic apheresis. The rising number
of spinal and cardiovascular surgeries being performed in this region and the growing geriatric population
are expected to further increase the demand for blood & blood components in Europe. According to the
European Commission, by 2025, more than 20% of Europeans will be aged 65 years and above, with a
rapid increase in the number of individuals aged over 80 years. Additionally, the growing demand for
pharmaceuticals derived from plasma will support the growth of this market. An increase in the number of
neurological cases and immunological conditions that are now recognized and treated with plasma
pharmaceuticals is also expected to increase the demand for plasma in the coming years.
However, factors such as the Eurozone debt crisis, intense competition among key players, budgetary
constraints among hospitals, and uncertainties & variations in reimbursement across the region may
hamper the growth of this market to a certain extent.
134
FIGURE 33 EUROPE: APHERESIS MARKET SNAPSHOT
EUROPE
27.1% Germany 8.4%

7.1% CAGR Share of the Region in the
The largest Market in Europe,
The CAGR of Germany During
(2019–2025) with a Share of 26.1% in
Global Market in 2018 the Forecast Period
2018
BY TECHNOLOGY, 2019 (USD MILLION) BY PROCEDURE, 2019 (USD MILLION)
Automated
Centrifugation 359.7 Blood
349.3
Collection
(Donor…
Membrane Therapeutic
97.4 107.8
Separation Apheresis
BY COUNTRY, 2019 (USD MILLION) FACTORS DRIVING MARKET GROWTH
COUNTRY/ CAGR  Presence of a well-established healthcare industry

MARKET SIZE
REGION (2019–2025)
 Growing geriatric population
Germany 120.9 8.4%
France 89.3 8.2%  Increasing incidence of chronic lifestyle diseases

and blood disorders
Italy 66.3 6.1%
UK 56.6 7.1%
Spain 31.7 5.8%
Rest of Europe 92.2 5.3%
Total 457.2 7.1%
135
TABLE 96 EUROPE: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
Germany 103.7 111.9 120.9 195.7 8.4%
France 76.7 82.7 89.3 143.6 8.2%
Italy 59.2 62.6 66.3 94.7 6.1%
UK 49.7 53.0 56.6 85.4 7.1%
Spain 28.6 30.1 31.7 44.5 5.8%
Rest of Europe 83.8 87.8 92.2 125.7 5.3%
Total 401.7 428.1 457.1 689.5 7.1%
Germany accounted for the largest share of 26.1% of the European apheresis market in 2018. This large
can be attributed to the presence of various large and medium-sized apheresis companies in Germany,
increasing healthcare expenditure, and increasing demand for source plasma for fractionation of plasma
products in the country. This market is projected to reach USD 195.7 million by 2025 from USD 120.9
TABLE 97 EUROPE: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 401.7 428.1 457.1 689.5 7.1%
TABLE 98 EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 77.2 80.3 83.6 108.7 4.5%
136
TABLE 99 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

308.3 327.9 349.3 520.0 6.9%
(Donor Apheresis)
Total 401.7 428.1 457.1 689.5 7.1%
TABLE 100 EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 93.4 100.2 107.8 169.6 7.9%
TABLE 101 EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPES,

Blood Disorders 26.2 28.1 30.2 47.1 7.7%
Renal Disorders 9.7 10.5 11.3 18.2 8.3%
Other Disorders 2.6 2.8 2.9 4.1 5.8%
Total 83.9 90.5 97.7 157.2 8.2%
137
TABLE 102 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 311.0 334.2 359.7 566.8 7.9%
Total 401.7 428.1 457.1 689.5 7.1%
TABLE 103 EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 311.0 334.2 359.7 566.8 7.9%
TABLE 104 EUROPE: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 184.7 197.9 212.3 329.8 7.6%
Leukapheresis 12.1 12.9 13.8 21.0 7.3%
Photopheresis 6.1 6.5 7.0 11.1 8.0%
Total 401.7 428.1 457.1 689.5 7.1%
138
TABLE 105 EUROPE: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

271.0 287.4 305.3 446.2 6.5%
Component Providers
Other End Users 20.6 21.7 22.8 31.8 5.7%
Total 401.7 428.1 457.1 689.5 7.1%
12.3.1 GERMANY
12.3.1.1 Germany is the fastest-growing market for apheresis in Europe
In 2018, Germany accounted for a share of 26.1% of the European apheresis market. This market is
projected to reach USD 195.7 million by 2025 from USD 120.9 million in 2019, at a CAGR of 8.4% during
The higher healthcare expenditure in the country—as compared to other European countries—is a major
driver for the market in Germany. The total healthcare expenditure in Germany increased to USD 414.4
billion (Euro 375.6 billion) in 2017 from USD 362.2 billion (Euro 328.3 billion) in 2016, an increase of
4.7%. This expenditure accounted for 11.5% of the gross domestic product in 2017.
TABLE 106 INCREASING HEALTHCARE EXPENDITURE IN GERMANY, 2015–2017 (USD MILLION)
Sources of Funding 2015 2016 2017
Public Budgets 17,168.3 18,855.0 17,820.1
Statutory Health Insurance 220,742.8 229,267.2 241,993.7
Statutory Long-term Care Insurance 30,860.7 325,71.6 42,038.6
Statutory Pension Insurance 4,929.6 5,012.3 5,301.3
Statutory Accident Insurance 5,952.9 6,171.0 6,487.6
Private Health Insurance 33,888.2 34,326.8 35,709.1
Employers 16,060.7 16,612.8 17,581.7
Households/Private Non-Profit Institutions 52,564.7 54,105.9 57,397.8
Total 382,167.9 396,922.6 424,331.0
Source: Statistisches Bundesamt
Germany has the highest plasma fractionation capacity in Europe, followed by France and Italy; it collected
2 million liters via apheresis in 2017. (Source: Transfusion and Apheresis Science). According to a report
(European Commission, 2016) in Germany, there are eight plasma collection centers collecting around
360,000 liters of plasma from 40,000 donors each year. According to the World Bank, Germany has one of
the fastest-growing aging populations in the world—about 21% of the total population of Germany was 65
years and above in 2015; this is expected to reach 34% by 2060. The rise in geriatric population is also
expected to support the growth of this market. According to the World Federation of Hemophilia, the
number of patients with hemophilia A&B was 3,351 and 616 in 2013; this increased to 3,686 and 672,
139
respectively, in 2016. A higher increase in the number of hemophilia cases will lead to further demand for
blood & blood components in Germany during the forecast period. In this region, membrane filtration is
more widely adopted for plasmapheresis and other types of apheresis procedures. However, the high price
of therapeutic apheresis procedures may hinder the growth of this market during the forecast period.
TABLE 107 GERMANY: KEY MACROINDICATORS FOR THE APHERESIS MARKET
Aging Population (Share of the Total Population) 2015 21%
Number of Blood Donation Centers 2013 70
TABLE 108 GERMANY: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 103.7 111.9 120.9 195.7 8.4%
TABLE 109 GERMANY: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 19.5 20.5 21.6 30.1 5.7%
140
TABLE 110 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

80.2 86.4 93.1 148.7 8.1%
(Donor Apheresis)
Total 103.7 111.9 120.9 195.7 8.4%
TABLE 111 GERMANY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 23.4 25.5 27.8 47.0 9.2%
TABLE 112 GERMANY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 6.32 6.87 7.48 12.54 9.0%
Renal Disorders 2.49 2.72 2.98 5.15 9.6%
Other Disorders 0.57 0.61 0.65 0.98 7.1%
Total 21.29 23.25 25.41 43.91 9.5%
141
TABLE 113 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 78.5 85.4 93.1 157.8 9.2%
Total 103.7 111.9 120.9 195.7 8.4%
TABLE 114 GERMANY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 78.5 85.4 93.1 157.8 9.2%
TABLE 115 GERMANY: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 47.6 51.6 56.0 93.5 8.9%
Leukapheresis 3.3 3.6 3.9 6.3 8.5%
Photopheresis 2.0 2.1 2.3 3.9 9.1%
Total 103.7 111.9 120.9 195.7 8.4%
142
TABLE 116 GERMANY: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

69.4 74.5 80.2 126.0 7.8%
Component Providers
Other End Users 6.1 6.5 6.9 10.3 6.8%
Total 103.7 111.9 120.9 195.7 8.4%
12.3.2 FRANCE
12.3.2.1 Increasing need for blood components to drive the market for
apheresis in France
France accounted for 19.3% of the European market in 2018. The market in France is expected to reach
USD 143.6 million by 2025 from USD 89.3 million in 2019, at a CAGR of 8.2% during the forecast period.
This market is mainly driven by factors such as the increasing incidence and prevalence of cardiovascular
diseases, increasing geriatric population, rising need for blood components, and growing healthcare
expenditure in the country.
Over the years, France has introduced various regulations and initiatives to improve its healthcare system.
According to the World Data Bank, the French government spent 11.54% of its GDP on healthcare in 2016,
as compared to 11.44% in 2013. This has helped expand the growth of the healthcare sector in France.
The national transfusion service—Établissement Français du Sang (EFS)—collects blood from donors across
the country and provides fresh blood products directly to hospitals. These plasma products are used for the
treatment of at least 80 different diseases affecting ~500,000 patients per year. In France, any
pharmaceutical company with a Marketing Authorization (MA) can bid for plasma product supply tenders
for hospitals and clinics. Only plasma products derived from unpaid donors are sold in France. Foreign
market players are expanding their presence in the apheresis market by bidding for product supply tenders
for hospitals and clinics.
The rising prevalence of blood disorders and the increasing number of surgical procedures performed in
hospitals, favorable government support, and growing aging population are some pivotal factors driving the
growth of the apheresis market in France. According to the French National Institute of Demographic
Studies, the population of France is expected to grow from ~64 million in 2016 to 72 million by 2050. This
growing population and a decrease in the mortality rate will result in an increase in the aging population in
the country; by 2033, ~28–30% of the French population will be above 60 years. The increase in the
geriatric population will boost the prevalence of cardiovascular diseases, autoimmune diseases, metabolic
diseases, and trauma cases, which is expected to drive the demand for blood and therapeutic apheresis
procedures.
However, France is under tremendous pressure to cut its healthcare expenditure and bring its deficit back
in line with the EU budget rules. Budgetary constraints may hamper the growth of the apheresis market.
Along with this, the high cost of apheresis devices and limited reimbursement is also expected to restrain
market growth.
143
TABLE 117 FRANCE: KEY MACROINDICATORS FOR THE APHERESIS MARKET
Total Population (Million) 2018 66. 99
Number of Blood Donations 2013 246,252
TABLE 118 FRANCE: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)

Total 76.7 82.7 89.3 143.6 8.2%
TABLE 119 FRANCE: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)

Total 15.1 15.9 16.7 23.2 5.6%
TABLE 120 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

58.4 62.8 67.6 107.3 8.0%
(Donor Apheresis)
Total 76.7 82.7 89.3 143.6 8.2%
144
TABLE 121 FRANCE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 18.4 20.0 21.7 36.3 9.0%
TABLE 122 FRANCE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 5.02 5.45 5.93 9.89 8.9%
Renal Disorders 1.90 2.08 2.27 3.90 9.5%
Other Disorders 0.54 0.58 0.62 0.92 7.0%
Total 16.36 17.84 19.48 33.41 9.4%
TABLE 123 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 60.5 65.8 71.6 120.6 9.1%
Total 76.7 82.7 89.3 143.6 8.2%
145
TABLE 124 FRANCE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 60.5 65.8 71.6 120.6 9.1%
TABLE 125 FRANCE: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 34.4 37.3 40.5 67.1 8.8%
Leukapheresis 2.4 2.6 2.8 4.6 8.4%
Photopheresis 1.0 1.1 1.2 2.0 9.0%
Total 76.7 82.7 89.3 143.6 8.2%
TABLE 126 FRANCE: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

50.5 54.1 58.1 90.4 7.6%
Blood Component Providers
Other End Users 4.3 4.6 4.8 7.1 6.7%
Total 76.7 82.7 89.3 143.6 8.2%
146
12.3.3 ITALY
12.3.3.1 Therapeutic plasma exchange and LDL apheresis are widely
adopted therapeutic apheresis procedures, thereby driving
market growth in Italy
Italy accounted for a share of 14.6% of the European apheresis market in 2018. This segment is projected
to reach USD 94.7 million by 2025 from USD 66.3 million in 2019, at a CAGR of 6.1% during the forecast
period. The major factors driving the growth of the market in Italy include rising healthcare expenditure;
increasing incidence of cardiovascular, neurological, and autoimmune diseases; growing geriatric
population; increasing demand for blood and blood components for transfusion; and the availability of
reimbursements for therapeutic apheresis procedures in the country.
Therapeutic plasma exchange and LDL apheresis are more widely adopted therapeutic apheresis
procedures in the country. Approximately 125 hospitals in the country perform therapeutic apheresis. The
increasing awareness of therapeutic apheresis along with the availability of reimbursement for therapeutic
apheresis procedures in Italy are major driving growths for this market.
In Italy, the plasma market is a part of the Blood System (BS). The BS, run under a public governance
scheme, operates under the major goal of achieving self-sufficiency in the production of plasma-derived
medicinal products. In Italy, there are more than 318 hospital-based blood transfusion centers and 1.7
million blood and blood component donors. To cater to the growing need for blood components, the
government and other health associations in the country are trying to increase donations by creating
awareness among the population.
According to the ISTAT—The System of Health Accounts Italy—the current healthcare expenditure in 2016
was equal to USD 164.6 million (Euro 149,500 million), that is 8.9% of the GDP, of which 75% was
financed by the public sector, and the rest by the private sector. The healthcare spending per capita was
USD 2,715.8 (Euro 2,466), with an average annual increase of 0.7% when compared to 2012. However,
the healthcare expenditure of Italy, in per capita terms and as a share of GDP, is significantly lower than
that of other major countries of the European Union. Rising healthcare costs and the growing prevalence of
various health diseases in the geriatric population are important factors driving market growth in Italy.
Improvements in quality and the accessibility of medical care, in addition to continuous advancements in
apheresis technologies, are further driving the market. However, the Italian market has witnessed slower
growth in the healthcare sector in the last few years due to the recent economic downturn and significant
financial cuts in the country.
TABLE 127 ITALY: KEY MACROINDICATORS FOR THE APHERESIS MARKET
Number of Hospitals Performing Therapeutic Apheresis 2018 125
147
TABLE 128 ITALY: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 59.2 62.6 66.3 94.7 6.1%
TABLE 129 ITALY: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 11.58 11.95 12.35 15.23 3.6%
TABLE 130 ITALY: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

Automated Blood Collection (Donor
45.2 47.6 50.3 70.9 5.9%
Apheresis)
Total 59.2 62.6 66.3 94.7 6.1%
TABLE 131 ITALY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 14.09 14.99 15.98 23.77 6.8%
148
TABLE 132 ITALY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 3.92 4.17 4.44 6.59 6.8%
Renal Disorders 1.45 1.55 1.67 2.54 7.3%
Other Disorders 0.43 0.45 0.47 0.62 4.9%
Total 12.57 13.44 14.38 21.91 7.3%
TABLE 133 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 46.5 49.6 52.9 79.1 6.9%
Total 59.2 62.6 66.3 94.7 6.1%
TABLE 134 ITALY: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 46.5 49.6 52.9 79.1 6.9%
149
TABLE 135 ITALY: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 26.78 28.45 30.28 44.62 6.7%
Leukapheresis 1.86 1.97 2.09 3.01 6.3%
Photopheresis 0.82 0.88 0.93 1.39 6.8%
Total 59.24 62.61 66.27 94.70 6.1%
TABLE 136 ITALY: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

39.6 41.7 43.9 60.7 5.6%
Component Providers
Other End Users 3.0 3.1 3.2 4.2 4.6%
Total 59.2 62.6 66.3 94.7 6.1%
12.3.4 UK
12.3.4.1 Increasing demand for source plasma to cater to the growing
consumption of plasma-derived products (IVIG) driving apheresis
market growth in the UK
The UK accounted for a share of 12.4% of the European apheresis market in 2018. This market is
expected to reach USD 85.4 million by 2025 from USD 56.6 million in 2019, at a CAGR of 7.1% during the
forecast period.
The demand for apheresis procedures and blood collection is expected to rise during the forecast period
due to an increase in health complications such as the rising incidences of spinal surgeries, chronic
diseases, various cancers, autoimmune diseases, and cardiovascular diseases. Furthermore, the
increased occurrence of sports-related injuries is a key contributor to market growth.
According to the British Heart Foundation’s health statistics (February 2015), there are around 7 million
people living with cardiovascular diseases (CVD) in the UK. According to the same source, coronary heart
diseases (CHD) lead to approximately 73,000 deaths annually in the UK. CHD causes an average of 200
deaths each day, and around 2.3 million patients suffering from CHD are in the UK. Owing to this, the
number of cardiovascular procedures performed in the country is recording steady growth. With the rising
prevalence of lifestyle disorders, the number of cardiovascular procedures is further expected to rise. The
150
increased prevalence of various diseases will cause a rise in the number of surgical procedures and blood
transfusion cases. The large amount of blood & blood components required in such procedures will act as
a driving factor for market growth.
Additionally, the volume of plasma-derived products, such as IVIG used for the treatment of autoimmune
diseases, is increasing on a yearly basis. According to the Immunoglobulins Database Report, the total
volume of immunoglobulins used in the UK in 2015-2016 was 4.6 million grams for the treatment of PID,
CIDP, MMN, Myasthenia Gravis, Guillain–Barré Syndrome, Chronic Lymphocytic Leukemia, and Immune
Thrombocytopenic Purpura-Acute, among others. The demand for source plasma is increasing in order to
cater to the growing demand for plasma-derived products, thus driving the growth of the plasmapheresis
market in the country.
TABLE 137 UK: KEY MACROINDICATORS FOR THE APHERESIS MARKET
TABLE 138 UK: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 49.7 53.0 56.6 85.4 7.1%
TABLE 139 UK: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 9.69 10.09 10.52 13.71 4.5%
151
TABLE 140 UK: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

38.0 40.4 43.1 64.1 6.8%
(Donor Apheresis)
Total 49.7 53.0 56.6 85.4 7.1%
TABLE 141 UK: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 11.73 12.59 13.54 21.27 7.8%
TABLE 142 UK: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 3.29 3.53 3.80 5.94 7.7%
Renal Disorders 1.21 1.30 1.41 2.27 8.3%
Other Disorders 0.35 0.37 0.39 0.55 5.8%
Total 10.49 11.31 12.22 19.64 8.2%
152
TABLE 143 UK: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 38.9 41.8 45.0 70.8 7.8%
Total 49.7 53.0 56.6 85.4 7.1%
TABLE 144 UK: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 38.9 41.8 45.0 70.8 7.8%
TABLE 145 UK: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 22.75 24.39 26.18 40.69 7.6%
Leukapheresis 1.40 1.50 1.60 2.43 7.2%
Photopheresis 0.92 0.99 1.06 1.66 7.8%
Total 49.72 53.02 56.63 85.38 7.1%
153
TABLE 146 UK: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

33.8 35.9 38.1 55.7 6.5%
Component Providers
Other End Users 2.2 2.3 2.4 3.4 5.5%
Total 49.7 53.0 56.6 85.4 7.1%
12.3.5 SPAIN
12.3.5.1 Growing demand for blood components and plasma-derived
products for the treatment of chronic diseases in the elderly is a
key factor driving market growth in Spain
Spain accounted for 7.0% of the apheresis market in Europe in 2018. This market is expected to reach
USD 44.5 million by 2025 from USD 31.7 million in 2019, at a CAGR of 5.8% during the forecast period.
The apheresis market in Spain is witnessing growth, primarily due to the growing demand for blood & blood
components for transfusion and plasma products for the treatment of various chronic diseases in the
elderly. According to the World Bank, in 2017, the population of individuals aged 65 years and above
accounted for 19.4% of Spain’s total population. Moreover, according to the Fundación General CSIC
(Spain), about 30% of the total population will be aged 65 and above, while the population aged 80 and
above will reach 4 million by 2050. The rising geriatric population is expected to drive the demand for
therapeutic apheresis procedures in the country.
According to the World Bank, although the healthcare industry in Spain was adversely affected by the
European economic crisis, it spent around 8.97% of the GDP on healthcare in 2016. This improving
healthcare expenditure has been accompanied by an increase in the overall life expectancy in Spain,
which, in turn, is contributing to the increase in the country’s geriatric population.
Spain was severely affected by the economic downturn and the Eurozone debt crisis, which hindered the
economic growth of the country and affected the growth of the apheresis market as well. The apheresis
market in Spain also faces several challenges, such as inadequate financing, late payments between
economic operators and public authorities/healthcare institutes, and cost-containment issues with SMEs.
These factors are expected to restrain the growth of the apheresis market in the country to a certain
extent.
154
TABLE 147 SPAIN: KEY MACROINDICATORS FOR THE APHERESIS MARKET
Number of Hospitals 2014 804
TABLE 148 SPAIN: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 28.6 30.1 31.7 44.5 5.8%
TABLE 149 SPAIN: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 5.53 5.69 5.86 7.09 3.2%
155
TABLE 150 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

21.9 23.0 24.2 33.5 5.6%
(Donor Apheresis)
Total 28.6 30.1 31.7 44.5 5.8%
TABLE 151 SPAIN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 6.68 7.09 7.53 11.00 6.5%
TABLE 152 SPAIN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 1.93 2.04 2.17 3.15 6.4%
Renal Disorders 0.69 0.74 0.79 1.18 7.0%
Other Disorders 0.20 0.21 0.22 0.28 4.6%
Total 5.99 6.38 6.81 10.18 6.9%
156
TABLE 153 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 22.3 23.6 25.1 36.7 6.5%
Total 28.6 30.1 31.7 44.5 5.8%
TABLE 154 SPAIN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 22.3 23.6 25.1 36.7 6.5%
TABLE 155 SPAIN: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 13.37 14.16 15.01 21.68 6.3%
Leukapheresis 0.76 0.80 0.84 1.19 5.9%
Photopheresis 0.39 0.42 0.44 0.65 6.5%
Total 28.56 30.09 31.75 44.51 5.8%
157
TABLE 156 SPAIN: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

19.4 20.4 21.4 29.1 5.3%
Component Providers
Other End Users 1.4 1.5 1.5 2.0 4.2%
Total 28.6 30.1 31.7 44.5 5.8%
12.3.6 REST OF EUROPE

The Rest of Europe accounted for 20.5% of the European apheresis market in 2018. This market is
expected to reach USD 125.7 million by 2025 from USD 92.2 million in 2019, at a CAGR of 5.3% during
the forecast period. The RoE includes Russia, Switzerland, the Netherlands, Sweden, Norway, Poland,
Portugal, Romania, Denmark, Estonia, Finland, Austria, and Belgium.
The growth of the apheresis market in these countries is relatively slower as compared to other European
countries, mainly due to budgetary challenges among governments and the unavailability of modern
technologies. However, over the past few years, RoE governments have begun to take initiatives to improve
the quality of healthcare. This has increased the accessibility to surgical procedures for patients in these
countries.
In the Netherlands, the Ministry for Health, Welfare, and Sport is responsible for framing the national blood
policy, while Sanquin (a not-for-profit plasma fractionator) provides blood services, inclusive of whole blood
collection, the supply of fresh blood products, plasma collection, and fractionation. In the Netherlands, as
per the Blood Supply Act, Sanquin used whole domestic plasma for the manufacturing of plasma products
for domestic use. Excess plasma product surplus to domestic requirements may be sold to other not-for-
profit organizations.
Similarly, in Norway, plasma is collected by hospital blood banks and sent to Octapharma AG (Norway) for
fractionation, under the frame of a national self-sufficiency project. Octapharma AG has fractionated
Norwegian plasma since 1988. All fractionated plasma products and fresh frozen plasma products are
sent back to Norway after fractionation for domestic use.
TABLE 157 ROE: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 83.8 87.8 92.2 125.7 5.3%
158
TABLE 158 ROE: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 15.82 16.17 16.57 19.38 2.6%
TABLE 159 ROE: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

64.7 67.7 71.0 95.4 5.1%
(Donor Apheresis)
Total 83.8 87.8 92.2 125.7 5.3%
TABLE 160 ROE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 19.02 20.09 21.25 30.22 6.0%
159
TABLE 161 ROE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 5.70 6.02 6.37 9.00 5.9%
Renal Disorders 1.95 2.07 2.20 3.21 6.5%
Other Disorders 0.56 0.58 0.60 0.76 4.1%
Total 17.23 18.27 19.40 28.17 6.4%
TABLE 162 ROE: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 64.3 67.9 71.8 101.8 6.0%
Total 83.8 87.8 92.2 125.7 5.3%
TABLE 163 ROE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 64.3 67.9 71.8 101.8 6.0%
160
TABLE 164 ROE: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 39.87 42.01 44.33 62.17 5.8%
Leukapheresis 2.30 2.42 2.54 3.50 5.4%
Photopheresis 0.98 1.04 1.10 1.55 6.0%
Total 83.76 87.81 92.22 125.66 5.3%
TABLE 165 ROE: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

58.26 60.81 63.57 84.15 4.8%
Blood Component Providers
Other End Users 3.62 3.74 3.87 4.83 3.8%
Total 83.76 87.81 92.22 125.66 5.3%
161
12.4 ASIA PACIFIC

In 2018, the Asia Pacific accounted for a share of 21.4% of the apheresis market. This regional segment is
projected to reach USD 654.1 million by 2025 from USD 369.6 million in 2019. APAC countries, especially
India and China, represent the highest growth potential for the apheresis market. The APAC market is
expected to grow at the highest CAGR of 10.0% during the forecast period of 2019–2025.
The Asia Pacific region represents the most lucrative healthcare market, owing to its large population and
rising healthcare needs. The increasing population in countries like India and China, the rapid growth in the
geriatric population, improving healthcare infrastructure, growing per capita income, rising focus of key
market players on emerging APAC countries, growing medical tourism, and an increasing number of
hospitals performing therapeutic apheresis are driving the growth of this market.
According to the Economist Intelligence Unit (EIU), healthcare spending in the APAC is expected to grow at
a rate of 7.1% from 2013 to 2017. The increasing number of initiatives undertaken to promote whole
blood and blood component donation in several APAC countries is another major factor responsible for
market growth. For instance, in August 2016, the Red Cross Society in Australia joined a global campaign
to encourage more people to donate blood and components on account of the global shortage of blood
and blood component donors.
FIGURE 34 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT
ASIA PACIFIC
10.0% CAGR USD 369.6 Million China 21.4%

Fastest-growing Country Share of the Region in the
(2019–2025) Market Size in 2019
in the Region Global Market in 2018
BY APPLICATION, 2019 (USD MILLION) BY COUNTRY, 2019 (USD MILLION)
CAGR
Plasmapheresis 180.0 COUNTRY/REGION MARKET SIZE,
(2019–2025)
Plateletpheresis 121.2
China 123.7 12.0%
Erythrocytapheresis 48.0
Leukapheresis 10.5 Japan 115.3 8.8%
Photopheresis 4.3 India 38.1 11.1%
Other Applications 5.7 RoAPAC 92.6 8.0%
FACTORS DRIVING MARKET GROWTH
 Growing geriatric population  Improving healthcare infrastructure and per capita

income
 Rising focus of key market players on emerging APAC
countries
162
TABLE 166 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
China 99.3 110.7 123.7 243.9 12.0%
Japan 98.0 106.2 115.3 191.5 8.8%
India 31.1 34.4 38.1 71.8 11.1%
Rest of Asia Pacific 79.9 85.9 92.6 147.0 8.0%
Total 308.3 337.2 369.6 654.1 10.0%
TABLE 167 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 308.3 337.2 369.6 654.1 10.0%
TABLE 168 ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 57.8 61.6 65.9 100.3 7.2%
TABLE 169 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

239.0 260.9 285.3 497.9 9.7%
(Donor Apheresis)
Total 308.3 337.2 369.6 654.1 10.0%
163
TABLE 170 ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,

Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 69.2 76.3 84.3 156.3 10.8%
TABLE 171 ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
Blood Disorders 19.43 21.39 23.59 43.14 10.6%
Renal Disorders 7.27 8.05 8.93 16.92 11.2%
Other Disorders 1.73 1.87 2.02 3.33 8.7%
Total 63.02 69.76 77.35 146.16 11.2%
TABLE 172 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 233.4 257.4 284.4 525.6 10.8%
Total 308.3 337.2 369.6 654.1 10.0%
164
TABLE 173 ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE,

Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 233.4 257.4 284.4 525.6 10.8%
TABLE 174 ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 148.7 163.4 180.0 327.3 10.5%
Leukapheresis 8.7 9.6 10.5 19.0 10.3%
Photopheresis 3.5 3.9 4.3 7.9 10.7%
Total 308.3 337.2 369.6 654.1 10.0%
TABLE 175 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

217.5 236.8 258.2 442.9 9.4%
Component Providers
Other End Users 13.8 14.9 16.1 26.4 8.6%
Total 308.3 337.2 369.6 654.1 10.0%
165
12.4.1 CHINA
12.4.1.1 China accounts for the largest share of the
APAC apheresis market
In 2018, China accounted for the largest share of 32.8% of the apheresis market in the APAC. The market
in China is expected to reach USD 243.9 million by 2025 from USD 123.7 million in 2019, at a CAGR of
12.0% during the forecast period. This growth can be attributed to the increasing demand for blood
components (owing to the rising number of surgical procedures and high prevalence of various diseases,
inclusive of blood disorders), growing awareness about therapeutic apheresis, rise in the demand for
plasma derivatives, and the increasing number of blood & plasma donations across the country,
An increasing prevalence of cancer, and cardiovascular, renal, & autoimmune diseases also boosts the
number of therapeutic apheresis procedures. According to WHO, in 2018, there are reports of ~20,066
new cases of multiple myeloma diagnosed in China. Moreover, the number of new cases of myeloma is
expected to increase in the coming years. This increase in the prevalence of cancer will also cause demand
for apheresis therapeutic procedures. Apart from this, rising incidences of renal diseases are also on the
rise in the country. This scenario proves beneficial for long-term country growth as it leads to a rise in the
demand for apheresis equipment, thereby driving the overall market growth for apheresis procedures.
Additionally, the rapid economic growth in China in the past few years, rising disposable income of the
middle-class population, and growing investments for the country’s healthcare infrastructure are major
factors driving market growth in the apheresis market. China’s GDP has grown at around 6–8% from 2012
to 2018. In 2019, the country’s economy continued to grow amidst the global recession, propelled by the
rising domestic demand for medical devices and the government's cautionary fiscal policy.
Over the past few years, China has emerged as the fastest-growing apheresis market, since China is the
second-largest plasma products market in the world, after the US, and also holds the largest market for
albumin. Rising incidents of diseases such as hypoalbuminemia from liver cirrhosis, liver cancer, and
hepatitis B is a major factor driving market growth for albumin in China. According to the Public Library of
Science (PLOS) One journal, HBV infections represent the leading cause of illness and death in China.
Every year, an estimated 300,000 to 400,000 persons in China die from HBV-related liver cancer or
cirrhosis, accounting for 37-50% of HBV-related deaths worldwide (Source: NCBI). Additionally, rising
growth in the geriatric population, increasing urbanization, and a higher prevalence rate of immune
deficiencies are further propelling the growth of the market.
China has approximately 30 licensed plasma fractionation plants, with a total capacity of about ~12.4
million liters. According to a LiveMint report, in 2016, the demand for plasma was estimated to be between
12,000–15,000 tons each year, while China’s total plasma collection amount in 2015 was about 5,800
tons. An increasing demand for plasma in China is also estimated to drive the growth of this market
segment during the forecast period.
166
TABLE 176 CHINA: KEY MACROINDICATORS FOR THE APHERESIS MARKET
Total Population (Million) 2018 1,392.73
TABLE 177 CHINA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 99.3 110.7 123.7 243.9 12.0%
TABLE 178 CHINA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2017 2017 2018 CAGR (2019–2025)
Total 18.8 20.4 22.2 37.7 9.2%
TABLE 179 CHINA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2017 2017 2018 CAGR (2019–2025)

76.7 85.3 95.0 184.8 11.7%
(Donor Apheresis)
Total 99.3 110.7 123.7 243.9 12.0%
167
TABLE 180 CHINA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 22.6 25.4 28.6 59.1 12.8%
TABLE 181 CHINA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 5.9 6.6 7.4 15.2 12.7%
Renal Disorders 2.4 2.7 3.1 6.5 13.2%
Other Disorders 0.5 0.6 0.7 1.2 10.7%
Total 20.5 23.1 26.2 55.1 13.2%
TABLE 182 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2017 2017 2018 CAGR (2019–2025)
Centrifugation 75.4 84.9 95.6 197.7 12.9%
Total 99.3 110.7 123.7 243.9 12.0%
168
TABLE 183 CHINA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2017 2017 2018 CAGR (2019–2025)
Total 75.4 84.9 95.6 197.7 12.9%
TABLE 184 CHINA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 47.2 52.8 59.3 120.4 12.5%
Leukapheresis 3.0 3.4 3.8 7.5 12.1%
Photopheresis 1.1 1.2 1.4 2.8 12.7%
Total 99.3 110.7 123.7 243.9 12.0%
TABLE 185 CHINA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2017 2017 2018 CAGR (2019–2025)

65.6 72.8 80.9 154.6 11.4%
Component Providers
Other End Users 5.4 5.9 6.5 11.7 10.3%
Total 99.3 110.7 123.7 243.9 12.0%
169
12.4.2 JAPAN
12.4.2.1 Increasing demand for technologically advanced products drives
the market growth in Japan
In 2018, Japan accounted for a share of 31.5% of the APAC apheresis market. This segment is projected to
reach USD 191.5 million by 2025 from USD 115.3 million in 2019, at a CAGR of 8.8% during the forecast
period.
Market growth is mainly attributed to the presence of a universal healthcare reimbursement policy and a
well-established healthcare system in the country. Japan is considered to be the second-largest healthcare
market in the world, after the US. However, the Japanese market has been hit hard by the economic
recession, owing to which the apheresis market in the country has witnessed hampered growth.
During the forecast period, the apheresis market in Japan is expected to be driven by a rapid increase in
the aging population, the increasing demand for technologically advanced products, and the high access to
healthcare. According to data from the World Bank, by 2050, the aging population (above 65 years) in
Japan is estimated to account for 35.7% of the total population, which is the highest across the world. Due
to this rise in the geriatric population, the prevalence of cardiovascular diseases and blood disorders in the
country is expected to grow multifold in the coming years. These factors will also contribute to the overall
apheresis market growth in the country.
The Japan Ministry of Health, Labour and Welfare provides reimbursement for therapeutic apheresis for
approved indications. For instance, Adacolumn, an apheresis device, is approved and reimbursed for the
treatment of patients with ulcerative colitis, Crohn’s disease, and pustular psoriasis.
TABLE 186 BLOOD DONATIONS IN JAPAN, BY TYPE OF DONATION, 2015
TYPES OF DONATIONS NUMBER OF DONATIONS
Whole blood 3,547,726
Apheresis 1,361,430
Total 4,909,156
Source: Japanese Red Cross Society
TABLE 187 JAPAN: KEY MACROINDICATORS FOR THE APHERESIS MARKET
Number of Hospitals performing therapeutic apheresis 2013 8,540
170
TABLE 188 JAPAN: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 98.0 106.2 115.3 191.5 8.8%
TABLE 189 JAPAN: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2017 2017 2018 CAGR (2019–2025)
Total 18.1 19.2 20.3 28.9 6.1%
TABLE 190 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2017 2017 2018 CAGR (2019–2025)

76.4 82.6 89.4 146.5 8.6%
(Donor Apheresis)
Total 98.0 106.2 115.3 191.5 8.8%
TABLE 191 JAPAN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 21.7 23.7 25.9 45.0 9.7%
171
TABLE 192 JAPAN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 6.17 6.74 7.36 12.68 9.5%
Renal Disorders 2.30 2.53 2.77 4.92 10.0%
Other Disorders 0.57 0.61 0.65 1.01 7.5%
Total 19.83 21.73 23.86 42.27 10.0%
TABLE 193 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 73.5 80.3 87.8 152.1 9.6%
Total 98.0 106.2 115.3 191.5 8.8%
TABLE 194 JAPAN: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 73.5 80.3 87.8 152.1 9.6%
172
TABLE 195 JAPAN: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 47.03 51.22 55.87 95.51 9.4%
Leukapheresis 2.94 3.19 3.47 5.80 9.0%
Photopheresis 1.30 1.42 1.55 2.68 9.5%
Total 98.0 106.2 115.3 191.5 8.8%
TABLE 196 JAPAN: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

69.0 74.5 80.5 130.3 8.4%
Component Providers
Other End Users 4.7 5.0 5.3 8.1 7.2%
Total 98.0 106.2 115.3 191.5 8.8%
12.4.3 INDIA
12.4.3.1 In India, the increasing demand for blood components and
growing applications of plasma derivatives are major factors
driving the growth of the apheresis market
India accounted for a share of 10.2% of the APAC apheresis market in 2018. This market is expected to
reach USD 71.8 million by 2025 from USD 38.1 million in 2019, at a CAGR of 11.1% during the forecast
period.
In India, the demand for blood and plasma products is dynamic. According to the Indian government, India
has more than 2,700 blood banks collecting about 10–11 million units of blood on an annual basis. The
increasing demand for blood components, growing applications of plasma derivatives, and the rising
incidence and prevalence of cancer and cardiovascular diseases are expected to drive the apheresis
market in the country. The integration of advanced technology has also created a positive impact on the
demand for apheresis devices.
The increasing focus of key market players on the Indian market, improving healthcare infrastructure,
rising disposable income levels, increasing demand for advanced medical treatments, and growing focus
on blood component collection to overcome blood shortages are the major factors driving the growth of the
apheresis market.
173
The increasing number of multispecialty and government hospitals in the country will also aid market
growth. Due to the constraints of limited budgets, most apheresis devices are purchased and installed at
government hospitals. Medium-sized hospitals avail apheresis technology by renting apheresis devices
from manufacturers. In December 2019, the Manipal Hospital Goa installed apheresis machines to
perform donor & therapeutic apheresis. Under the National Health Mission for 2015-2016, Madhya
Pradesh and Assam were granted 11 new blood banks. Similarly, under the National AIDS Control
Programme-IV, the government is continuously strengthening blood transfusion services programs in order
to promote voluntary non-remunerated blood donation in partnership with NGOs and not-for-profit
organizations. Initiatives such as these will increase the demand for apheresis devices and related
disposables in India during the forecast period.
However, uncertainties in healthcare policies, poor medical insurance coverage, limited access to
healthcare in rural areas, and the high cost of apheresis devices & therapeutic procedures are expected to
hinder the growth of this market during the forecast period. In India, an apheresis machine costs USD
2,105.2 to 2,806.9 (INR 15 lakh to 20 lakhs). Apheresis kits, which are required for separating blood
components, cost USD 70.0 to 140 (INR 5,000 to 10,000), which is expensive for low-income individuals.
Thus, the high capital investment and cost associated with this procedure acts as a major restraint for the
apheresis market in India.
TABLE 197 INDIA: KEY MACROINDICATORS FOR THE APHERESIS MARKET
Total Population (Million) 2018 1,352.62
Source: US Census Bureau, World Bank Data, and OECD
TABLE 198 INDIA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 31.1 34.4 38.1 71.8 11.1%
174
TABLE 199 INDIA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 5.9 6.4 6.9 11.1 8.4%
TABLE 200 INDIA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

24.0 26.5 29.3 54.5 10.9%
(Donor Apheresis)
Total 31.1 34.4 38.1 71.8 11.1%
TABLE 201 INDIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 7.06 7.87 8.79 17.28 11.9%
175
TABLE 202 INDIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 2.055 2.290 2.555 4.987 11.8%
Renal Disorders 0.734 0.822 0.922 1.855 12.4%
Other Disorders 0.172 0.188 0.206 0.361 9.8%
Total 6.397 7.160 8.025 16.109 12.3%
TABLE 203 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 23.8 26.5 29.6 58.1 11.9%
Total 31.1 34.4 38.1 71.8 11.1%
TABLE 204 INDIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 23.8 26.5 29.6 58.1 11.9%
176
TABLE 205 INDIA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 14.750 16.399 18.263 35.367 11.6%
Leukapheresis 1.187 1.315 1.459 2.770 11.3%
Photopheresis 0.420 0.468 0.522 1.022 11.9%
Total 31.073 34.382 38.109 71.757 11.1%
TABLE 206 INDIA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

22.4 24.7 27.3 50.0 10.6%
Component Providers
Other End Users 1.2 1.3 1.4 2.4 9.5%
Total 31.1 34.4 38.1 71.8 11.1%
12.4.4 REST OF ASIA PACIFIC

The RoAPAC includes Malaysia, South Korea, Australia, Indonesia, Malaysia, Singapore, Vietnam, and New
Zealand. This regional segment accounted for a share of 25.5% of the APAC apheresis market in 2018.
The RoAPAC market is projected to reach USD 147.0 million by 2025 from USD 92.6 million in 2019, at a
The growth of this market is driven by the increasing incidence of various diseases, growth in the aging
population, growing awareness about healthcare services, rising healthcare expenditure, and improving
healthcare infrastructure in many RoAPAC countries.
Authorities in several countries in the RoAPAC, including Taiwan, Singapore, New Zealand, and South
Korea, are focusing on the development of their respective healthcare infrastructures. However, the
adoption of advanced treatments, such as therapeutic apheresis, is still very low in these countries. The
high cost of apheresis technology, limited reimbursements, and low awareness of apheresis are some of
the factors restraining market growth in these countries.
177
TABLE 207 ROAPAC: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 79.9 85.9 92.6 147.0 8.0%
TABLE 208 ROAPAC: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 15.0 15.7 16.5 22.6 5.3%
TABLE 209 ROAPAC: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

62.0 66.5 71.5 112.1 7.8%
(Donor Apheresis)
Total 79.9 85.9 92.6 147.0 8.0%
TABLE 210 ROAPAC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 17.88 19.38 21.03 34.90 8.8%
178
TABLE 211 ROAPAC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 5.31 5.75 6.23 10.26 8.7%
Renal Disorders 1.81 1.97 2.15 3.65 9.2%
Other Disorders 0.44 0.47 0.50 0.73 6.7%
Total 16.28 17.72 19.30 32.66 9.2%
TABLE 212 ROAPAC: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 60.7 65.8 71.4 117.7 8.7%
Total 79.9 85.9 92.6 147.0 8.0%
TABLE 213 ROAPAC: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 60.7 65.8 71.4 117.7 8.7%
179
TABLE 214 ROAPAC: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 39.78 42.99 46.53 75.97 8.5%
Leukapheresis 1.57 1.69 1.83 2.92 8.1%
Photopheresis 0.71 0.77 0.84 1.38 8.7%
Total 79.89 85.92 92.56 146.97 8.0%
TABLE 215 ROAPAC: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

60.4 64.8 69.5 108.1 7.6%
Component Providers
Other End Users 2.6 2.7 2.9 4.2 6.4%
Total 79.9 85.9 92.6 147.0 8.0%
180
12.5 LATIN AMERICA

In 2018, Latin America accounted for 3.5% of the apheresis market. This regional segment is estimated to
reach USD 102.7 million by 2025 from USD 60.8 million in 2019, at a CAGR of 9.1% from 2019 to 2025.
The implementation of government initiatives to promote healthcare services, rising geriatric population,
and the increasing incidence of bleeding disorders & various immunological diseases in Latin American
countries such as Brazil and Mexico are expected to drive the growth of the apheresis market in this
region.
The growing incidence of accidents & injury cases and an increasing incidence of cancer, neurological,
cardiovascular, renal, and autoimmune diseases have resulted in an increase in the number of blood
transfusions. The rising demand for blood transfusions leads to an increasing demand for blood & blood
components. Therefore, the government in this region is focusing on increasing awareness of blood
donations and encouraging the adoption of apheresis for automated blood component collection.
According to the WHO (2015), in the Caribbean and Latin America, voluntary blood donations increased to
44.1% in 2015 from 38.5% in 2013. However, the high cost of apheresis devices, limited reimbursement,
and a dearth of skilled professionals to perform therapeutic apheresis procedures hamper the growth of
the market in the region.
TABLE 216 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
Country 2017 2018 2019 2025 CAGR (2019–2025)
Brazil 20.6 22.5 24.6 42.4 9.5%
Mexico 18.1 19.6 21.3 35.7 9.0%
RoLA 12.7 13.7 14.9 24.6 8.8%
Total 51.4 55.8 60.8 102.7 9.1%
Brazil accounted for the largest share of 40.3% of the Latin American apheresis market in 2018. This large
share can be attributed to the availability of apheresis systems in the country, as global apheresis players
have strong distribution networks in the country. This market is projected to reach USD 42.4 million by
2025 from USD 24.6 million in 2019, at a CAGR of 9.5% during the forecast period.
TABLE 217 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 51.4 55.8 60.8 102.7 9.1%
181
TABLE 218 LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 9.7 10.3 10.9 15.8 6.4%
TABLE 219 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

39.8 43.1 46.8 78.1 8.9%
(Donor Apheresis)
Total 51.4 55.8 60.8 102.7 9.1%
TABLE 220 LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,

Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 11.59 12.69 13.92 24.56 9.9%
182
TABLE 221 LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,
Blood Disorders 3.475 3.803 4.168 7.302 9.8%
Renal Disorders 1.205 1.326 1.461 2.638 10.4%
Other Disorders 0.308 0.331 0.357 0.562 7.9%
Total 10.523 11.566 12.732 22.924 10.3%
TABLE 222 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 39.2 42.9 47.1 82.8 9.9%
Total 51.4 55.8 60.8 102.7 9.1%
TABLE 223 LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE,

Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 39.2 42.9 47.1 82.8 9.9%
183
TABLE 224 LATIN AMERICA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 25.06 27.36 29.93 52.01 9.6%
Leukapheresis 1.59 1.73 1.89 3.22 9.3%
Photopheresis 0.41 0.45 0.50 0.88 9.9%
Total 51.37 55.82 60.76 102.70 9.1%
TABLE 225 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

36.0 38.9 42.2 69.3 8.6%
Component Providers
Other End Users 2.2 2.3 2.5 3.9 7.6%
Total 51.4 55.8 60.8 102.7 9.1%
12.5.1 BRAZIL
12.5.1.1 Brazil offers lucrative growth opportunities in the apheresis
market due to an increasing number of blood and plasma
donations
Brazil accounted for a share of 40.3% of the Latin American apheresis market in 2018. This market is
forecast period.
The apheresis market in Brazil is expected to witness significant growth during the forecast period, due to
the growing demand for plasma-derived products and increasing blood & plasma donations in the country.
Brazil is a better choice for the establishment of plasma fractionation plants as the country produces
approximately 0.5 million liters of plasma annually from whole blood donations. Over 3.7 million whole
blood and apheresis units are collected annually in public and private collection centers, generating
approximately 800,000 plasma and cryoprecipitate products in Brazil.
According to the World Bank, the healthcare expenditure (% of GDP) in Brazil has increased from 10.2% in
2013 to 11.76% in 2016. Brazil has approximately 6,800 public and private hospitals, 195,000 service
units, and 500,000 hospital beds. The rising prevalence of chronic diseases also increases the number of
surgeries requiring blood transfusion, which, in turn, drives the growth of the apheresis market in this
country.
184
TABLE 226 BRAZIL: KEY MACROINDICATORS FOR THE APHERESIS MARKET
TABLE 227 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 20.6 22.5 24.6 42.4 9.5%
TABLE 228 BRAZIL: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 3.90 4.15 4.42 6.56 6.8%
185
TABLE 229 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

15.9 17.3 18.9 32.2 9.3%
(Donor Apheresis)
Total 20.6 22.5 24.6 42.4 9.5%
TABLE 230 BRAZIL: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 4.68 5.14 5.66 10.18 10.3%
TABLE 231 BRAZIL: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 1.384 1.519 1.671 2.989 10.2%
Renal Disorders 0.489 0.540 0.597 1.100 10.7%
Other Disorders 0.131 0.141 0.153 0.246 8.2%
Total 4.240 4.677 5.165 9.490 10.7%
186
TABLE 232 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 15.8 17.3 19.1 34.3 10.3%
Total 20.6 22.5 24.6 42.4 9.5%
TABLE 233 BRAZIL: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 15.8 17.3 19.1 34.3 10.3%
TABLE 234 BRAZIL: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 9.83 10.77 11.82 20.98 10.0%
Leukapheresis 0.72 0.79 0.87 1.50 9.7%
Photopheresis 0.20 0.22 0.25 0.44 10.2%
Total 20.62 22.48 24.56 42.36 9.5%
187
TABLE 235 BRAZIL: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

14.2 15.5 16.8 28.2 9.0%
Component Providers
Other End Users 1.0 1.1 1.2 1.8 7.9%
Total 20.6 22.5 24.6 42.4 9.5%
12.5.2 MEXICO
12.5.2.1 Rapidly growing geriatric population is a key factor driving
market growth in Mexico
Mexico accounted for a share of 35.1% of the Latin American apheresis market in 2018. This market is
forecast period.
Market growth in Mexico is primarily driven by the rising prevalence of chronic diseases, increasing per
capita healthcare expenditure, and the growing preference for blood collection using apheresis.
Additionally, Mexico’s geriatric population is growing steadily. According to the World Ageing Population
(2017), the population aged 60 years and above in Mexico is expected to reach 40.3 million by 2050 from
13.0 million in 2017. This aging population is more prone to various diseases, thereby leading to an
increase in the number of surgeries requiring blood component transfusion, thus driving market demand
for apheresis devices and related disposables in the country.
TABLE 236 MEXICO: KEY MACROINDICATORS FOR THE APHERESIS MARKET
Total Population (Million) 2018 126.19 Million
Number of Hospitals 2015 421*
*This number includes hospitals and clinical laboratories in Brazil

188
TABLE 237 MEXICO: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 18.1 19.6 21.3 35.7 9.0%
TABLE 238 MEXICO: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 3.40 3.60 3.82 5.49 6.2%
TABLE 239 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

14.0 15.2 16.4 27.2 8.7%
(Donor Apheresis)
Total 18.1 19.6 21.3 35.7 9.0%
TABLE 240 MEXICO: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 4.08 4.46 4.88 8.54 9.8%
189
TABLE 241 MEXICO: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 1.225 1.339 1.465 2.543 9.6%
Renal Disorders 0.424 0.465 0.511 0.915 10.2%
Other Disorders 0.100 0.107 0.115 0.179 7.7%
Total 3.705 4.066 4.469 7.973 10.1%
TABLE 242 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 13.8 15.1 16.5 28.8 9.7%
Total 18.1 19.6 21.3 35.7 9.0%
TABLE 243 MEXICO: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 13.8 15.1 16.5 28.8 9.7%
190
TABLE 244 MEXICO: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 8.92 9.72 10.62 18.27 9.5%
Leukapheresis 0.58 0.63 0.68 1.15 9.1%
Photopheresis 0.13 0.14 0.16 0.27 9.7%
Total 18.08 19.62 21.33 35.70 9.0%
TABLE 245 MEXICO: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

12.68 13.70 14.82 24.13 8.5%
Component Providers
Other End Users 0.78 0.83 0.89 1.36 7.4%
Total 18.08 19.62 21.33 35.70 9.0%
12.5.3 REST OF LATIN AMERICA

The rest of Latin America (RoLA) accounted for a share of 24.6% of the Latin American apheresis market in
2018. This market is expected to reach USD 24.6 million by 2025 from USD 14.9 million in 2019, at a
CAGR of 8.8% during the forecast period. Rising health awareness, improving medical infrastructures, and
increasing adoption of technologically advanced medical practices are driving the growth of this market.
TABLE 246 ROLA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 12.7 13.7 14.9 24.6 8.8%
191
TABLE 247 ROLA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 2.37 2.50 2.65 3.76 6.0%
TABLE 248 ROLA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

9.8 10.6 11.5 18.8 8.5%
(Donor Apheresis)
Total 12.7 13.7 14.9 24.6 8.8%
TABLE 249 ROLA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 2.83 3.09 3.38 5.84 9.6%
192
TABLE 250 ROLA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 0.87 0.94 1.03 1.77 9.4%
Renal Disorders 0.29 0.32 0.35 0.62 10.0%
Other Disorders 0.08 0.08 0.09 0.14 7.5%
Total 2.58 2.82 3.10 5.46 9.9%
TABLE 251 ROLA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 9.6 10.5 11.5 19.7 9.5%
Total 12.7 13.7 14.9 24.6 8.8%
TABLE 252 ROLA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 9.6 10.5 11.5 19.7 9.5%
193
TABLE 253 ROLA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)

Plasmapheresis 6.316 6.873 7.491 12.754 9.3%
Leukapheresis 0.287 0.312 0.339 0.565 8.9%
Photopheresis 0.079 0.086 0.094 0.162 9.5%
Total 12.665 13.716 14.879 24.629 8.8%
TABLE 254 ROLA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

9.08 9.79 10.58 17.03 8.3%
Component Providers
Other End Users 0.41 0.43 0.46 0.70 7.2%
Total 12.66 13.72 14.88 24.63 8.8%
12.6 MIDDLE EAST & AFRICA

In 2018, the Middle East & Africa accounted for 2.6% of the apheresis market. This regional segment is
estimated to reach USD 67.7 million by 2025 from USD 43.5 million in 2019, at a CAGR of 7.7% from
2019 to 2025. Market growth in this region can be attributed to factors such as increasing healthcare
expenditure, rising number of advanced healthcare facilities, and growing awareness on therapeutic
Saudi Arabia, UAE, Egypt, Israel, Qatar, Oman, Kuwait, Bahrain, and Turkey are the major markets for
apheresis in the Middle East. Israel, Egypt, and Iran have their own plasma fractionation plants. Israel has
two plasma fractionation plants that fulfill half the country’s requirement of plasma products. In Saudi
Arabia, LFB Arabia LLC (a joint venture between Healthcare Development Holding Co. and LFB Group
(France)) established a plant in 2015 for the extraction of human blood derivatives in the Kingdom of
Saudi Arabia (KSA). This plant is expected to fulfill 30% of Saudi Arabia’s requirement for blood products.
Currently, KSA spends approximately USD 88.64 million (SR332 million) annually for the import of blood
products to treat patients in the country.
The Blood Transfusion Service (BTS) in Saudi Arabia is basically a hospital-based blood banking system
where blood banks are responsible for the whole service, inclusive of the recruitment of donors; testing
donated blood for infective agents; and the preparation, storage and issue of components (packed RBCs,
fresh frozen plasma, platelet concentrates, cryoprecipitates, and filtered products). Saudi Arabia is
focusing on blood donations using apheresis technology in order to match the increasing clinical needs for
different blood derivatives and to sustain self-sufficiency,
194
The governments in these countries employ various strategies to invest and develop their respective
medical infrastructures. These initiatives are aimed at catering to the growing demand for effective
healthcare facilities, thereby also attracting foreign investments in the healthcare sector. In the last five
years, more than 15 hospitals have been accredited in the UAE by the Joint Commission International, one
of the leading accreditation organizations. Similarly, countries like Saudi Arabia are focusing on improving
their healthcare infrastructure in order to increase the accessibility and affordability of healthcare services
for their population. According to the Saudi Arabia Healthcare Industry Report (published by Global Health
Exhibition in 2019), the healthcare sector holds 15.6% in budget expenditure in 2019. The government of
Saudi Arabia has increased its budget allocation for the healthcare sector by 8% to reach USD 45.85 billion
(SAR 172 billion) in 2019, as compared to USD 42.38 billion (SAR 159 billion) in 2018. This increase in
budget allocation reflects a strong indication of growth & improvement in the healthcare sector. The
government is also focusing on diverting funds by building new hospitals, thereby aiming to create a robust
healthcare infrastructure. Currently, there are 275 government hospitals, 158 private hospitals, and 45
Quasi-governmental hospitals. By 2030, the Saudi Arabian government is willing to increase the number of
hospitals and privatization. These efficient developmental initiatives undertaken by the government are
expected to increase the adoption of medical devices, including apheresis devices in the Saudi Arabian
region.
Moreover, major hospital construction projects in Oman, Qatar, Kuwait, and the UAE also drive growth in
the medical healthcare industry. There are additional initiatives to transform Dubai (UAE) into a medical
tourism hub. These hospitals aim to provide advanced medical facilities for patients, with apheresis
technology being included in the near future. Developmental projects at such a large scale in these regions
are also expected to boost the growth of the apheresis market. Significant growth in the pharmaceutical
and medical devices market in this region is expected to drive the overall demand for the apheresis market
in the Middle East.
Factors such as the growing geriatric population, increasing prevalence of chronic diseases, and an
increase in discretionary incomes are driving the demand for apheresis in the Middle East and Africa.
TABLE 255 MEA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 37.8 40.5 43.5 67.7 7.7%
TABLE 256 MEA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 7.06 7.38 7.73 10.34 5.0%
195
TABLE 257 MEA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION)
Procedure 2017 2018 2019 2025 CAGR (2019–2025)

29.3 31.3 33.6 51.6 7.4%
(Donor Apheresis)
Total 37.8 40.5 43.5 67.7 7.7%
TABLE 258 MEA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION)
Product 2017 2018 2019 2025 CAGR (2019–2025)
Total 8.45 9.13 9.88 16.09 8.5%
TABLE 259 MEA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE,

Blood Disorders 2.55 2.75 2.97 4.80 8.3%
Renal Disorders 0.87 0.94 1.02 1.70 8.9%
Other Disorders 0.21 0.22 0.23 0.34 6.4%
Total 7.69 8.34 9.06 15.06 8.8%
196
TABLE 260 MEA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
Technology 2017 2018 2019 2025 CAGR (2019–2025)
Centrifugation 28.7 31.0 33.5 54.3 8.4%
Total 37.8 40.5 43.5 67.7 7.7%
TABLE 261 MEA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION)
Type 2017 2018 2019 2025 CAGR (2019–2025)
Total 28.7 31.0 33.5 54.3 8.4%
TABLE 262 MEA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
Plasmapheresis 17.83 19.22 20.75 33.33 8.2%
Leukapheresis 0.97 1.04 1.12 1.76 7.8%
Photopheresis 0.30 0.33 0.35 0.57 8.4%
Total 37.75 40.47 43.47 67.73 7.7%
197
TABLE 263 MEA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION)
End User 2017 2018 2019 2025 CAGR (2019–2025)

26.7 28.5 30.4 46.2 7.2%
Component Providers
Other End Users 1.6 1.7 1.8 2.6 6.1%
Total 37.8 40.5 43.5 67.7 7.7%
198
13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
The competitive landscape includes the analysis of the key growth strategies adopted by major players in
the apheresis market between 2017 and 2019. The players in the global apheresis market have employed
various strategies to expand their global footprints and increase their market shares. The key strategies
adopted by the top players in this market include new product launches; expansions; acquisitions; and
partnerships, agreements, and collaborations.
The prominent players in the global apheresis market include Terumo BCT, Inc. (US), Fresenius SE & Co.
KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen
AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan),
Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Macopharma SA (France), Miltenyi Biotec
(Germany), Otsuka Holdings Co. Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (UK), Medicap Clinic
GmbH (Germany), Lmb Technologies GmbH (Germany), Bioelettronica (Italy), Infomed (Switzerland),
Cytosorbents Corporation (US), and Toray Medical Co. Ltd. (Japan) among other key players.
FIGURE 35 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2017 TO 2019
ORGANIC STRATEGIES INORGANIC STRATEGIES
COMPANY
NAME PRODUCT LAUNCHES PARTNERSHIPS, AGREEMENTS,
EXPANSIONS ACQUISITIONS
& APPROVALS AND COLLABORATIONS
 Expanded its  Acquired
production site for NxStage
medical devices in Haina Medical, Inc.
FRESENIUS (Dominic Republic)
(GERMANY)
 Opened an extension of
its production plant in
Mihla, Germany
 Collaborated with UniCAR-
TERUMO BCT
Therapy Bio-Medicine Technology
(US)
Co. (China)
HAEMONETICS  Opened its new corporate
CORPORATION headquarters in
(US) Downtown Boston, US
BAXTER
 Launched the
INTERNATIONAL
PrisMax system
(US)
 Received approval  Signed a distribution agreement
from Health with Kedrion Biopharma (Italy)
Canada for the  Entered into a supply agreement
INTERCEPT Blood with CTCM (Spain) to provide the
CERUS System for
CORPORATION INTERCEPT Blood System for
platelets platelets
(US)
 Received approval
from the US FDA
for the INTERCEPT
Blood System
Note: indicates events that will have a significant impact on the market.
Source: Company Websites and Press Releases
199
13.2 MARKET SHARE ANALYSIS
13.2.1 GLOBAL APHERESIS MARKET SHARE ANALYSIS

The global apheresis market is consolidated with the top players being Terumo BCT, Inc. (US), Fresenius SE
& Co. KGaA (Germany), and Haemonetics Corporation (US). These three players accounted for a combined
market share of 71.4% in 2018.
These leading market players are based across countries, such as the US and Europe. Various small and
medium-sized players operating in both developed and emerging markets are making this a highly
competitive market. On the other hand, dominant market players have numerous advantages, such as
stronger marketing & distribution networks, larger budgets for R&D, and better brand recognition.
Companies are increasing their focus on R&D activities in order to add innovative products to their
portfolios, which, in turn, helps in strengthening their market presence. Additionally, lucrative growth
opportunities in the APAC and Latin American markets are also encouraging market players to strengthen
their presence in these regions.
FIGURE 36 GLOBAL APHERESIS MARKET SHARE, BY KEY PLAYER, 2018
28.6%
38.6%
Fresenius SE & CO. KGAA (Germany)

6.1%
Others
26.7%
Note: Others majorly include Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US),
Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Macopharma SA
(France), Miltenyi Biotec (Germany), Otsuka Holdings Co. Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (UK), Medicap Clinic
GmbH (Germany), Lmb Technologies GmbH (Germany), Bioelettronica (Italy), Infomed (Switzerland), Cytosorbents Corporation (US),
and Toray Medical Co. Ltd. (Japan).
Source: Annual Reports, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis Source: Annual Reports,
Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis

Terumo BCT accounted for a share of 38.6% of the global apheresis market in 2018. The company is
known for its diversified product offerings in the field of apheresis. Terumo’s products include Spectra
Optia, COBE Spectra, and Trima Accel; these products are widely adopted by blood centers, blood
component providers, hospitals, and transfusion centers for donor & therapeutic apheresis purposes. The
company has a significant global footprint owing to its strong sales and distribution network. Additionally,
strong after-sales services such as maintenance and re-installation of instruments give the company a
competitive advantage over other players in the apheresis market.
The company’s extensive R&D activities enable it to increase its depth of capabilities in technologies.
Significant investments also assist the company in launching innovative products in the market space.
Terumo BCT continuously focuses on product & technological innovations, further leading to an increase in
the company’s overall revenue.
200
The company also focuses on acquiring new consumers through expansions, partnerships, and
collaborations in emerging markets such as China, India, and South Korea. In October 2018, Terumo BCT
collaborated with UniCAR-Therapy Bio-Medicine Technology Co. (China) to advance CAR-T Cell therapies
and create a Center of Excellence in Shanghai, China.
In the last five years, the company has also focused on bringing technologically advanced instruments to
the market space to enhance efficiency. Terumo has also previously entered into strategic agreements with
medical organizations to democratize treatments and improve the quality of life for patients. For instance,
in August 2019, Terumo BCT provided funds to ABRALE (Associação Brasileira de Linfoma e Leucemia or
the Brazilian Association of Lymphoma and Leukemia) to provide and improve the treatment of blood
cancer in Brazil using Terumo’s apheresis systems.
Fresenius SE & Co. KGaA (Germany)

Fresenius is a global player in the apheresis market, with wide geographic coverage. The company has
maintained its leading position in the market through its strong distribution networks across the Asia
Pacific, North America, Europe, Latin America, and the Middle East & Africa. The company offers apheresis
systems and related disposables for both donor & therapeutic apheresis through its Fresenius Kabi and
Fresenius Medical Care business segments.
The company strengthens its business operations by expanding its presence in emerging markets. For
instance, in 2016, Fresenius introduced the AmiCORE apheresis device in Malaysia, Thailand, and
Vietnam. It has a strong product portfolio, and its CE-approved products have helped it in further enhancing
its presence in the apheresis market.
13.2.2 GLOBAL CENTRIFUGATION MARKET SHARE ANALYSIS

The global centrifugation market is consolidated with the three top players being Terumo BCT, Inc. (US),
Fresenius Kabi (Germany), and Haemonetics Corporation (US). These players have accounted for a
combined market share of 82.7% in 2018.
FIGURE 37 GLOBAL CENTRIFUGATION MARKET SHARE, BY KEY PLAYER, 2018
17.3%
7.9% Fresenius Kabi (Germany)

49.8%
25.0% Others
Note: Others majorly include Mallinckrodt plc (UK).

201
Haemonetics Corporation
Haemonetics Corporation is a key competitor in the apheresis market for both the collection of cells and
therapeutic apheresis. The company has a strong product profile in automated blood component
collection. Haemonetics also has a wide geographic presence across the US, Europe, Japan, and Asia,
which enables it to cater to its customers across the globe. Around 62% of the company’s revenue is
generated from the US market. Haemonetics also focuses on high-growth emerging countries in order to
increase its share in the apheresis market. For instance, in 2015, the company expanded its
manufacturing unit in Penang (Malaysia). The firm was also granted a full income tax exemption for ten
years (from 2016 to 2026) from the Malaysian government to manufacture whole blood and apheresis
devices. These developments in recent years have helped the company maintain its leading position and
increase its market share in the apheresis market.
13.2.3 GLOBAL MEMBRANE SEPARATION MARKET SHARE ANALYSIS

The global membrane separation market is consolidated, with the top players being Fresenius Medical
Care (Germany), Baxter International, Inc. (US), and Asahi Kasei Medical Co. Ltd. (Japan). These three
players accounted for a combined market share of 61.1% in 2018.
FIGURE 38 GLOBAL MEMBRANE SEPARATION MARKET SHARE, BY KEY PLAYER, 2018
Fresenius Medical Care (Germany)

32.7%
38.9% Baxter International, Inc. (US)
Asahi Kasei Medical Co., Ltd. (Japan)
Others
7.8% 20.6%
Note: Others majorly include B. Braun Melsungen AG (Germany), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi
Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Otsuka Holdings Co. Ltd.
(Japan), Medica S.p.A. (Italy), Medicap Clinic GmbH (Germany), Lmb Technologies GmbH (Germany), Bioelettronica (Italy), Infomed
(Switzerland), Cytosorbents Corporation (US), and Toray Medical Co. Ltd. (Japan).
13.3 COMPETITIVE LEADERSHIP MAPPING

This section reviews the top 21 companies that offer various types of devices in the apheresis market and
outlines the findings and analyses of how well each vendor performs within the global market space.
Players in the global market have employed prominent growth strategies to strengthen their product
portfolios and expand their businesses. The evaluation criteria considered for measuring the strength of
the product strategy include the breadth and depth of product portfolio, product innovation, breadth of
applications catered to, and product branding. The business strategy is evaluated by the geographic
footprint, the effectiveness of organic growth strategy, inorganic growth strategies adopted, and the
channel strategy and fit.
202
The top 21 players mapped in this section include Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA
(Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG
(Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi
Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Macopharma SA (France), Miltenyi Biotec (Germany),
Otsuka Holdings Co. Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (UK), Medicap Clinic GmbH
(Germany), Lmb Technologies GmbH (Germany), Bioelettronica (Italy), Infomed (Switzerland), Cytosorbents
Corporation (US), and Toray Medical Co. Ltd. (Japan).
13.3.1 VISIONARY LEADERS

Players that have a strong and established product portfolio as well as a strong geographic and market
presence are recognized as visionary leaders. Asahi Kasei Medical Co. Ltd. (Japan), Haemonetics
Corporation (US), Fresenius SE & Co. KGaA (Germany), Terumo BCT, Inc. (US), and Cerus Corporation (US)
are the visionary leaders in the apheresis market.
These companies offer advanced, reputable, and easily deployable products in the apheresis market. They
also focus on maintaining and upgrading their product portfolios. They are also known for their large
market shares, vast geographical presence, diverse product portfolios, and prominent distribution
networks spread across the globe. These players are known to adopt strong business strategies such as
product launches, expansions, collaborations, and acquisitions to increase their foothold in the market.
13.3.2 INNOVATORS
Innovators demonstrate substantial product innovation as compared to their competitors and have a
focused approach towards enhancing their product portfolio. The key innovators in the apheresis market
include Otsuka Holdings Co. Ltd. (Japan), Nikkiso Co., Ltd. (Japan), and Toray Medical Co. Ltd. (Japan).
The companies falling under the innovators segment also focus on innovative new products with an aim to
improve quality and increase customer satisfaction. These products are designed to meet the gaps or
unmet needs of the end users and to be on par with the visionary leaders. However, in comparison to
visionary leaders, the companies falling under this segment do not have strong growth strategies for
overall business development.
13.3.3 DYNAMIC DIFFERENTIATORS

Dynamic differentiators comprise of companies that have strong business strategies but weaker product
offerings as compared to other players in the market. These companies are known to focus on specific
product offerings as opposed to cultivating an elaborate portfolio.
B. Braun Melsungen AG (Germany) and Baxter International Inc. (US) are the two companies that fall under
this category in the apheresis market.
13.3.4 EMERGING COMPANIES

The emerging companies in this market include Kaneka Corporation (Japan), Kawasumi Laboratories, Inc.
(Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Medica S.p.A. (Italy), Mallinckrodt plc (UK),
Medicap Clinic GmbH (Germany), Lmb Technologies GmbH (Germany), Bioelettronica (Italy), Infomed
(Switzerland), and Cytosorbents Corporation (US). These players do not have strong business strategies as
compared to other vendors.
These players have the potential to build a strong product portfolio and business strategy in order to
compete in the apheresis market with the leading firms. However, they might be new entrants in the
market and may require some time to gain significant traction in the market.
203
FIGURE 39 APHERESIS MARKET: COMPETITIVE LEADERSHIP MAPPING (2018)
INNOVATORS VISIONARY LEADERS
Terumo BCT, Inc.
Fresenius SE & Co. KGaA
Haemonetics Corporation
Otsuka Holdings Asahi Kasei Medical Co. Ltd.
Nikkiso Co., Ltd.
Toray Medical Co., Ltd. Cerus Corporation
Kaneka Corporation Baxter International Inc.

Medica SpA Miltenyi Biotec
B. Braun Melsungen AG
Bioelettronica Srl Macopharma SA
Kawasumi
Infomed Laboratories, Inc.
STRENGTH OF PRODUCT PORTFOLIO
Medicap Clinic GmbH Mallinckrodt plc
Lmb Technologies Cytosorbents

GmbH Corporation
EMERGING COMPANIES DYNAMIC DIFFERENTIATORS
BUSINESS STRATEGY EXCELLENCE
Source: Press Releases, Expert Interviews, and MarketsandMarkets Analysis
13.4 COMPETITIVE SITUATION AND TRENDS

This segment studies the growth strategies adopted by players between 2017 and 2019 in the global
apheresis market. The market is highly competitive, involving a large number of global and local market
players. In order to expand their geographic presence and garner higher shares in the global market, the
major players operating in this market adopt various growth strategies, such as expansions; product
launches & product approvals; acquisitions, collaborations, and agreements.
13.4.1 PRODUCT LAUNCHES & APPROVALS

The demand for user-friendly and innovative blood separation devices has led to a number of product
launches in the apheresis market. The companies that adopted the strategy of product launches did so to
develop new products, strengthen their product portfolios, and cater to the unmet needs of their
customers.
The key players that adopted this strategy include Baxter International Inc. (US), Cerus Corporation (US),
and Toray Medical Co. Ltd. (Japan).
204
TABLE 264 PRODUCT LAUNCHES & APPROVALS (2017–2019)
MONTH & YEAR COMPANY SEGMENT PRODUCT
Baxter International launched the PrisMax system

Baxter International
July 2019 Apheresis Devices in the US. This product launch is expected to
Inc. (US)
increase the company’s presence in the US.
Toray launched the TORAMYXIN device in the

Toray Medical Co.
June 2019 Apheresis Devices European region. This will increase the company’s
Ltd. (Japan)
presence in this region.
Cerus Corporation announced that Health Canada

Cerus Corporation
April 2018 Apheresis Devices approved the commercialization of its INTERCEPT
(US)
Blood System for platelets.
Cerus Corporation announced that the Community

Blood Center (CBC) of Appleton, Wisconsin received
Cerus Corporation approval by the US FDA for the Biologics License
March 2018 Apheresis Devices
(US) Application (BLA) requesting allowance of interstate
distribution of platelets that have been pathogen-
reduced with the INTERCEPT Blood System.
Source: Press Releases
13.4.2 EXPANSIONS
Companies that adopted the strategy of expansions did so in order to enhance their geographical presence
and widen their consumer bases. This strategy helped companies expand their manufacturing capabilities
and open new subsidiaries, thus strengthening their positions across various regions. The key players that
adopted this strategy include Haemonetics Corporation (US), Cytosorbents Corporation (US), Fresenius
Kabi (Germany), B. Braun (Germany), and Lmb Technologies (Germany).
TABLE 265 EXPANSIONS (2017–2019)
MONTH & YEAR COMPANY LOCATION DESCRIPTION
The company opened its new corporate

December Haemonetics
US headquarters in Downtown Boston. This will help
2019 Corporation (US)
the firm increase its presence in the US.
Cytosorbents expanded the distribution of

Cytosorbents Brazil, Colombia, and CytoSorb in Brazil, Colombia, and Costa Rica. This
August 2019
Corporation (US) Costa Rica will increase the company’s market share in the
Latin American region.
Cytosorbents expanded the direct sales of

Poland, the CytoSorb for all applications to Poland and the
Cytosorbents Netherlands, Netherlands, and for critical care applications in
March 2019
Corporation (US) Sweden, Denmark, Sweden, Denmark, and Norway. This will increase
and Norway the company’s market share in the European
region.
Cytosorbents expanded the distribution of

Cytosorbents CytoSorb to 53 countries across the globe. This
July 2018 53 Countries
Corporation (US) helped the company to increase its presence
across these countries.
205
Cytosorbents opened a new manufacturing facility

Cytosorbents in the US. This helped the company to increase its
June 2018 US
Corporation (US) manufacturing capabilities and cater to the
growing demand for CytoSorb.
13.4.3 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS

Companies adopted this strategy to distribute products in the local and global markets, jointly develop
innovative solutions, increase their market reach, and enhance the availability of capital. The companies
that opt for these strategies aim to differentiate themselves in the market and enhance their current
position. The market players that adopted this strategy include Terumo BCT (US), Fresenius Medical Care
(Germany), Cerus Corporation (US), and Cytosorbents Corporation (US).
TABLE 266 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2017–2019)
MONTH & YEAR APPROACH COMPANY 1 COMPANY 2 DESCRIPTION
This research collaboration aimed to

further expand the understanding of the
underlying mechanism of action for
extracorporeal photopheresis, and its
February Mallinckrodt plc Transimmune AG
Collaboration application toward the development of
2019 (UK) (Germany)
potential next-generation photopheresis,
with plans to expand on Mallinckrodt's
current Therakos photopheresis
platform through new clinical trials.
Cytosorbents partnered with Fresenius

to distribute CytoSorb for acute care and
Fresenius
Cytosorbents other hospital applications in Korea and
August 2019 Partnership Medical Care
Corporation (US) Mexico. This partnership will increase
(Germany)
the company’s geographic reach in
Korea and Mexico.
According to this distribution agreement,

Kedrion is to distribute Cerus’
Distribution Cerus Kedrion INTERCEPT blood system portfolio in
August 2019
Agreement Corporation (US) Biopharma (Italy) Italy. This agreement will help Cerus
expand its market presence in Southern
Europe.
This collaboration aimed at advancing

UniCAR-Therapy CAR T-cell therapies by creating a new
Terumo BCT Bio-Medicine Shanghai Center of Excellence. This
October 2018 Collaboration
(US) Technology Co. development also helped Terumo widen
(China) its applications of apheresis and
leukapheresis procedures.
Cytosorbents extended its strategic

partnership with Biocon to launch and
February Cytosorbents Biocon Ltd.
Partnership distribute CytoSorb in Malaysia. This
2018 Corporation (US) (India)
partnership helped Cytosorbents
increase its presence in Malaysia.
206
13.4.4 ACQUISITIONS
Market players adopted acquisitions as a strategy to further strengthen their market presence and expand
their product portfolios in the apheresis market.
TABLE 267 ACQUISITIONS (2017)
MONTH & YEAR COMPANY 1 COMPANY 2 DESCRIPTION
Announced acquisition aimed to further grow Fresenius

Fresenius NxStage Medical,
August 2017 Medical Care company in renal care and critical care
Medical Care Inc. (US)
area
TABLE 268 OTHER STRATEGIES (2018–2019)
MONTH & YEAR APPROACH COMPANY DESCRIPTION
Terumo provided a three-year grant to Abrale, an NGO

working to democratize treatment and improve the
quality of life for patients with blood cancer in Brazil.
August 2019 Funding Terumo BCT
This collaboration will further strengthen the
company’s business among research & academic
institutions.
The company announced plans to transfer the

ownership (as well as the operating assets and certain
inventories) of Haemonetics Union, its South Carolina
Haemonetics
May 2019 Divestiture manufacturing facility, to CSL Plasma. The facility
Corporation (US)
produces liquid saline and sodium citrate, which are
solutions used in the plasmapheresis or plasma
collection process.
Cerus Corporation received additional funding of USD

15 million from the Biomedical Advanced Research
Cerus Corporation
May 2018 Funding and Development Authority (BARDA) to support the
(US)
development of the company’s INTERCEPT Blood
System for red blood cells.
207
14 COMPANY PROFILES
14.1 TERUMO BCT, INC.
14.1.1 BUSINESS OVERVIEW

Terumo BCT, originally established in 1964 as COBE Laboratories, is headquartered in Colorado, US.
Terumo BCT was formed through the integration of CaridianBCT and Terumo Transfusion, following Terumo
Transfusion’s acquisition of CaridianBCT. Terumo BCT acts like a wholly owned subsidiary of Terumo
Corporation.
Terumo BCT provides therapeutic apheresis, blood components, and cellular technologies. The company
offers products such as apheresis collections, manual & automated whole blood processing, and pathogen
reduction, coupled with therapeutic apheresis and cell-processing technologies. The company operates
through three business segments, Blood Centers, Therapeutic Apheresis and Cell Collection, and Cell
Therapy Technologies. Terumo offers apheresis devices and related disposables for automated blood
collection (donor apheresis) through its Blood Centers segment and therapeutic apheresis devices through
the Therapeutic Apheresis and Cell Collection business segment. The major end users of the company
include hospitals & therapeutic apheresis centers, blood banks, and biotech & cell processing centers.
The company, together with its subsidiaries, operates across the US, Europe, and the Asia Pacific. The
major subsidiaries of the company include Terumo BCT Holding Corporation (US), Terumo BCT, Inc. (US),
Terumo BCT Ltd. (UK), Terumo BCT Asia Pte. Ltd. (Singapore), Terumo BCT Vietnam Co., Ltd. (Vietnam),
Terumo BCT Japan, Inc. Terumo BCT Latin America S.A. (Argentina), and Terumo BCT Europe N.V.
(Belgium).
FIGURE 40 TERUMO BCT, INC.: COMPANY SNAPSHOT (2018)
COMPANY AT A GLANCE RECENT FINANCIALS

1,000.0 20.0%
16.1%
14.4% 15.0%
Total Revenue (USD Million)
800.0
15.0%
Operating Margin (%)
Founded: 1964
Headquarters: Colorado, US 600.0
10.0%
Total Revenue: USD 947.2 Million 400.0
R&D Expenditure: USD 87.5 Million 5.0%
200.0
Ownership: Public 874.2 945.2 947.2
0.0 0.0%
2016 2017 2018
BUSINESS REVENUE MIX GEOGRAPHIC REVENUE MIX

7.4%
Blood Centers
11.9%
The Americas
20.3% 40.2% EMEA
Therapeutic 23.1%
Apheresis and Cell Asia and Others
72.3% Collection
Japan
Cell Therapy 24.8%
Technologies
Note: Information for the Recent Financials, Business Revenue Mix, and Geographic Revenue Mix was not available for the Blood
Centers or Therapeutic Apheresis and Cell Collection segments. Hence, these sections have been provided for the overall company.
Source: Company Website, Company Presentations, and Annual Reports
208
14.1.2 PRODUCTS OFFERED

CATEGORY PRODUCT
 COBE Spectra Apheresis System

Therapeutic Apheresis
 Spectra Optia Apheresis System
 Trima Accel Automated Blood Collection System
Blood Center Services  TACSI System Terumo Automated Centrifuge & Separator Integration
 Mirasol Pathogen Reduction Technology System
Cell Therapy Technologies  Elutra Cell Separation System
14.1.3 RECENT DEVELOPMENTS

Collaborations
This collaboration aimed at advancing CAR T-

cell therapies by creating a new Shanghai
October UniCAR-Therapy Bio-Medicine
Terumo BCT Center of Excellence. This development also
2018 Technology Co. (China)
helped Terumo widen its applications of
apheresis and leukapheresis procedures.
Product approvals
MONTH & YEAR SEGMENT DESCRIPTION
Mallinckrodt plc and Terumo BCT announced that UVADEX (methoxsalen)

received regulatory approval in Australia by the Australian Therapeutic Goods
Administration (TGA) for extracorporeal administration with the THERAKOS
October 2019 Photopheresis CELLEX Photopheresis System for the treatment of Chronic Graft-versus-host
Disease (cGvHD) and skin manifestations of cutaneous T-cell lymphoma (CTCL)
in Adults. This is expected to increase the demand for photopheresis
procedures in Australia.
209
Funding activities
Terumo provided a three-year grant to Abrale,

Abrale (Associação Brasileira
an NGO working to democratize treatment and
de Linfoma e Leucemia or the
August 2019 Terumo BCT improve the quality of life for patients with blood
Brazilian Association of
cancer in Brazil. With this collaboration, Terumo
Lymphoma and Leukemia)
expanded its market presence in Brazil.
14.1.4 STRATEGIC OVERVIEW

TERUMO BCT: BUSINESS STRATEGY AND RIGHT-TO-WIN
GEOGRAPHIC TECHNOLOGY CUSTOMER SALES VALUE M&As/

PRODUCT
FOCUS FOCUS SEGMENT MODEL PROPOSITION PARTNERS
 Apheresis  North America  Centrifugation  Hospitals &  Direct Selling  Strong Apheresis  Alliances Only
CORE STRENGTH
Devices  Europe Transfusion  Selling via Local Product Portfolio

 Disposables  Japan Centers Partners Based on
 Blood Collection Centrifugation
Centers & Blood Technology and
Component Strong After-sales
Providers Support
OPPORTUNITY AREA
 Asia Pacific  Membrane  All Options Open

Separation
 Others  Emergency  None

Medical Service  Acquisitions Only
Providers
 Acute Care Centers
Source: MarketsandMarkets Analysis
14.1.5 COMPETITIVE ANALYSIS

Terumo BCT is a leading player in the blood component, therapeutic apheresis, and cellular technologies
markets. The company’s business segments—Blood Centers and Therapeutic Apheresis and Cell
Collection—provide apheresis products and are major contributors to the company’s overall revenue.
Strengthening R&D: Terumo BCT invests a significant amount of its revenue in research & development to
launch technologically advanced products in the market. The company increased its R&D expenditure by
15.4% from 2017 to 2018. The company also focuses on entering into strategic joint ventures to enhance
its product capabilities and develop new application areas for existing products.
Terumo’s Advantage Over Other Companies: The company’s major competitors in the apheresis market are
Fresenius and Haemonetics. Terumo offers a wider range of technologically advanced products in
comparison with the other market players. For instance, the company’s Spectra Optia system is a
centrifugation-based apheresis device that is designed for therapeutic apheresis as well as automated cell
collection (donor apheresis). It is an easier-to-use device when compared to the other products available in
the market. In addition to this, the company also focuses on including various other disease indications
and medical specialties in its product portfolio. This shift is expected to impact Terumo’s share in the
apheresis market. The company also focuses on strategies such as expansions, mergers, agreements, and
collaborations to strengthen its presence in the market.
210
14.2 FRESENIUS SE & CO. KGAA

Established in 1912 and headquartered in Bad Homburg, Germany, Fresenius is a global healthcare
company that provides products and services for dialysis, hospitals, and medical care. The company
operates through four major business segments, namely, Fresenius Medical Care, Fresenius Kabi,
Fresenius Helios, and Fresenius Vamed.
The company provides apheresis products through its Fresenius Kabi and Fresenius Medical Care business
segments. Fresenius Medical Care provides therapeutic apheresis products based on the membrane
filtration technology, while Fresenius Kabi offers products for the collection and processing of blood
components based on the centrifugation technology through its Medical Devices/Transfusion Technology
subsegment.
Fresenius has an international sales network and maintains more than 90 production sites across the
globe. These large production sites are located in the US, China, Japan, Germany, and Sweden. Some of its
major subsidiaries include Fresenius Medical Care North America (US), Fresenius Kabi Pharmaceuticals
Holding (US), Fresenius Kabi USA, Fresenius Kabi Canada, Fresenius Kabi (Germany), Fresenius Medical
Care Management AG (Germany), Fresenius Kabi (France), Fresenius Kabi Italia, Fresenius Kabi (Japan),
Fresenius Kabi (India), and Fresenius Kabi de Mexico.
FIGURE 41 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2018)

20.00 20.0%
Total Revenue (USD Billion)
Founded: 1996 14.5% 13.6% 14.2%

15.00 15.0%

Headquarters: Bad Homburg, Germany
No. of Employees: 120,328 (As of December 2018) 10.00 10.0%
Total Revenue: USD 19.54 Billion
5.00 5.0%
R&D Expenditure: USD 158.3 Million
18.34 18.91 19.54
Ownership: Public 0.00 0.0%
2016 2017 2018

4.2%
10.2% North America
19.8%
Healthcare Europe/Middle
Services East/Africa
15.6%
Healthcare Asia Pacific
80.2% Products 69.9%
Latin America
Note: In the Geographic Revenue Mix, corporate constitutes 0.1% of the total revenue for 2018.
Source: Company Website and Annual Reports
211
FIGURE 42 FRESENIUS KABI: COMPANY SNAPSHOT (2018)

10.00 25.0%
19.5%

Founded: 1999 18.5% 17.4%
8.00 20.0%

Headquarters: Bad Homburg, Germany
6.00 15.0%
No. of Employees: 37,843 (As of December 2018)
4.00 10.0%
R&D Expenditure: USD 630.7 Million 2.00 5.0%
6.65 7.18 7.73
2016 2017 2018

IV Drugs
14.2% 9.7%
Clinical Nutrition North America
41.8% 36.0% Europe
16.6% 19.9%
Medical Asia Pacific
Devices/Transfusion
Technology Latin America/Africa
27.4%
Infusion Therapy 34.4%
Note: The company operates through four business divisions. Of these divisions, two operate in the apheresis market, for which
financial details have been provided.

CATEGORY PRODUCT
 Fenwal Alyx Component Collection System

 Apheresis Kits & Alyx Accessories
Apheresis Collection Systems  Fenwal Amicus Separator

 Therapeutic Apheresis and Cell Collection Kits
 Amicus Accessories and Ancillaries
 Aurora Plasmapheresis Systems

 Aurora Xi Plasmapheresis Systems
Plasmapheresis Systems  Plasmapheresis Disposable Sets

 Plasmapheresis Disposable Accessories
 Sealers and Accessories
 Fenwal Amicus
Therapeutic Apheresis  AmiCORE Platelet Apheresis System

 COM.TEC
212
NxStage Medical, Inc.  NxStage System One S with NxView
 GLOBAFFIN immunoadsorber
 LIGASORB IgG adsorber
 IgEnio for Removal of IgE
Therapeutic Apheresis  DALI Lipoprotein Apheresis

 MONET Lipoprotein Apheresis
 Prometheus for Liver Support Therapy
 Art Universal Machine

Expansions
MONTH & YEAR COUNTRY DESCRIPTION INVESTMENT
Fresenius Kabi expanded its production site for medical devices in

Haina, Dominican Republic (US). The Haina plant manufactures
and exports apheresis systems for plasma and platelet collection,
April 2018 US as well as medical devices for blood separation. With this new NA
production facility, the company aims to enhance its production
capabilities and meet the increasing demand for apheresis
systems.
Fresenius Kabi opened an extension of its production plant in

Mihla, Germany. In this production plant, the company
December USD 11.8 Million
Germany manufactures injection-molded components for pharmaceutical
2017 (Euro 10 Million)
containers, such as feeding tubes and giving sets used in infusion
and apheresis therapies.
Acquisitions
Fresenius Medical Care acquired NxStage Medical

February Fresenius Medical NxStage Medical,
to widen its product portfolio in the areas of renal
2019 Care Inc. (US)
care and critical care.
213

FRESENIUS: BUSINESS STRATEGY AND RIGHT-TO-WIN

PRODUCT
 Apheresis  North America  Centrifugation  Hospitals &  Direct Selling  Strong Apheresis  Mergers Only
CORE STRENGTH
Devices  Europe  Membrane Transfusion  Selling via Local Product Portfolio

 Disposables Separation Centers Partners Based on
 Blood Collection Centrifugation and
Centers & Blood Membrane
Component Technologies
Providers
OPPORTUNITY AREA
 Asia Pacific  All Options Open

 Latin America
 MEA  Emergency  None

Medical Service  Alliances Only
Providers

Fresenius SE & Co. KGaA is one of the leading companies in the apheresis market. The company offers
apheresis devices through its Fresenius Medical Care and Fresenius Kabi business segments.
Growth Strategy: Fresenius Kabi focuses on launching its products in emerging countries to gain a
competitive edge in the market. For instance, in 2016, the company introduced its AmiCORE apheresis
device in Malaysia, Thailand, and Vietnam.
Strengthening R&D: The company invests heavily in R&D to optimize its portfolio. This is expected to help
fuel its future growth and the ability to remain competitive in the healthcare business segment. Fresenius
Kabi invested USD 630.7 million, USD 630.5 million, and USD 584.3 million in 2018, 2017, and 2016,
respectively, particularly in R&D activities. These continual investments for the development of new
products and the upgrading of existing products are expected to ensure Fresenius’s overall growth, thus
enhancing its share in the apheresis market.
214
14.3 HAEMONETICS CORPORATION

Haemonetics is a global blood management solutions company. It supplies systems and software that
facilitate blood transfusions and cell processing. The company's business solutions include devices &
consumables, information technology platforms, and consulting services, which help customers improve
their clinical outcomes and reduce healthcare costs. The company provides a wide range of blood
collection and processing systems, which are used for the separation of blood components.
Haemonetics Corporation operates through three business segments, namely, Plasma, Blood Center, and
Hospital. The company offers apheresis equipment through its Plasma and Blood Center segments.
Haemonetics’ manufacturing facilities are located in the US, Mexico, and Malaysia. The company’s
products are marketed in more than 90 countries. Haemonetics Corporation, along with its subsidiary Pall
Corporation (US), focuses on the transfusion medicine business. Some major subsidiaries of the company
are Haemonetics Manufacturing, Inc. (US), Haemonetics Canada Ltd., Haemonetics (UK) Limited,
Haemonetics GmbH (Germany), Inlog SAS (France), Haemonetics Italia s.r.l. Haemonetics Healthcare India
Private Limited, Haemonetics Japan GK, Haemonetics Malaysia Sdn. Bhd., Haemonetics Puerto Rico LLC,
and Haemonetics Hospitalar EIRELI (Brazil).
FIGURE 43 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2019)

1,200.0 8.6% 10.0%
6.2%
Founded: 1971 1,000.0 8.0%

800.0 6.0%
Headquarters: Massachusetts, US
4.0%
No. of Employees: 3,216 (As of March 2019) 600.0
2.0%
Total Revenue: USD 967.6 Million 400.0
-2.2% 0.0%
R&D Expenditure: USD 35.7 Million 200.0 -2.0%
886.1 903.9 967.6
Ownership: Public 0.0 -4.0%
2017 2018 2019

0.8%
12.3% US
20.3%
Plasma Japan
Blood Center 17.0%
51.9% Europe
27.8% Hospital 62.7% Asia
7.2% Others
Note: Information for the Recent Financials, Business Revenue Mix, and Geographic Revenue Mix was not available for the Plasma or
Blood Center segments. Hence, these sections have been provided for the overall company.
Source: Company Website, SEC Filings, and Annual Reports
215

CATEGORY PRODUCT
 NexSys PCS Plasmapheresis equipment and related disposables

Plasma
 PCS2/ PCS 300 Plasma Collection System
 MCS Multicomponent Collection System

 Disposable Collection Sets for MCS+ 8150
Blood Center
 MCS+ 9000 Mobile Platelet Collection System
 Disposable Collection Sets for MCS+ 9000
 Leukotrap WB with SAVE System

 Acrodose- PL & PLus Systems
Collection and Processing  Leukoreduction Filter Sets

 Microaggregate Blood Transfusion Filter
 Salvaged Blood Filters

Expansions
MONTH & YEAR COUNTRY DESCRIPTION
The company opened its new corporate headquarters in Downtown Boston.

December 2019 US
This will help the firm increase its presence in the US.
Divestiture
MONTH & YEAR DESCRIPTION
The company announced plans to transfer the ownership (as well as the
operating assets and certain inventories) of Haemonetics Union, its South
May 2019 Carolina manufacturing facility, to CSL Plasma. The facility produces liquid
saline and sodium citrate, which are solutions used in the plasmapheresis or
plasma collection process.
216

HAEMONETICS: BUSINESS STRATEGY AND RIGHT-TO-WIN

PRODUCT
 Apheresis  North America  Centrifugation  Blood Collection  Direct Selling  Strong Apheresis  None
CORE STRENGTH
Devices  Europe  Membrane Centers & Blood  Selling via Local Products Based on
 Disposables Separation Component Partners Centrifugation and
Providers Membrane
Filtration
Technologies at
Low Costs
OPPORTUNITY AREA
 Asia  Hospitals &

 Other Transfusion Centers
 Japan  Emergency  Alliances Only

Medical Service  Mergers Only
Providers  All Options Open

Haemonetics Corporation has successfully positioned itself as a leading player in the apheresis market.
The company majorly provides donor apheresis services in the market. Haemonetics’ automated blood cell
separators are used by hospitals and blood collection centers.
Growth Strategy: The company focuses on the development of new products and the enhancement of its
old portfolio. In July 2017, Haemonetics designed the PCS 300 Plasma Collection System for the
separation of whole blood using the centrifugation technology. The PCS 300 is the next generation of the
predicate Haemonetics PCS2 Plasma Collection System. The efficient automation and low cost of these
systems drive the growth of the corporation in the donor apheresis market.
Geographical Strength: Haemonetics has a global presence, and around 62.7% of its revenue is generated
from the US. This may result in increased exposure of the company to the risk of demand fluctuations in
local markets. In order to curb this risk, Haemonetics is now also actively focusing on the Asian and Latin
American markets. Additionally, the company was granted a full income tax exemption for ten years (from
2016 to 2026) from the Malaysian government to manufacture whole-blood and apheresis devices. The
company’s operating margin increased from −4.8% in 2016 to 8.6% in 2019.
In the years 2019, 2018, and 2017, ten customers accounted for approximately 52%, 45%, and 42% of
the company’s net revenue, respectively. The loss of these customers could affect the company’s overall
revenue in the coming years.
217
14.4 BAXTER INTERNATIONAL INC.

Baxter is engaged in the manufacturing and marketing of medical devices, pharmaceuticals, and
biotechnology products for a wide range of acute and chronic diseases. The company manages its
business based on three geographic segments: The Americas (North and South America), EMEA (Europe,
the Middle East, and Africa), and APAC (Asia Pacific). The company’s global business units (GBUs) include
Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies,
and Others. The company offers apheresis devices and disposables for the treatment of renal diseases
through the Acute Therapies business segment.
The company has a global presence, with manufacturing sites in 20 countries and sales networks in more
than 100 countries. Some of its major subsidiaries are Gambro Renal Products, Inc. (US), Baxter
Healthcare Holding GmbH (Switzerland), Baxter Healthcare Limited (UK), Baxter Healthcare Corporation
(US), Synovis Life Technologies, Inc. (US), Baxter Sales and Distribution LLC (US), Baxter SA (Belgium),
Gambro Dialysatoren GmbH (Germany), and Baxter Pharmaceuticals India Pvt Ltd (India).
FIGURE 44 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2018)

14.4%
12.00 15.0%
12.2%
Founded: 1931 10.00 12.0%

Headquarters: Illinois, US 8.00 7.3% 9.0%
No. of Employees: 50,000 (As of December 2018) 6.00
6.0%
Total Revenue: USD 11.13 Billion 4.00
R&D Expenditure: USD 655 Million 2.00 3.0%
10.16 10.56 11.13
2016 2017 2018

4.6% 4.6%
7.2% Renal Care
Medication Delivery 19.8% The Americas (North
32.9% and South America)
7.9% Clinical Nutrition
EMEA
18.8% Advanced Surgery 53.6%
26.6%
24.0% Acute Therapies Asia Pacific
Others
Note: Information for the Recent Financials, Business Revenue Mix, and Geographic Revenue Mix was not available for the Acute
Therapies segment. Hence, these sections have been provided for the overall company.
218

CATEGORY PRODUCT
 The PRISMAFLEX System

 Disposable PRISMAFLEX TPE Hemofilter 2000 Set (Filter)
 Disposable PRISMAFLEX HF1000/HF1400 Sets
 PRISMAFLEX HF1000/HF1400 Hemofilter Set
Apheresis Devices and  PRISMAFLEX M60/M100/M150 Hemofilter Set

Disposables  PRISMAX System
 PRISMAFLO II(S) HOOKS Blood Warmer Heating Sleeve
 PRISMAFLO IIS HIGH Flow Heating Sleeve Replacement
 PRISMAFLO IIS Low Flow Heating Sleeve Replacement
 Prismaflex 7.21 Control Unit

Product launches
The company launched the PrisMax system in the US. This product
July 2019 Apheresis Devices launch is expected to significantly expand the company’s presence
in the US.

BAXTER: BUSINESS STRATEGY AND RIGHT-TO-WIN

PRODUCT
 Apheresis  North America  Membrane  Hospitals &  Direct Selling  Strong Product  None
CORE STRENGTH
Devices  Europe Separation Transfusion  Selling via Local Portfolio for

 Disposables Centers Partners Plasmapheresis
OPPORTUNITY AREA
 Asia  Centrifugation  Blood Collection

Centers & Blood
Component
Providers
 Other  Emergency  Alliances Only

Medical Service  Mergers Only
219

The company generates approximately 60% of its revenues outside the US, and maintains approximately
50 manufacturing facilities and over 100 distribution facilities in the US, Europe, Asia Pacific, Latin
America, and Canada.
Growth Strategy: Baxter International mainly focuses on developing new products as its key growth strategy.
The company is in the midst of launching more than 100 products by 2023, in areas such as chronic and
acute renal care, smart pump technology, hospital pharmaceuticals and nutrition products, and surgical
sealants, among others. These comprise a mix of entirely new offerings, marked improvements on existing
technologies, and the expansion of current products into new geographies. In July 2019, Baxter also
launched the PrisMax System for CRRT and therapeutic plasmapheresis in the US. With this development,
the company is expected to significantly increase its market share in the apheresis market.
220
14.5 ASAHI KASEI MEDICAL CO. LTD. (A SUBSIDIARY

OF ASAHI KASEI CORPORATION)

Asahi Kasei Medical operates as a wholly owned subsidiary of Asahi Kasei Corporation. Asahi Kasei
Corporation has three business segments, namely, Material, Homes, and Healthcare. The Healthcare
business segment of the company is engaged in the manufacturing and distribution of hemodialyzers,
therapeutic apheresis products, leukocyte reduction filters, virus removal filters, and diagnostic reagents.
Asahi Kasei Medical operates through four business segments, namely, Dialysis, Therapeutic Apheresis,
Blood Transfusion, and Bioprocess. The company sells apheresis systems and leukocyte reduction filters
through its Therapeutic Apheresis and Blood Transfusion segments.
The company has a strong geographical presence across the Americas, Japan, Europe, and Asia/Oceania.
Asahi Kasei operates through nine subsidiaries across the globe. These include Asahi Kasei Medical
Europe GmbH (Germany), Asahi Kasei Medical America, Inc. (US), Asahi Kasei Medical (Hangzhou) Co., Ltd.
(China), Asahi Kasei Medical Trading (Korea) Co., Ltd. (South Korea), N.V. Asahi Kasei Bioprocess Europe
S.A. (Belgium), Asahi Kasei Bioprocess America, Inc. (US), Asahi Kasei Transfusion Technology Co., Ltd.
(China), Med-Tech, Inc. (Japan), and Asahi Kasei Medical MT Corp. (Japan).
FIGURE 45 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2018)
COMPANY AT A GLANCE RECENT FINANCIALS (HEALTHCARE)

3.00 12.7% 13.3% 15.0%
11.8%
Founded: 1931 2.50 12.0%

Headquarters: Tokyo, Japan 2.00
9.0%
No. of Employees: 34,670 (As of December 2018) 1.50
6.0%
2.53 2.41 2.79
2016 2017 2018

2.1%
14.3% Material 19.2% Japan

Homes US
9.0%
52.7% Healthcare China
30.9% 62.4%
9.4%
Others* Other Regions
*Others include plant engineering and environmental engineering, research and analysis, and employment agency/staffing
operations.
Note: Information for the Business Revenue Mix and Geographic Revenue Mix was not available for the Healthcare business
segment. Hence, these sections have been provided for the overall company.
221

CATEGORY PRODUCT
 PlasautoΣ Therapeutic Apheresis Equipment

 Plasmaflo OP Filter
 Cascadeflo EC Filter
Plasmapheresis  IMMUSORBA TR Filter

 IMMUSORBA PH Filter
 PLASORBA BR Filter
 Rheofilter
Continuous Renal Replacement  PlasautoΣ Therapeutic Apheresis Equipment

Therapy (CRRT)  CUREFLO Filter
 PlasautoΣ Therapeutic Apheresis Equipment

Leukocytapheresis (LCAP)
 Cellsorba EX Filter
 Platelet Filtration
 Sepacell PLX-5 Filter- Reduction of Leukocytes
Blood Transfusion
 Sepacell RZ-2000 Filter- Reduction of Leukocytes
 Sepacell R-S11 Filter- Reduction of Leukocytes
Note: No significant developments were reported by this company in the apheresis market between January 2017 and December
2019.

ASAHI KASEI: BUSINESS STRATEGY AND RIGHT-TO-WIN

PRODUCT
 Apheresis  North America  Membrane  Hospitals &  Direct Selling  Apheresis Devices  None
Devices  Japan Separation Transfusion  Selling via Local and Disposables
 Disposables Centers Partners Designed
Specifically for
Renal Diseases
 Asia  Centrifugation  Blood Collection

Centers & Blood
Component
Providers
 Europe  Emergency  Alliances Only

 Others Medical Service  Mergers Only
222

Asahi Kasei is a leading player in the apheresis market. The company’s state-of-the-art membrane
separation and adsorption separation technologies have helped it gain a competitive edge in the apheresis
market. Asahi Kasei has a well-balanced product portfolio, which can be used to treat more than 30
disorders covered by Japan’s national health insurance.
Company Segmental Growth: The revenue generated from the company’s Healthcare segment increased by
USD 235.6 million from USD 2,675.0 million in 2018, thus accounting for an increase of shares by 14.3%
of the total revenue in 2018. The Healthcare segment also reported an increase in revenue owing to the
increased installations of medical devices.
Asahi Kasei has a strong presence across the globe, covering the Americas, Europe, and Asia/Oceania. In
the therapeutic apheresis business, Asahi Kasei shows robust market growth by leveraging its advanced
membrane separation and adsorption separation technology platforms.
223
14.6 B. BRAUN MELSUNGEN AG

B. Braun Melsungen is engaged in the development and manufacturing of products for cardiology,
anesthesia, intensive care, and extracorporeal blood treatment. The company offers products under four
major business segments, namely, Hospital Care, Aesculap, Outpatient Market (OPM), and B. Braun
Avitum. The company offers apheresis products under its B. Braun Avitum division. B. Braun’s major end
users include hospitals, private practitioners, and home care treatment providers.
B. Braun Melsungen has a strong presence across 64 countries spanning North America, Europe, the Asia
Pacific, the Middle East, Africa, and Latin America. The company has around 282 fully consolidated
companies across the globe. B. Braun’s manufacturing sites are mainly located in the US, Germany, Brazil,
China, Dominican Republic, France, Hungary, India, Italy, Japan, Malaysia, Poland, Romania, Switzerland,
Spain, and Vietnam. Some of its major subsidiaries include B. Braun Avitum AG (Germany), B. Braun
Avitum Saxonia GmbH (Germany), B. Braun Avitum France SAS, B. Braun Avitum Italy S.p.A., B. Braun
Avitum (Shanghai) Trading Co. Ltd. (China), B. Braun of America (US), B. Braun Medical (US), Aesculap
International (Germany), B. Braun Hospicare (Ireland), and B. Braun Medical (India).
FIGURE 46 B. BRAUN: COMPANY SNAPSHOT (2018)

9.2%
10.00 8.5% 10.0%
7.5%
Founded: 1839 8.00 8.0%

Headquarters: Melsungen, Germany
6.00 6.0%
No. of Employees: 63,751 (As of December 2018)
4.00 4.0%
7.16 7.67 8.16
2016 2017 2018

0.4%
6.0% 3.1%
Germany
Hospital Care
15.7% Europe
16.8%
Aesculap
45.3% 18.0% North America
12.2% OPM
Asia Pacific
B. Braun Avitum
26.4% 33.0% Latin America
23.1%
Other Sales
Africa and the Middle East
Note: Information for the Recent Financials, Business Revenue Mix, and Geographic Revenue Mix was not available for the B. Braun
Avitum segment. Hence, these sections have been provided for the overall company.
224

CATEGORY PRODUCT
Machines Plasmat Futura
 Haemoselect 0,5 / 0,7 m 2 Plasmafilter

 H.E.L.P. Ultrafilter HIPS 20
Filters/Adsorbers
 H.E.L.P. Heparinadsorber
 H.E.L.P. Precipitatefilter
Bloodline Systems Plasmat Futura Kit

Expansions
MONTH & YEAR LOCATION DESCRIPTION
B. Braun opened five new medical production facilities in Penang,

April 2018 Malaysia Malaysia. These facilities aided in the production of medical
devices, inclusive of apheresis devices and disposables.
14.6.4 MNM VIEW

B. Braun is one of the leading players in the apheresis market with a wide geographical presence across
the globe. The company’s Avitum division provides products and services for chronic and acute kidney
failure patients by focusing on three major therapies, namely, hemodialysis, acute dialysis, and apheresis.
B. Braun has increased its market share by expanding its existing dialysis centers, constructing new
centers, and acquiring other centers in various countries. In 2018, the sales of the Avitum division grew by
4.9% as compared to 2017. This strong growth was particularly noted in the Philippines, Germany, and
China for consumables, apheresis machines, and dialysis machines.
225
14.7 CERUS CORPORATION

Cerus Corporation is engaged in the manufacturing and distribution of pathogen reduction blood systems
to enhance blood safety. The company’s INTERCEPT Blood System controls biological replication and
reduces blood-borne pathogens (bacteria and viruses) during transfusions. This system can be used for
different components such as platelets and plasma; currently, an INTERCEPT Blood System for RBCs is
under clinical development. Cerus Corporation operates in only one segment, Blood Safety.
The company currently markets and sells the INTERCEPT Blood System in the US, Europe, the
Commonwealth of the Independent States, the Middle East, and selected countries in other regions around
the world. Cerus has 80 centers in 15 countries across Europe, the Middle East, Russia, and Asia. The
company’s operations outside of the US include a wholly owned subsidiary, headquartered in Europe.
Cerus’ operations in the US are responsible for the R&D and global & domestic commercialization of the
INTERCEPT Blood System, while operations in Europe, the Commonwealth of Independent States, and the
Middle East are responsible for the commercialization efforts of platelet and plasma systems.
FIGURE 47 CERUS CORPORATION: COMPANY SNAPSHOT (2018)

100.0 200.0%
150.0%
Incorporated: 1991

50.0 100.0%
Headquarters: California, US
39.28 51.33 76.05 50.0%
No. of Employees: 240 (As of December 2018) 0.0 0.0%
Total Revenue: USD 76.05 Million 2016 2017 2018 -50.0%
R&D Expenditure: USD 42.6 Million -50.0 -100.0%
-72.3%
-112.1% -150.0%
Ownership: Public
-100.0 -156.5% -200.0%
GEOGRAPHIC REVENUE MIX

2.1%
20.8% Europe, Middle East, and Africa
North America
77.1% Others
Note: Cerus Corporation operates through only one business segment. Hence, the Business Revenue Mix for the company has not
been provided here.
226

CATEGORY PRODUCT
 INTERCEPT Blood System for Platelets and Plasma

Blood Safety
 INTERCEPT Blood System for RBS (in clinical phase)

Agreements
MONTH & YEAR COMPANY 1 COMPANY 2 APPROACH DESCRIPTION
According to this distribution

agreement, Kedrion is to distribute
Cerus Kedrion Distribution Cerus’ INTERCEPT blood system
August 2019
Corporation (US) Biopharma (Italy) Agreement portfolio in Italy. This agreement will
help Cerus expand its market presence
in Southern Europe.
Cerus entered into a supply agreement

Centro de with CTCM to provide the INTERCEPT
Cerus Transfusión de la Supply Blood System for platelets. CTCM is one
October 2017
Corporation (US) Comunidad de Agreement of the largest blood banks in Spain and
Madrid (CTCM) provides blood & blood components to
all hospitals in Madrid.
Product approvals
Cerus Corporation announced that Health Canada approved the

April 2018 Plateletpheresis
commercialization of its INTERCEPT Blood System for platelets.
Cerus Corporation announced that the Community Blood Center

(CBC) of Appleton, Wisconsin received approval by the US FDA for
March 2018 Plateletpheresis the Biologics License Application (BLA) requesting allowance of
interstate distribution of platelets that have been pathogen-
reduced with the INTERCEPT Blood System.
227
Funding activities
Cerus Corporation received additional funding of USD 15 million from the

Biomedical Advanced Research and Development Authority (BARDA) to
May 2018
support the development of the company’s INTERCEPT Blood System for red
blood cells.
14.7.4 MNM VIEW

Cerus Corporation is one of the leading companies in the apheresis market. The company has around 12
US patents and 99 foreign patents related to the INTERCEPT Blood System. The company focuses on
clinical research to expand the INTERCEPT’s capabilities to include RBCs.
The company’s product revenue increased by USD 17.3 million during 2018, as compared to 2017,
primarily due to the year-over-year sales volume growth for disposable kits in Europe. The majority of this
rise primarily resulted from the nationwide adoption of the platelet system in France and increased
disposable kit sales for the platelet system in the US. The product revenue of the company is further
expected to increase during the forecast period.
Cerus Corporation has a strong presence across Europe, with a moderate presence in the Middle East and
Asia. A strong focus on inorganic growth strategies such as partnerships and agreements has provided
Cerus with significant opportunities to scale ahead in the apheresis market. However, increasing
competition from rivals may hamper the growth of the company to a certain extent.
228
14.8 KANEKA CORPORATION

Founded in 1949 and headquartered in Tokyo, Japan, Kaneka Corporation manufactures and distributes
chemicals, functional plastics, foodstuff, expandable plastics & products, life science products, electronic
products, and synthetic fibers & others. Kaneka Corporation operates through four business segments,
namely, Material Solutions Unit, Quality of Life Solutions Unit, Healthcare Solutions Unit, and Nutrition
Solutions Unit. Through its Healthcare Solutions unit, the company manufactures and sells medical
devices, including apheresis systems and low-molecular pharmaceutical materials, APIs, and
biopharmaceuticals.
The company’s subsidiary, Kaneka Medix Corporation, operates in the life science products segment and
manufactures catheters for blood vessels, blood purification systems, and other medical equipment.
Kaneka Corporation operates across the globe through its 110 subsidiaries in Japan and other countries—
Belgium, Germany, the US, Brazil, Singapore, Vietnam, Indonesia, China, India, Malaysia, South Korea,
Taiwan, and Australia. Its major subsidiaries include Kaneka Medix Corporation (Japan), Kaneka Belgium
N.V. (Belgium), Kaneka Asia Co., Ltd. (China), Kaneka India Pvt., Ltd., Kaneka Taiwan Corporation, Kaneka
Korea Corporation (South Korea), and Kaneka Americas Holding, Inc. (US).
FIGURE 48 KANEKA CORPORATION: COMPANY SNAPSHOT (2019)

7.00 6.0% 6.2% 7.0%
5.8%
Founded: 1949 6.00 6.0%

5.00 5.0%
Headquarters: Tokyo, Japan
4.00 4.0%
No. of Employees: 10,234 (As of March 2019)
3.00 3.0%
2.00 2.0%
5.07 5.38 5.60
2017 2018 2019
0.3% 4.2%
Material Solutions Unit Japan
9.5%
Quality of Life Solutions Unit 7.9%
25.6% Asia
41.2%
Healthcare Solutions Unit North America
7.7% 18.6% 59.8%
Nutrition Solutions Unit Europe
25.2% Other* Other Areas
Note 1: In the Business Revenue Mix, Others is a business segment that is not included in the reporting segments and includes
property and life insurance agency services. It constitutes 0.3% of the total revenue.
Note 2: Information for the Recent Financials, Business Revenue Mix, and Geographic Revenue Mix was not available for the
Healthcare Solutions Unit. Hence, these sections have been provided for the overall company.
229

CATEGORY PRODUCT
 LIPOSORBER System
 Adsorption Type Plasma Purification Device
 LIPOSORBER LA-15
 LIPOSORBER LA-40S
 Membrane Type Plasmaseparator
 Sulflux FP
 Tubing system for Plasmapheresis
 NK-M3R
 Apheresis Machine (for Plasma Purification)
 MA-03
 SULFLUX (Membrane-type plasma separator)
 Selesorb System
Blood Purification  Adsorption Type Plasma Purification Device

 Selesorb
 Membrane Type Plasmaseparator
 Sulflux FP
 Tubing system for Plasmapheresis
 NK-M3R
 Apheresis Machine (for Plasma Purification)
 MA-03
 Lixelle
 Adsorption Type Plasma Purification Device
 Lixelle S-15
 Lixelle S-25
 Lixelle S-35
2019.
230
14.9 KAWASUMI LABORATORIES, INC.

Founded in 1957 and headquartered in Tokyo, Japan, Kawasumi Laboratories Inc. is engaged in the
manufacturing and distribution of medical devices, instruments, and other pharmaceuticals. The company
operates through two business segments—Hemodialysis & Plasmapheresis and Blood Transfusion &
Endovascular. It develops ecofriendly blood collection and transfusion products under its Blood
Transfusion & Endovascular segment.
The company has five production facilities; three in Japan and two in other countries. Kawasumi
Laboratories operates across Japan, the US, and Southeast Asia through its subsidiaries—Kawasumi
Laboratories America, Inc. (US), Kawasumi Laboratories Thailand Co., Ltd., and Fresenius-Kawasumi Co.,
Ltd. (Japan).
FIGURE 49 KAWASUMI LABORATORIES: COMPANY SNAPSHOT (2019)

400.0 3.7% 4.0%
Founded: 1957 2.7%
300.0 2.5% 3.0%

No. of Employees: 2,404 (As of September 2019) 200.0 2.0%
Total Revenue: USD 217.4 Million
100.0 1.0%
228.7 229.6 217.4
2017 2018 2019
Hemodialysis &
Plasmapheresis 33.0% Japan
47.3%
52.7% Overseas
Blood Transfusion & 67.0%
Endovascular
Note: Information for the Recent Financials, Business Revenue Mix, and Geographic Revenue Mix was not available for the Blood
Transfusion & Endovascular business segment. Hence, these sections have been provided for the overall company.
231

CATEGORY PRODUCT
 Plasma Separator Plasmacure PE
Plasmapheresis Systems  Plasma Separator Evacure/Evaclio (EC-4C, EC-2C)

 Plasma Separator Evaflux (2A, 3A, 4A, 5A)
 KARMI Blood Bag Single and Multiple Blood Collection System
Blood Banking and Transfusion  KARMI PO Bag Platelet Collection and Storage Bag
 Potassium Adsorption Filter
2019.
232
14.10 NIKKISO CO., LTD.

Founded in 1950 and headquartered in Tokyo, Japan, Nikkiso Co., Ltd. is engaged in the manufacturing
and distribution of medical equipment and industrial instruments. The company operates through two
business segments, namely, Industrial and Medical. The Industrial segment involves the manufacturing,
distribution, and maintenance of industrial pumps, carbon fiber-reinforced plastics, water conditioning
equipment, and other industrial equipment. The Medical segment is subsegmented into Dialysis Machines,
Disposables, Services, CRRT, and Others. Under the Medical segment, the company manufactures and
distributes hemodialysis-related equipment, data communications systems, blood tubing lines, and
therapeutic apheresis products. At present, the company’s apheresis products are available in Europe.
The company is present across Japan, Asia, North America, Europe, and the Rest of the World (RoW). Some
major subsidiaries of the company are NIKKISO Europe GmbH (Germany), Nikkiso Belgium bvba, Nikkiso
Eiko Co., Ltd. (Japan), Nikkiso-Therm Co., Ltd. (Japan), Nikkiso Giken Co., Ltd. (Japan), Nikkiso America, Inc.
(US), Nikkiso Cryo, Inc. (US), and Nikkiso Critical Care Medical Supplies (Shanghai) Co., Ltd. (China), among
others.
FIGURE 50 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2018)

2.00 8.0%
6.2%
6.2%
Founded: 1950
1.50 6.0%

3.7%
No. of Employees: 8,346 (As of September 2019) 1.00 4.0%
0.50 2.0%
R&D Expenditure: USD20.8 Million
1.15 1.25 1.49
2016 2017 2018
BUSINESS REVENUE MIX (MEDICAL) GEOGRAPHIC REVENUE MIX (MEDICAL)

3.0%
Dialysis Machines 1.0% Japan

19.0% 12.0%
29.0% Disposables Asia
8.0% 15.0% North America
Service
11.0% Europe
CRRT 69.0%
33.0% Others
Others
Note: Information for the Recent Financials was not available for the Medical business segment. Hence, this section has been
provided for the overall company
233

CATEGORY PRODUCT
 Aquarius Systems
 Aquarius System Filters & Sets
 Aquamax
Apheresis Systems  Aquaset

 CitrasetRCA
 Immunopure Apheresis Systems
 Hemofilters, Plasmafilters, Tubing sets, and catheters
2019.
234
14.11 MACOPHARMA SA

Founded in 1977 and headquartered in Mouvaux, France, Macopharma develops, manufactures, and sells
infusion, transfusion, and biotherapy systems for patients and healthcare providers. Its transfusion
systems include automatic blood component separators, blood & transfusion bags, leukocyte reduction in-
line filters, and blood safety products. The company sells its products to hospitals, R&D centers, and
pharmaceutical companies.
Macopharma has a presence in more than 80 countries with four manufacturing facilities in Europe, 18
subsidiaries, and 70 distributors across the globe. Some of its major subsidiaries are Macopharma USA,
Macopharma Canada, Inc., Maco Pharma International GmbH (Germany), MacoPharma Italia,
MacoPharma Nederland B.V., Maco Spania, MacoPharma Nordic (Norway), Maco Pharma International
GmbH (Switzerland), MacoPharma New Zealand, and Macopharma India Transfusion Solution Pvt. Ltd.
Note: Macopharma SA is a privately held company, and no financial information is available in the public domain. Hence, no financial
details are added in this section.

CATEGORY PRODUCT
 Photopheresis
Biotherapy  Macogenic G2
 Bag for U.V. treatment of blood cells
 Blood Processing
 Automatic blood components separator
 Macopress Smart
 Blood Bags
 Dockable Filters
 LEUCOLAB LCG2B / LCG4
Transfusion  THROMBOFLEX TXP

 Inline Filters
 Leucoflex LXT
 Leucoflex MLT1
 Leucoflex LCRD2
 Leucoflex LCRD
 Leucoflex CGP
2019.
235
14.12 MILTENYI BIOTEC

Founded in 1989 and headquartered in Germany, Miltenyi is involved in the development and
manufacturing of cell-labeling reagents and instruments for cell separation and analysis. The company
provides magnetic cell sorting technologies, which are used in biomedical research areas. Miltenyi’s
TheraSorb Therapeutic Apheresis system, with its specific adsorbers, is based on the selective removal of
pathogenic substances from the patient’s plasma.
The company has its presence in more than 100 countries through a network of distributors. Annually,
2,500 patients receive treatment with apheresis products from Miltenyi Biotec. The company has 475
employees in the R&D, engineering, and clinical development domains.
Note: Miltenyi Biotec is a privately held company, and no financial information is available in the public domain. Hence, no financial
details are added in this section.
236

CATEGORY PRODUCT
 TheraSorb Therapeutic Apheresis system

 LIFE 21 apheresis unit
 LIFE 18 apheresis unit
 Disposables
 LIFE 18 – disk separator
 LIFE 18 – TPE Line
 LIFE 18 – TPE complete treatment set
 TheraSorb – Ig flex complete disposables set
 TheraSorb – Ig flex adsorber kit
 TheraSorb – LDL pro complete disposables set
 TheraSorb – Ig pro complete disposables set
 TheraSorb – LDL pro adsorber kit
 TheraSorb – Ig pro adsorber kit
 TheraSorb – IgE complete disposables set
Therapeutic Apheresis Systems  TheraSorb – IgE adsorber kit

 TheraSorb – TS TPE
 TheraSorb – TS IA 100
 TheraSorb – DS 100
 LIFE 18 – Theraline pro
 LIFE 21 – disposables set
 TheraSorb – LDL adsorber kit
 TheraSorb – Ig omni adsorber kit
 TheraSorb – LDL complete disposables set
 LIFE 21 – Ig omni 5 disposables set
 Ig omni 1 complete set LIFE 18
 Ig omni 1 complete treatment set LIFE 21
 LIFE 21 – Ig omni 1 disposable set
 LIFE 18 – Ig omni 5 disposables set
 LIFE 21 – TPE complete treatment set
2019.
237
14.13 OTSUKA HOLDINGS CO., LTD.

Otsuka Holdings Company Limited is engaged in the development and sales of pharmaceutical and
nutraceutical medical devices. The company operates through four business segments, namely,
Pharmaceuticals, Nutraceuticals, Consumer Products, and Others.
The Pharmaceuticals segment provides Cardiovascular Systems, Gastroenterology Systems,

Ophthalmology Systems, Diagnostic Systems, IV Solutions, and Medical Devices. Otsuka’s medical devices
primarily focus on minimally invasive and innovative therapeutic devices. The company sells apheresis
systems through its Medical Devices segment.
Otsuka has a strong presence across Japan, the Americas, Europe, and Asia/Oceania. The company
operates through 162 subsidiaries and 26 affiliates across the globe. These include Avanir
Pharmaceuticals, Inc. (US), Otsuka America, Inc. (US), Otsuka Pharmaceuticals (UK) Limited, Otsuka
Pharmaceutical Co., Ltd., (Japan), Otsuka Pharmaceutical Factory, Inc. (Japan), Taiho Pharmaceutical Co.,
Ltd. (Japan), Otsuka Chemical Co., Ltd. (Japan), Otsuka Medical Devices Co., Ltd (Japan), Suzhou Otsuka
Pharmaceutical Co., Ltd.(China), Otsuka Pharmaceutical India Private Limited, P.T. Widatra Bhakti
(Indonesia), Diatranz Otsuka Limited (New Zealand), and J.O. Pharma Co., Ltd. (Japan).
FIGURE 51 OTSUKA HOLDINGS COMPANY LIMITED: COMPANY SNAPSHOT (2018)
COMPANY AT A GLANCE RECENT FINANCIALS (PHARMACEUTICALS)

8.00 16.0%
12.2%
Founded: 1950 10.7% 10.4%

6.00 12.0%

No. of Employees: 46,000 4.00 8.0%
Total Revenue: USD 7.40 Billion (Pharmaceuticals)
2.00 4.0%
R&D Expenditure: USD 1.8 Billion (Pharmaceuticals)
6.94 6.91 7.40
2016 2017 2018
8.0%
2.6%
Pharmaceuticals
23.1% Japan
Nutraceuticals
50.0% North America
26.2%
Consumer Products
63.2% 26.9% Others
Others
Note: Information for the Business Revenue Mix and Geographic Revenue Mix was not available for the Pharmaceuticals segment.
Hence, these sections have been provided for the overall company.

CATEGORY PRODUCT
Apheresis Systems AdaColumn
Note: No significant developments were reported by the company in the apheresis market between January 2017 and December
2019.
238
14.14 MEDICA SPA

Founded in 1985 and headquartered in Italy, Medica develops, manufactures, and commercializes
medical devices for blood purification. The company has three production facilities; two in Italy and one in
Tunisia. In addition to the portfolio of disposable medical devices and electromedical equipment, Medica
also offers a wide range of machines for disposable medical products through its subsidiary, Tecnoideal,
Note: Medica S.p.A. is a privately held company, and no financial information is available in the public domain. Hence, no financial
details are added in this section

CATEGORY PRODUCT
 AFERsmart
 ACUSmart
Critical Care-CRRT-Apheresis
 LEUKOsmart
 Leukocyte Apheresis- Leukocyte Adsorber LA25
2019.
239
14.15 MALLINCKRODT PLC

Founded in 1867 and headquartered in Thames, UK, Mallinckrodt plc manufacturers, markets, and
distributes pharmaceutical products & therapies. The company's Specialty Brands segment is an area of
focus since it includes specialty areas like neurology, rheumatology, nephrology, pulmonology, and
ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics. The
company’s Specialty Generics and Amitiza segments include specialty generic drugs, active
pharmaceutical ingredients (API), and Amitiza (lubiprostone).
In August 2015, Mallinckrodt acquired Therakos, Inc., a global leader in autologous immune cell therapy
delivered through extracorporeal photopheresis (ECP). Therakos Photopheresis is approved by the US
FDA for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) in people
who have not been responsive to other forms of treatment. Outside the US, Therakos Photopheresis is also
broadly approved for ECP, and is approved to treat several other serious diseases that arise from immune
system imbalances.
The company sells the Therakos CELLEX Photopheresis System to academic medical centers, hospitals
and treatment centers in more than 25 countries. Terumo BCT is the exclusive distributor of the Therakos
ECP platform in Australia, as well as Latin America and select countries in Europe.
FIGURE 52 MALLINCKRODT PLC : COMPANY SNAPSHOT (2018)

4.00 20.0%
3.50
Founded: 1876 18.7%
3.00 15.0%
Headquarters: Thames, UK 2.50 15.3%
No. of Employees: 3,400 (As of December 2018) 2.00 10.0%
1.00 5.0%
0.50 3.38 3.22 3.22
2016 2017 2018
PRODUCT REVENUE MIX GEOGRAPHIC REVENUE MIX

3.4% 1.7%
0.9% 3.9%
Acthar Gel 8.0%
7.4%
SpecGx US
11.0% INOmax
35.5%
OFIRMEV Europe, Middle East and
17.4% Therakos Africa
Specialty Generics and AMITIZA 88.1% Other
22.7%
BioVectra
Others
Source: Company Website, Company Presentations, SEC Filings, and Annual Reports
240

CATEGORY PRODUCT
Apheresis System THERAKOS CELLEX Photopheresis System

Collaborations
This research collaboration aimed to further expand the

understanding of the underlying mechanism of action for
extracorporeal photopheresis, and its application toward
February Mallinckrodt plc Transimmune AG
the development of potential next-generation
2019 (UK) (Germany)
photopheresis, with plans to expand on Mallinckrodt's
current Therakos photopheresis platform through new
clinical trials.
241
14.16 MEDICAP CLINIC GMBH

Medicap Clinic GmbH is a part of Medicap GmbH, established in 1981 and headquartered in Germany. The
company is involved in the manufacturing of technologically advanced apheresis equipment and oxygen
concentrators. The apheresis devices developed by the firm are extensively utilized by healthcare
professionals for the separation of blood components. Medicap Clinic GmbH has leveraged its in-house
capabilities to develop apheresis equipment, which delivers maximum flexibility.
Note: Medicap GmbH is a privately held company, and no financial information is available in the public domain. Hence, financial
details are not added in this section.

CATEGORY PRODUCT
Membrane Separators ADAsorb
2019.
242
14.17 LMB TECHNOLOGIE GMBH

Founded in 1982, Lmb Technologie GmbH was incorporated in Germany. Lmb Technologie is focused on
introducing innovative products that help in the separation and processing of blood components. The
company’s key product offerings include blood donation monitors, blood separators, blood filtration stands,
blood storage devices, tube strippers, tube sealers, donor lounges, and consumables. Blood separators
include apheresis products that are highly preferred during several therapeutic procedures. The company
has its presence in China, India, Austria, France, Istanbul, and Russia.
Note: Lmb Technologie GmbH is a privately held company, and no financial information is available in the public domain. Hence,
financial details are not added in this section.

CATEGORY PRODUCT
 LUXOmatic V2
 LUXOmatic
 NOVOmatic
Blood Separators  Dualpress

 Sepamatic
 Mikromatic
 Manual plasma extractor

Product launches
Lmb launched LUXOmatic, a blood separator, in England. This

January 2018 Blood Separator expansion increased the company’s presence in the European
region.
243
14.18 BIOELETTRONICA SRL

Founded in 1995 and headquartered in Italy, Bioelettronica is engaged in the manufacturing and
marketing of products and devices for blood collection & separation. The company’s product portfolio
includes PVC tube sealers, blood component extractors, and blood scale mixers. Bioelettronica develops
superior-quality blood bags that help in the sealing of the apheresis material. The company’s plasma
extractors are highly efficient and widely adopted by healthcare professionals. Bioelettronica provides
technical assistance and services across the Middle East, Europe, Far East, and Brazil. The firm has its
distribution channels in Europe, Asia, and Latin America.
Note: Bioelettronica Srl is a privately held company, and no financial information is available in the public domain. Hence, financial
details are not added in this section.

CATEGORY PRODUCT
 Bio Sealer CR4

 Bio Sealer CR6
 Bio Sealer CR6-PS
 BT Sealer BIO21
PVC Tube Sealers
 HD Sealer BIO22
 PW Sealer BIO23
 M5 Sealer BIO25
 Tube Mixer BIO11
 Bag Extractor BIO15

Blood Component Extractors
 Bag Press BIO45
 Bag Mixer BIO33

 Bag Mixer HED02
Blood Scale Mixers
 Biomixer BM330
 Biomixer BM323
2019.
244
14.19 INFOMED

Established in 1997 and headquartered in Geneva, Switzerland, the company is engaged in the design,
manufacturing, and distribution of blood purification devices. The company’s products include blood
collection devices, therapeutic apheresis devices, tubing sets, filters, and sorbents. Infomed has patents
for its advanced medical therapies that have provided the company with a competitive edge.
Note: Infomed is a privately held company, and no financial information is available in the public domain. Hence, financial details are
not added in this section.

CATEGORY PRODUCT
 CF200 for TPE
Plasmapheresis Equipment  CF300

 HF440 for TPE
2019.
245
14.20 CYTOSORBENTS CORPORATION

Cytosorbents Corporation is a critical care immunotherapy company and is engaged in the development of
blood purification devices for treating patients suffering from cardiac diseases. The company’s product
offerings include CytoSorb, ContrastSorb, Hemodefend, VetResQ, and DrugSorb. CytoSorb, a membrane-
based apheresis device, is used to remove cytokines from blood. It is designed to remove inflammation in
critically ill patients in intensive care units (ICUs) and those undergoing complex open-heart surgery.
CytoSorb has been utilized for the treatment of around 73,000 people. Recently, the use of CytoSorb has
also been approved by the European Union for cytokines and bacterial toxins.
CytoSorb is directly sold in European countries such as Germany, Austria, and Switzerland. The company
also has a strong presence in France, Mexico, South Korea, Finland, and the Czech Republic. In all these
countries, Cytosorbents distributes its products through Fresenius Medical Care. Cytosorbents also plans
to promote its products in India, Sri Lanka, and Malaysia, through its strategic partner Biocon Ltd.
FIGURE 53 CYTOSORBENTS CORPORATION: COMPANY SNAPSHOT (2018)

50.0 50.0%
8.2 13.3 20.1

Founded: 1997

0.0 0.0%
Headquarters: New Jersey, US 2016 2017 2018
-50.0 -50.0%
No. of Employees: 125 (As of February 2019)
-100.0 -74.3% -100.0%
Total Revenue: USD 20.2 Million -77.4%
R&D Expenditure: USD 7.7 Million -150.0 -150.0%
-140.1%
Ownership: Public -200.0 -200.0%

0.5% 0.5%
US
CytoSorb Sales 41.4%
Other Sales Germany
58.1% Other Countries*
99.5%
*Other countries include South Africa, Brazil, Colombia, Costa Rica, Denmark, and Sweden

CATEGORY PRODUCT
Blood Purification Technology CytoSorb
246

Expansions
MONTH & YEAR LOCATION DESCRIPTION
Cytosorbents expanded the distribution of CytoSorb in Brazil, Colombia,

Brazil, Colombia, and
August 2019 and Costa Rica. This will increase the company’s market share in the
Costa Rica
Latin American region.
Cytosorbents expanded the direct sales of CytoSorb for all applications

Poland, the
to Poland and the Netherlands, and for critical care applications in
March 2019 Netherlands, Sweden,
Sweden, Denmark, and Norway. This will increase the company’s
Denmark, and Norway
market share in the European region.
Cytosorbents expanded the distribution of CytoSorb to 53 countries

July 2018 53 Countries across the globe. This helped the company to increase its presence
across these countries.
Cytosorbents opened a new manufacturing facility in the US. This helped

June 2018 US the company to increase its manufacturing capabilities and cater to the
growing demand for CytoSorb.
Partnerships & collaborations
MONTH & YEAR COMPANY 1 COMPANY 2 APPROACH DESCRIPTION
Cytosorbents partnered with Fresenius to

Cytosorbents Fresenius distribute CytoSorb for acute care and other
August 2019 Corporation Medical Care Partnership hospital applications in Korea and Mexico.
(US) (Germany) This partnership will increase the company’s
geographic reach in Korea and Mexico.
Cytosorbents extended its strategic

Cytosorbents partnership with Biocon to launch and
Biocon Ltd.
February 2018 Corporation Partnership distribute CytoSorb in Malaysia. This
(India)
(US) partnership helped Cytosorbents increase
its presence in Malaysia.
Cytosorbents partnered with Dr. Reddy’s to

Cytosorbents Dr. Reddy’s
distribute CytoSorb in South Africa. This
March 2017 Corporation Laboratories Partnership
partnership will increase the company’s
(US) (India)
geographic reach in South Africa.
Cytosorbents collaborated with Aferetica to

jointly develop the PerLife ex-vivo organ
perfusion system with Cytosorbents’ novel
adsorption technologies that can cleanse
Cytosorbents
September Aferetica srl and recondition harvested solid organs such
Corporation Collaboration
2017 (Italy) as the kidneys, lungs, heart, and liver, prior
(US)
to transplantation. The goal of the therapy is
to improve the functioning and viability of
the organs, while reducing the risk of
primary graft failure and organ rejection.
247
Droguería Cytosorbents partnered with DRGR to

Ramón
Cytosorbents expand the sales and distribution of
González
July 2017 Corporation Partnership CytoSorb in Panama. With this, the company
Revilla
(US) increased its presence in the Latin America
(DRGR)
region.
(Panama)
Cytosorbents announced the renewal of its

partnership with Aferetica to exclusively
Cytosorbents
Aferetica srl distribute CytoSorb in Italy for critical care
May 2017 Corporation Partnership
(Italy) and cardiac surgery applications. This
(US)
helped Cytosorbents to increase its market
share in Italy.
Cytosorbents extended its original

partnership with Fresenius to add an
Cytosorbents Fresenius expansive co-marketing agreement for
January 2017 Corporation Medical Care Partnership CytoSorb in France, Poland, Sweden,
(US) (Germany) Denmark, Finland, and Norway. This helped
the company to increase its reach in these
European countries.
248
14.21 TORAY MEDICAL CO., LTD.

Toray Medical Co. Ltd. was established in 1980 and is headquartered in Tokyo, Japan. Toray Medical is
engaged in the manufacturing and sales of medical devices and pharmaceuticals. It is a member company
of Toray Industries, specializing in the healthcare business. Toray Medical’s medical devices include
dialysis-related products, critical care-related products, and interventional cardiology-related products. The
company has TORAYMYXIN through a long-term collaboration with the Shiga University of Medical Science.
TORAYMYXIN is an extracorporeal hemoperfusion cartridge designed for the selective removal of
endotoxins from circulating blood.
Toray Industries has a strong presence across Japan, the Americas, Europe, and Asia. The company
operates through 185 consolidated subsidiaries and 55 subsidiaries. Toray operates in 26 countries, and a
majority of its revenue is derived from Asian countries such as Japan. Some of the company’s subsidiaries
include Toray Medical Co., Ltd. (Japan), Toray Textiles Europe Ltd. (UK), Toray Industries (H.K.) Ltd. (China),
and Toray Plastics (America), Inc. (US).
FIGURE 54 TORAY MEDICAL CO. LTD.: COMPANY SNAPSHOT (2019)

600.0 5.0%
3.9%
500.0 3.5% 4.0%
Established: 1980
400.0 2.4%
Headquarters: Tokyo, Japan 3.0%
300.0
No. of Employees: 474 (As of March 2019) 2.0%
200.0
Total Revenue: USD 484.8 Million
100.0 1.0%
Ownership: Public 451.54 497.70 484.80
0.0 0.0%
2017 2018 2019
Note: The Business Revenue Mix and Geographic Revenue Mix were not available; hence, these sections have not been provided in
the company snapshot.

CATEGORY PRODUCT
Adhesive Blood-purifying Device TORAMYXIN

Product launches
June 2019 Toray launched TORAMYXIN, a blood-purifying device, in Europe.
249
15 APPENDIX
15.1 INSIGHTS FROM INDUSTRY EXPERTS
The global apheresis market is expected to grow at a double- digit rate over the
next five years. Blood shortages and growing concerns regarding blood safety
across the globe will drive the growth of this market.
– Sales Director, Leading Apheresis Devices Provider
Apheresis devices are most commonly used for plasmapheresis. The increasing
demand for plasma from biopharmaceutical companies and the use of
plasmapheresis in clinical applications are the primary factors driving
the growth of the plasmapheresis market.
– Therapeutic Apheresis Nurse, Leading Hospital
250
15.2 DISCUSSION GUIDE
Q. 1. What are your views on the growth prospects of the apheresis market? What is the current scenario, and at what
rate is the market expected to grow in the next five years (2019–2025)?
Primary’s Viewpoint: ________________________________________________________________________
Q. 2. What is the estimated size of the apheresis market in 2019 [in terms of value (USD million)]?
Q. 3. What are the major drivers, restraints, opportunities, and challenges impacting the apheresis market (country
level)?
Q. 4. Kindly provide the market shares of the following key players in the apheresis market. Please let us know if any
major player is missing.
SR. NO. COMPANY NAME MARKET SHARE (2018)
1 Haemonetics Corporation (US) %
2 Fresenius SE & CO. KGAA (Germany) %
3 Terumo BCT, Inc. (US) %
4 B. Braun Melsungen AG (Germany) %
5 Kawasumi Laboratories Inc. (Japan) %
6 Cerus Corporation (US) %
7 Asahi Kasei Medical Co., Ltd. (Japan) %
8 Kaneka Corporation (Japan) %
9 Nikkiso Co., Ltd. (Japan) %
10 Baxter International Inc. (US) %
11 Medica S.p.A. (Italy) %
12 Miltenyi Biotech (Germany) %
13 Otsuka Holdings Company Limited (Japan) %
14 Macopharma SA (France) %
15 Mallinckrodt plc (UK) %
16 Medicap Clinic GmbH (Germany) %
17 Lmb Technologies GmbH (Germany) %
18 Bioelettronica S.r.l. (Italy) %
251
19 Infomed (Switzerland) %
20 Cytosorbents Corporation (US) %
21 Toray Medical Co. Ltd. (Japan) %
Q. 5. Kindly provide the market shares and projected growth rates of the following procedure segments in the apheresis
market. What are the key factors that will drive the fastest-growing segment of the market (2019–2025)?
(Please validate the market segmentation and let us know if we are missing any major segment or if there is any overlap between
segments)
PROCEDURE MARKET SHARE (2018) CAGR (2019–2025)
Automated/Apheresis Blood
% %
Collection (Donor apheresis)
Therapeutic Apheresis % %
Q. 6. Kindly provide the market shares and projected growth rates of the following procedure segments in the
therapeutic apheresis market. What are the key factors that will drive the fastest-growing segment of the market
(2019–2025)?
segments)
PROCEDURE, BY PRODUCT MARKET SHARE (2018) CAGR (2019–2025)
Therapeutic Apheresis Disposables % %
Therapeutic Apheresis Devices % %
Q. 7. Kindly provide the market shares and projected growth rates of the following disease segments in the therapeutic
apheresis disposables market. What are the key factors that will drive the fastest-growing segment of the market
(2019–2025)?
segments)
DISEASE TYPE MARKET SHARE (2018) CAGR (2019–2025)
Neurological Disorders % %
Blood Disorders % %
Cardiovascular Disorders % %
Renal Disorders % %
Autoimmune Disorders % %
Metabolic Disorders % %
Other Disorders % %
252
Q. 8. Kindly provide the market shares and projected growth rates of the following product segments in the apheresis
segments)
PRODUCT MARKET SHARE (2018) CAGR (2019–2025)
Apheresis Devices % %
Apheresis Disposables % %
Q. 9. Kindly provide the market shares and projected growth rates of the following apheresis device segments in the
apheresis market. What are the key factors that will drive the fastest-growing segment of the market (2019–
2025)?
segments)
DEVICE TYPE MARKET SHARE (2018) CAGR (2019–2025)
Centrifugal Apheresis Devices % %
Membrane Separators % %
Q. 10. Kindly provide the market shares and projected growth rates of the following technology segments in the apheresis
segments)
TECHNOLOGY MARKET SHARE (2018) CAGR (2019–2025)
Centrifugation % %
Membrane Separation % %
253
Q. 11. Kindly provide the market shares and projected growth rates of the following application segments in the
apheresis market. What are the key factors that will drive the fastest-growing segment of the market (2019–
2025)?
segments)
APPLICATION MARKET SHARE (2018) CAGR (2019–2025)
Plasmapheresis % %
Plateletpheresis % %
Erythrocytapheresis % %
Leukapheresis % %
Photopheresis % %
Other Applications % %
Q. 12. Kindly provide the market shares and projected growth rates of the following end-user segments in the apheresis
segments)
END USER MARKET SHARE (2018) CAGR (2019–2025)

% %
Component Providers
Hospitals and Transfusion Centers % %
Other End Users % %
Q. 13. Kindly provide the market shares and projected growth rates of the following regions of the apheresis market.
REGION MARKET SHARE (2018) CAGR (2019–2025)
North America % %
Europe % %
Asia Pacific % %
Latin America % %
Middle East & Africa % %
254
Q. 14. Kindly provide the market shares and projected growth rates of the following countries in the North American
apheresis market.
COUNTRY MARKET SHARE (2018) CAGR (2019–2025)
US % %
Canada % %
Q. 15. Kindly provide the market shares and projected growth rates of the following countries in the European apheresis
market.
COUNTRY/REGION MARKET SHARE (2018) CAGR (2019–2025)
Germany % %
UK % %
France % %
Italy % %
Spain % %
Rest of Europe (RoE) % %
Q. 16. Kindly provide the market shares and projected growth rates of the following countries in the Asia Pacific apheresis
market.
Japan % %
China % %
India % %
Australia % %
Rest of Asia Pacific (RoAPAC) % %
Q. 17. Kindly provide the market shares and projected growth rates of the following countries in the Asia Pacific apheresis
market.
Brazil % %
Mexico % %
Rest of Latin America (RoLA) % %
255
15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION

PORTAL
Knowledge Store contains MarketsandMarkets’ unique market insights. As a subscriber, you will have
access to all the published titles and any new ones added over the course of the subscription period. You
can subscribe to a specific number of reports or domains of interest.
Knowledge Store enables you to:

 View & download all subscribed reports from a single, online platform
 Contact our analysts to answer any questions related to our reports or request a custom
research
 Share comments on specific reports with the other users of your organization
 Suggest titles/topics to our research teams that you would like us to cover in our future reports
 Identify reports published on the high-growth markets within your industry
Get started now by requesting a demo and learning more about Knowledge Store: www.mnmks.com/
MARKETSANDMARKETS’ KNOWLEDGE STORE SNAPSHOT
256
MARKETSANDMARKETS’ KNOWLEDGE STORE: HEALTHCARE INDUSTRY SNAPSHOT
257
15.4 AVAILABLE CUSTOMIZATIONS

With the given market data, MarketsandMarkets offers customizations as per the company’s specific
needs. The following customization options are available for the report:
GEOGRAPHIC ANALYSIS
 Further breakdown of the Rest of Asia Pacific apheresis market into South Korea, Australia,
New Zealand, and others
 Further breakdown of the Rest of Europe apheresis market into Switzerland, Belgium, Russia,
the Netherlands, and others
 Further breakdown of the Rest of Latin America apheresis market into Argentina, Peru, Chile,
and others
COMPANY INFORMATION
 Detailed analysis and profiling of additional market players (Up to 5)
15.5 RELATED REPORTS

SR. NO. REPORT TITLE PUBLISHING DATE
PLASMA FRACTIONATION MARKET - GLOBAL FORECAST TO 2024

By Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease
2 Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End March 2019
User (Hospital, Clinic, Academic Institute)
https://www.marketsandmarkets.com/Market-Reports/plasma-fractionation-
market-93798284.html
LEUKAPHERESIS MARKET - GLOBAL FORECAST TO 2023

By Product (Apheresis Machine, Leukocyte Filter, Column, Disposables), Leukopak
1 (Mobilized, Non-Mobilized, Human Primary Cells), Application (Research, August 2018
Therapeutic), End User (Hospitals, Research Institute)
https://www.marketsandmarkets.com/Market-Reports/leukapheresis-market-
20283148.html
US THERAPEUTIC PLASMA EXCHANGE MARKET - FORECASTS TO 2021

Size & Share by Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis,
3 Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis), July 2016
Indication (Neurological & Autoimmune Disorders)
https://www.marketsandmarkets.com/Market-Reports/us-therapeutic-plasma-
exchange-market-87153046.html
258
15.6 AUTHOR DETAILS

Rajiv Kalia Rajiv has over 12 years of experience in market research and consulting in the
Associate Vice President, healthcare vertical. He has worked across diverse areas in the pharma/biotech, medical
Healthcare device, and healthcare IT industries.
He has been instrumental in tracking high-growth and niche markets in the healthcare
vertical and has worked on a number of projects requiring expertise in market
estimations, primary & secondary research techniques, strategic & competitive
assessment of companies, investment opportunity analysis, and product opportunity
evaluations. His current role involves tracking industry developments to come up with
research areas in collaboration with clients.
Rajiv has diligently worked on addressing the problems of clients regarding market and
product strategy, and formulated detailed solutions in terms of research and consulting
outputs. He has completed his Master's degree in Pharmacy with a major in
Pharmacology from Manipal University and also has a Postgraduate Diploma in Financial
Management.
Contributors Awanish Pandey

Assistant Manager
Mayur Jain
Team Leader
Gauri Shirode
Research Analyst
259
Disclaimer: MarketsandMarkets™ provides strategic analysis services to a select group of customers in

response to orders. Our customers acknowledge when ordering that these strategic analysis services are
solely for internal use and not for general publication or disclosure to any third party.
MarketsandMarkets™ does not endorse any vendor, product, or service profiled in its publications.
MarketsandMarkets’™ strategic analysis constitutes estimations and projections based on secondary and
primary research and is therefore subject to variations.
MarketsandMarkets™ disclaims all warranties, expressed or implied, with respect to this research, including
any warranties of merchantability or fitness, for any particular purpose.
MarketsandMarkets™ takes no responsibility for incorrect information supplied to it by manufacturers or

users.
Trademarks, copyrights, and other forms of intellectual property belong to MarketsandMarkets™ or their
respective owners and are protected by law. Under no circumstance may any of these be reproduced, copied,
or circulated in any form, without the prior written approval of MarketsandMarkets™ or its owner—as the case
may be.
No part of this strategic analysis service may be given, lent, resold, or disclosed to any third party, without
express permission from MarketsandMarkets™.
Reproduction and/or transmission in any form and by any means, including photocopying, mechanical,
electronic, recording, or otherwise, without the permission of MarketsandMarkets™, is prohibited.
For information regarding permission, contact:

Tel: 1-888-600-6441
260

Apheresis Market - Global Forecast to 2025

Uploaded by

Copyright:

Available Formats

You might also like

Apheresis Market - Global Forecast to 2025

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Apheresis Market - Global Forecast to 2025

Uploaded by

Copyright:

Available Formats

APHERESIS MARKET - GLOBAL FORECAST TO 2025

Copyright © 2020 MarketsandMarkets™

2 RESEARCH METHODOLOGY ...................................................................................... 28

3 EXECUTIVE SUMMARY .............................................................................................. 36

4 PREMIUM INSIGHTS ................................................................................................ 43

5.2.1.3 Rising demand for blood components and growing concerns

6 INDUSTRY INSIGHTS ................................................................................................ 56

7 APHERESIS MARKET, BY PRODUCT .......................................................................... 64

7.3.1 CENTRIFUGAL APHERESIS DEVICES ................................................................................ 68

8 APHERESIS MARKET, BY PROCEDURE ...................................................................... 73

9 APHERESIS MARKET, BY TECHNOLOGY ..................................................................... 92

9.2.2 INTERMITTENT FLOW CENTRIFUGATION........................................................................... 97

10 APHERESIS MARKET, BY APPLICATION ................................................................... 101

11 APHERESIS MARKET, BY END USER........................................................................ 112

12 APHERESIS MARKET, BY REGION ........................................................................... 118

12.3.1 GERMANY ....................................................................................................................139

13 COMPETITIVE LANDSCAPE ..................................................................................... 199

13.3 COMPETITIVE LEADERSHIP MAPPING ........................................................................................ 202

14 COMPANY PROFILES .............................................................................................. 208

14.6 B. BRAUN MELSUNGEN AG ........................................................................................................ 224

14.18 BIOELETTRONICA SRL ................................................................................................................ 244

15 APPENDIX .............................................................................................................. 250

TABLE 1 REQUIRED UNITS OF BLOOD AND BLOOD COMPONENTS, BY TYPE OF SURGERY 50

TABLE 32 THERAPEUTIC APHERESIS DEVICES MARKET, BY COUNTRY,

TABLE 101 EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE

TABLE 173 ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE,

TABLE 210 ROAPAC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT,

TABLE 243 MEXICO: CENTRIFUGATION APHERESIS MARKET, BY TYPE,

FIGURE 1 APHERESIS MARKET 25

FIGURE 33 EUROPE: APHERESIS MARKET SNAPSHOT 135

ABBREVIATIONS FULL FORM

AABB American Association of Blood Banks

AACR American Association of Cancer Research

AAI American Association of Immunologists

ACS American Cancer Society

AMD Age-related Macular Degeneration

APAC Asia Pacific

ASBP Armed Service Blood Program

ASCO American Society of Clinical Oncology

ASFA American Society for Apheresis

BBTS British Blood Transfusion Society

CAG Canadian Apheresis Group

CAGR Compound Annual Growth Rate

CBER Center for Biologics Evaluation and Research

CBS Canadian Blood Services

CDC Centers for Disease Control and Prevention

CFDA China’s Food and Drug Administration

CFR Code of Federal Regulations

CHD Coronary Heart Disease

CIDP Chronic Inflammatory Demyelinating Polyneuropathy

CKD Chronic Kidney Disease

CMS Centers for Medicare & Medicaid Services

CPR Canadian Plasma Resources

CROs Contract Research Organizations

CTCL Cutaneous T-cell Lymphomas

CVD Cardiovascular Disease

DALYs Disability-adjusted Life Years

DCGI Drug Controller General of India

ECI Extracorporeal Immunoadsorption